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1 Abstract 
This thesis describes the impact of FK506 binding protein 51 (FKBP51) on molecular, 
cellular and physiological processes in neural systems and their resulting effects in behavioral 
phenotypes. FKBP51 is an important mediator of stress effects on various cellular and 
physiological processes. Initially this thesis contributed functional analyses of the FKBP51-
dependent activity on the glucocorticoid receptor to studies that elucidated FKBP51’s role in 
physiological stress response in mice and to studies that compared FKBP51 and related 
proteins with respect to their effect on steroid receptors. 
In the first main part of this thesis, the influence of FKBP51 on Akt signaling and 
downstream events including autophagy was analyzed. Akt (protein kinase B) is a central hub 
of various signaling cascades. FKBP51 has been found to interact with Akt and to inhibit its 
catalytical activity by recruiting PHLPP phosphatase, which catalyzes the dephosphorylation 
of Akt at serine 473. As shown by in vitro and in vivo approaches, Akt affected downstream 
processes via mTOR (mammalian target of rapamycin) on autophagic markers in an FKBP51-
dependent manner. These effects converged with those found for the antidepressants (ADs) 
amitriptyline, fluoxetine and paroxetine. In FKBP51-deficient mice treated with paroxetine, 
the forced swim paradigm showed no behavioral alterations indicative for efficacious AD 
actions, whereas wild-type littermates expressed an AD-like phenotype. Analysis of protein 
expression in the hippocampus and prefrontal cortex of these mice revealed an FKBP51-
dependent regulation of Akt downstream effectors and autophagy markers in response to 
paroxetine exposure. Since autophagy has been recently linked to synaptic processes, it was 
assessed whether FKBP51 influences neurotransmission in combination with ADs. It was 
found that paroxetine exerted stimulatory effects on CA3-CA1 synapses of the hippocampus 
in mice expressing FKBP51, but not in FKBP51-deficient mice. To assess whether the 
molecular findings could be transferred to clinical settings, certain protein markers of 
peripheral blood mononuclear cells (PBMCs) from healthy subjects were analyzed. Similar 
correlations of FKBP51 levels with Akt serine 473 phosphorylation and autophagic markers 
Beclin1 and Atg12 (autophagy related gene 12) were found and an increased inducibility of 
these markers when these cells were cultivated ex vivo and exposed to ADs. 
In the second part of the thesis, the focus was on the protein kinase glycogen synthase kinase 
3 β (GSK3β) since this kinase modulates crucial neuronal functions. Accumulating evidence 
indicated an abnormal regulation of GSK3β in mood disorders. Here, a physical interaction of 
FKBP51 and GSK3β was found for the first time. This interaction resulted in elevated levels 
of serine 9 phosphorylation at GSK3β, which is the inactive form of GSK3β. Furthermore, 
  1 Abstract 
___________________________________________________________________________ 
  2 
paroxetine and the mood stabilizer lithium shared common pathways with FKBP51 via 
inhibition of GSK3β. These findings were consolidated in vitro and in vivo. In a mass 
spectrometry based kinase assay, it was confirmed that lithium potently and directly inhibited 
the enzymatic activity of GSK3β. In addition, it also was found to directly inhibit GSK3β. 
Lithium and paroxetine strengthened the physical binding between FKBP51 and GSK3β as 
determined by co-immunoprecipitation (CoIP) experiments. Reporter gene assays measuring 
the activity of GSK3β by means of monitoring the activity of the downstream transcription 
factors TCF/LEF revealed a GSK3β inhibitory effect of ectopically expressed FKBP51 and of 
exposure to lithium or paroxetine. Moreover a synergistic effect of ADs and overexpressed 
FKBP51 was detected. In the absence of either GSK3β or FKBP51, reporter gene assays 
showed no inhibitory effects by lithium or paroxetine; in the absence of FKBP51, no 
elevation of inhibitory phosphorylation at pGSK3β (S9) was observed. Behavioral tests 
carried out in collaboration to determine AD effects in transgenic mice lacking FKBP51 
showed no AD-like properties as compared to wild-type mice treated with either lithium or 
paroxetine. In human PBMCs, strong correlations between pGSK3β (S9) and FKBP51 protein 
expression were found. The stimulatory effects of lithium and paroxetine on pGSK3β 
phosphorylation at S9 were dependent on the FKBP51 expression level. To corroborate our 
molecular findings with clinical data, we used PBMCs from patients suffering from 
depression. In these cells, pGSK3β (S9) levels as well as its downstream substrate pTau 
(S622) were associated with clinical AD response.  
In summary, this work provides new insights into the FKBP51 regulatory networks. FKBP51 
crucially impacts various cell signaling events thereby affecting physiological and 
pathophysiological processes. This work corroborates FKBP51 in its pivotal role as a 
determinant of treatment response to psycho-active drugs. 
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2 Introduction 
2.1 FKBP51 in psychiatric disorders and neurological diseases  
Originally, Hsp90 (heat-shock protein 90) co-chaperone FKBP51 (FK506 binding protein 51) 
was identified as potentially relevant to stress-related diseases through its potent inhibition of 
glucocorticoid receptor (GR) function (Wochnik et al. 2005). Subsequently, FKBP51 was 
established as a crucial regulator of stress physiology by controlling the stress hormone axis. 
In genome-wide association studies, fkbp5 (the gene encoding FKBP51) was linked to 
psychiatric disorders like major depression and post traumatic stress disorders (Binder et al. 
2004).  
The closest homologue of FKBP51 is FKBP52 which features the same domain structure, but 
has divergent functional roles. For example, both proteins are regulators of steroid hormone 
receptor signaling, hormone binding, translocation as well as receptor maturation, but 
FKBP51 counteracts the stimulatory actions of FKBP52 and vice versa. During the last two 
decades, FKBP51 and FKBP52 emerged as key molecules in a variety of diseases including 
certain types of cancer, neurodegeneration, hormone-dependent diseases and stress-related 
illnesses (Wochnik et al. 2005; Storer et al. 2011). Binder et al. identified single nucleotide 
polymorphisms (SNPs) within fkbp5 that significantly associated with antidepressant (AD) 
response and the recurrence of depressive episodes. These genotypes could be linked to 
elevated protein levels of intracellular FKBP51 with adaptive effects on GR function: patients 
carrying these SNPs had a decreased stress axis activity during depressive episodes (Binder et 
al. 2004). Recently Klengel et al. found that SNPs in the fkbp5 gene play a decisive role in 
individuals developing posttraumatic stress disorders (PTSDs) when exposed to traumatic 
events in early childhood. These functional polymorphisms determines how long-range 
chromatin interactions between fkbp5’s transcription start site and intronic glucocorticoid-
response elements (GREs) are changed by childhood-trauma through alterations of DNA-
methylation; this underlies decreased or increased risk for stress-related psychiatric illnesses 
in adults. Through this mechanism, this DNA modification resulted in an enhanced 
transcription of stress-related genes leading to long-term imbalance of the stress hormone axis 
(Klengel et al. 2013). In addition to its importance in stress physiology, FKBP51 plays also an 
important role in neurodegenerative diseases like Alzheimer’s: in addition to an abnormal 
aggregation of the microtubule-associated protein tau, age-related differences in the cell’s 
chaperone repertoire were also found. In this context FKBP51, prevents tau clearance and 
modulates its phosphorylation status. In vitro FKBP51 isomerizes tau, and stabilizes 
microtubules (Jinwal et al. 2010). FKBP51 as an immunophilin plays a crucial part for 
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immune-related diseases and inflammation. It was reported that in a certain cell type of bone 
marrow of patients with rheumatoid arthritis fkbp5 mRNA levels were elevated (Matsushita et 
al. 2010). Other studies provided evidence that FKBP51 modulates NFκB (nuclear factor 
Kappa-light-chain-enhancer of activated B-cells) signaling, resulting in changed expression of 
genes driven by NFκB transcription factors. This sheds light on FKBP51’s link to immune 
regulation, inflammation, cell proliferation, metabolism, and hematopoesis (Jiang et al. 2008; 
Baker et al. 2011). FKBP51 also influences NFAT (nuclear factor of activated T-cells) signal 
transduction via binding and inhibition of the NFAT regulating phosphatase calcineurin. This 
is thought to link FKBP51 to autoimmune diseases such as multiple sclerosis (Baughman et 
al. 1995).  
Hence, FKBP51 is a versatile player in a multitude of cellular networks affecting 
physiological and pathophysiological processes. This is explained by the observations that 
FKBP51 as a co-chaperone interacts directly and indirectly with numerous proteins 
influencing downstream events (Storer et al. 2011). 
 
2.2 FKBP51 – interaction, structure, signaling 
FKBP51 was first described as binding partner of the progesterone receptor. Numerous 
studies demonstrate that beyond binding to steroid hormone receptors FKBP51 interacts with 
phosphatases and kinases resulting in changes of protein phosphorylation and modification of 
signaling molecules. As an Hsp90 co-chaperone, FKBP51 interacts with several proteins via 
Hsp90. Direct interaction of FKBP51 was demonstrated with Akt as well as with the protein 
phosphatase calcineurin. The interaction of these proteins with FKBP51 results in a change of 
their activity, with a series of consequences for downstream cascades (Pei et al. 2009; Li et al. 
2002).  
 
 
 
Figure 1: Functional domains of human FKBP51 
FK1: domain with PPIase activity; FK2; homologues to FK1, but without enzymatic 
activity; TPR: domain responsible for binding to Hsp90; CBD: binding to calmodulin. 
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As depicted in figure 1 the FKBP51 protein consists of three main structural domains. The N-
terminal FKBP12 like domain 1 (FK1) comprises the protein’s enzymatic activity. As a 
peptidylprolyl isomerase (PPIase) FKBP51 catalyzes the cis trans conversion of peptidyl-
prolyl bonds in proteins. The physiological relevance of this catalytic ability remained largely 
enigmatic. However, it proofed to be of some importance for the regulation of the 
stabilization of microtubules and phosphorylation of tau. Protein interactions described so far 
were not dependent on FKBP51’s isomerization activity (Jinwal et al. 2010). The structural 
homologues FK2 domain does not contain an enzymatic function. As mentioned above, 
FKBP51 includes three tetratricopeptide repeat motifs that mediate Hsp90 bridged binding to 
client proteins. In proximity of the C-terminus of the FKBP51 molecule, a small region called 
calmodulin binding domain (CBD) enables binding of the calcium binding messenger protein 
calmodulin to FKBP51 (Sinars et al. 2003).  
 
2.3 Pathways of FKBP51 and therapeutics 
 
2.3.1 Akt-mTOR pathway 
Pei et al. recently discovered that FKBP51 binds to the protein kinase Akt. Acting as a 
scaffolding protein, FKBP51 recruits protein phosphatase PHLPP (PH domain and leucine 
rich protein phosphatase) to Akt. PHLPP dephosphorylates Akt at serine 473 that leads to a 
reduced kinase activity and decreased phosphorylation of substrates including FoxO 
transcription factors or Iκκ (inhibitor of κB kinase). Pei et al. described that FKBP51 protein 
expression levels determine the cancer patient’s response to chemotherapeutics. Through 
modulation of Akt signaling, FKBP51 regulates pathways important for cell proliferation. 
Cells lacking FKBP51 proteins did not respond to chemotherapeutics targeting these 
pathways (Pei et al. 2009). Akt has multiple functions in a variety of cellular processes like 
cell survival, proliferation, transcription and glucose metabolism. In the context of psychiatric 
disorders, Akt seems to be a decisive factor for treatment response to a multitude of 
psychoactive drugs (Beaulieu et al. 2009). Psychotherapeutics were described as both 
inhibitors and stimulators of the Akt kinase, indicated by changes in the phosphorylation 
status at S473 or T308 that are both important for a fully active protein (Freyberg et al. 2010).  
Akt and the protein kinase mTOR were found to crosstalk. Akt phosphorylates mTOR at 
S2448 modulating its kinase activity (see also fig. 2). mTOR is a central player of cell growth 
and survival, cellular plasticity, and processing of damaged protein aggregates by autophagy. 
Treatment of the immunosuppressant drug rapamycin leads to inactivation of mTOR and 
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hence abolished kinase activity. Rapamycin was shown to increase autophagy and decrease 
apoptosis. Behavioral trials with rapamycin revealed antidepressant-like effects in a forced 
swim paradigm implying that mTOR is a potential therapeutic target for antidepressant drugs 
(Cleary et al. 2008). 
 
 
 
Figure 2: Regulating macroautophagy via Akt and mTOR 
Autophagy is triggered by inhibition of mTOR and Akt which in turn results in less 
inhibitory phosphorylation of Beclin1. Active Beclin1 in series with Atgs triggers 
membrane nucleation. To facilitate sequestration of autophagosomes LC3I is lipidated 
to LC3II. 
 
2.3.2 Autophagy 
Macroautophagy (here referred as to autophagy) is a conserved lysosomal process that 
regulates cytoplasmic integrity by elimination of damaged cell organelles and protein 
aggregates. Autophagy underlies the control of a multitude of regulators and signaling 
cascades initiating the engulfment of degradable molecules into double-membrane vesicles 
fusing to lysosomes. A series of Atgs (autophagy related genes), partly controlled by the 
mTOR kinase, regulate initial steps of autophagy processing. Recently, Wang et al. identified 
Atg6 (also beclin1) as a substrate of the Akt kinase. Beclin1 phosphorylation through Akt 
results in a decrease in autophagic flux and can proceed independently of mTOR signaling 
(Wang et al. 2012). For the assessment of autophagy, several markers can be used: lipidation 
of LC3-I to LC3-II (light chain of microtubule associated protein), expression levels of Vps34 
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(class III phosphoinositide 3-kinase), Beclin1, and certain Atgs (see Fig.2) (Funderburk et al. 
2010). Autophagy was shown to play important roles in many cellular and physiological 
processes, reflecting its effects on energy balance and disposal of damaged macromolecules. 
Hernandez et al. linked autophagy to the regulation of neurotransmission. They found 
autophagic vacuoles in prejunctional dopaminergic axons associated with a reduced axonal 
volume, synaptic vesicle numbers as well as a decrease in evoked dopamine release 
(Hernandez et al. 2012). 
Several studies indicate that autophagy can be targeted by different types of therapeutics. In 
2011 Zschocke et al. showed that ADs amitriptyline (AMI) and citalopram elevate autophagic 
markers and finally lead to a higher degradation of macromolecules (Zschocke et al. 2011; 
Zschocke & Rein 2011).  
Rubinsztein and colleagues put forward that the modulation of autophagy is a promising 
therapeutic target for the treatment of various diseases. The authors claimed that an increase 
in autophagic flux and the improved homeostasis can be advantageous for treatment of 
diverse illnesses such as distinct types of cancer and infectious and neurodegenrative diseases 
(Rubinsztein et al. 2012). 
 
2.3.3 GSK3 signaling 
Glycogen synthase kinase 3 (GSK3) is a serine and threonine kinase and is encoded by two 
genes, GSK3α and GSK3β, with homologues structure but diverse function. GSK3 is 
established as a key regulator of a variety of signaling cascades and physiological processes 
and plays important roles in insulin and Wnt (wingless-type MMTV oncogene integration-
site) signaling as well as in neurodegeneration. Unlike many other kinases involved in 
regulatory signals, GSK3 is active by default. GSK3 changes its active state only in the 
presence of external signals. GSK3’s crystal structure revealed a catalytically active 
conformation in the absence of activation-segment phosphorylation (Dajani et al. 2001; Aoki 
et al. 2000). Aberle et al. described that through Wnt-signaling, GSK3β phosphorylates β-
catenin, promoting its ubiquitination and successive degradation. Degradation only occurs 
when GSK3β is complexed with APC (adenomatous-polyposis-coli protein), Axin and β-
catenin. When Wnt is active, the β-catenin destruction complex is inhibited via dishevelled 
allowing upregulation of β-catenin levels and subsequent elevation of the levels of 
transcription factors TCF (transcription factor) and LEF (lymphoid enhancer-binding factor) 
(Kimelman & Xu 2006). Among others, TCF and LEF target proliferative genes like c-Myc 
(myelocytomatosis oncogene) (Brüschtle et al. 1993; Aberle et al. 1997).  
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2.3.4 GSK3 and therapeutics - Two ways to inhibit GSK3β 
The actions of lithium are manifold and have important cellular impacts as well as therapeutic 
effect for the treatment of bipolar disorders. Several molecular mechanisms underlying the 
effects of lithium have been identified so far. The therapeutic effects of lithium become 
manifest after a few weeks of treatment; plasma concentrations of about 1 mM are to be 
tightly controlled. One of the main targets of lithium is GSK3β. By inhibiting GSK3β, lithium 
modulates a multitude of cellular processes (Grimes & Jope 2001). To date, two mechanisms 
have been identified which explain the inhibitory effect of lithium on GSK3β: first, lithium 
inhibits GSK3β by direct interaction. Second, indirect inhibition of GSK3β through 
phosphorylation of S9 is triggered by lithium treatment (Jope 2003).  
 
Direct effects of small-molecule inhibitors on certain enzymes usually involve binding to a 
cofactor or an important domain to block the catalytic activity. The direct effect of lithium on 
GSK3β is typical for this category of drugs. As a direct reversible inhibitor, lithium competes 
with Mg2+ with an IC50 of ~2 mM (Ryves & Harwood 2001). However the exact site lithium 
binds to remains elusive.  
Indirect inhibition through post-translational modifications is a further mechanism to inhibit 
GSK3β’s activity by lithium. De Sarno and colleagues demonstrated that GSK3β as well as its 
close homologue GSK3α is phosphorylated at a serine residue in their N-terminal region (S9, 
S21 respectively). An elevation of the phosphorylation of GSK3 results in a decreased 
enzymatic activity. Chronic treatment with lithium in rodents showed a marked increase in S9 
phosphorylation at GSK3β (De Sarno et al. 2002). Kinases targeting this particular serine 
seem to vary depending on the cell type, condition, and treatment. This modification was 
shown to be catalyzed by Akt, protein kinase A (PKA) and protein kinase C (PKC). 
Reactivation of GSK3β and maintenance of a balanced phosphorylation status of GSK3β is 
regulated by phosphatases calcineurin (PP2B) and protein phosphatase 1 (PP1), 
dephosphorylate GSK3β at S9 (Jope 2003; Kim et al. 2009).  
A recent publication by Omata et al. showed that in behavioral studies with rodents, inhibition 
of GSK3β has antidepressant-like effects. The authors used shRNA mediated knockdown of 
GSK3β in distinct brain regions. In diverse behavioral paradigms, they observed behavior 
comparable to mice treated with antidepressants (Omata et al. 2011). 
Vice versa, ADs as well as other psychoactive drugs were found to modulate GSK3β’s 
activity by increasing phosphorylation of the inhibitory serine residue. For example, mood 
stabilizers of different classes like VPA and lamotrigine produced elevated elevated levels of 
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pGSK3β (S9) (De Sarno et al. 2002; Tomasiewicz et al. 2006). The ADs imipramine and 
fluoxetine (FLX), also increased pGSK3β (S9) levels in mouse brains, when administered in 
combination with risperidone (Li et al. 2007).  
 
 
 
Figure 3: Pathways involved in GSK3β inhibition 
In active state, GSK3β catalyzes the phosphorylation of many substrate proteins. 
GSK3β is inhibited by phosphorylation at serine in the N-terminal domain. This 
modification can be catalyzed by diverse kinases: Akt, PKA: protein kinase A, PKC: 
protein kinase C. The inactive phopho-serine can be reactivated by protein 
phosphatases: PP2B: calcineurin, PP2A: protein phosphatase 2A, PP1: protein 
phosphatase 1. Cyclin dependent kinase 5 can elevate inhibitory phosphorylation (S9) 
by inhibiting PP2A or PP1. Lithim increased phosphorylation at S9 or inhibits GSK3β 
directly. 
 
 
2.4 Aims of the study 
The goal of this thesis was to shed light on FKBP51 modulated molecular pathways and 
convergent signaling events driven by psychoactive drugs.  
Several studies point to a critical role of FKBP51 in Akt signaling and hence on autophagic 
pathways (Pei et al. 2009; Eskelinen 2011). However, molecular modes of action of FKBP51 
still remain enigmatic. Foremost, the identification of novel interaction partners of FKBP51 
and the assessments of the cellular and physiological impacts of these complexes are of 
greatest importance. In order to understand the role of FKBP51 in the context of AD 
treatment and response, potentially converging pathways of FKBP51 and ADs were analyzed 
in vitro and in vivo: experiments that aimed at addressing these questions included, the 
investigation of marker molecules indicative of autophagy, the forced swim test (FST) and 
electrophysiological monitoring using FKBP51-deficient animals.  
  2 Introduction 
___________________________________________________________________________ 
  10 
As described in the literature, FKBP51 was found to interact with and inhibit Akt kinase by 
recruiting the phosphatase PHLPP. Putative effects of FKBP51 on one of Akt’s most 
prominent substrates, GSK3β were not evaluated so far (Pei et al. 2009). Therefore, the 
physical interaction of FKBP51 to GSK3β was also characterized in detail. Next, the 
underlying mechanisms and functional relevance including the role of CDK5 were evaluated. 
Various studies evidenced the effects of ADs and mood stabilizers, especially lithium, on 
GSK3β activity. Therefore, the impact of FKBP51 on GSK3β in combination with 
psychoactive drugs was analyzed in vitro and in vivo. 
Finally, to translate the findings to the clinical situation, peripheral blood mononuclear cells 
(PBMCs) were used to correlate FKBP51 expression levels to the expression of the distinct 
marker molecules. 
  
  3 Results 
___________________________________________________________________________ 
  11 
3 Results 
The following section summarizes the results obtained from the manuscripts, highlighting the 
contributions of this thesis. Full length results including supplementary information and the 
applied methods are presented in the articles (see appendix). 
 
The first part of the thesis contributed to the characterization of FKBP51 in cellular and 
physiological stress response. In the manuscript of Schülke et al. 2010 Differential impact of 
tetratricopeptide repeat proteins on the steroid hormone receptors the effect of seven Hsp90 
binding proteins on the function of the five steroid receptors was determined. The 
contribution of this thesis was to explore the impact on GR response to stress hormones by 
GRE driven reporter gene assays in FKBP52-deficient mouse embryonic fibroblasts (MEFs). 
Loss of FKBP52 led to a decreased GR activity (see Fig. 12, Schülke et al. 2010). The 
manuscript by Touma et al. 2011 FK506 binding protein 5 shapes stress responsiveness: 
modulation of neuroendocrine reactivity and coping behavior characterized FKBP51-
deficient mice in different behavioral paradigms. It revealed that under basal conditions, 
FKBP51 knock outs showed no significant differences to wild-type animals. When FKBP51 
knock-out mice were exposed to different types of acute stress, an increase in active stress 
coping behavior was observed. Loss of FKBP51 diminished HPA-axis reactivity and resulted 
in changes of GR expression in response to stressors. The contribution of this thesis was to 
determine the effect of FKBP51 deficiency on GR function; reporter gene assays in FKBP51-/- 
and FKBP51+/+ MEFs indicated increased GR hormone affinity in cells devoid of FKBP51. 
When FKBP51 was ectopically expressed in FKBP51+/+ MEFs, hormone affinity was 
decreased (see Fig. 1 A&B; Touma et al. 2011). Ectopic expression of FKBP52 in MEF 
FKBP52-/- and FKBP51 into FKBP51-/- cells respectively were carried out to mimic wild-type 
protein status that excluded effects by compensatory mechanisms often found in knock out 
cells. 
  
In the third manuscript described here, Gassen et al. FKBP51 shapes antidepressant action, 
(in the following referred as to MS-I), the FKBP51-dependency of antidepressant effects on 
Akt-pathways including autophagy was investigated in cells, in mice and in humans. First, the 
interacting domains of FKBP51 with Akt1 and PHLPP phosphatase were fine-mapped. HEK 
(human embryonic kidney) 293 cells were chosen for co-immunoprecipitation (CoIPs) 
experiments, because they expressed sufficient amounts of each protein to be analyzed and 
could be efficiently manipulated. FKBP51 interacted with Akt1 independent of Hsp90 and its 
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catalytic PPIase activity since FKBP51 TPRmut and PPImut constructs precipitated equally 
efficiently with Akt1 compared with full-length FKBP51. Interaction was mapped mainly to 
the FK1 domain of FKBP51. FKBP52 interacted with Akt1 but not with PHLPP. The 
functional consequence of the interaction of FKBP51 with Akt1 and PHLPP was studied by 
Western Blot analyses of pAkt S473 and T308, indicating active forms of Akt, and in addition 
of the Akt downstream target pFoxO3a (S318). A lack of binding to PHLPP phosphatase as 
shown for FKBP52 and FKBP51 ΔFK1 ΔFK2 also resulted in a loss of Akt 
dephosphorylation (S473) and downstream effects on pFoxO3a (S318) and its transcriptional 
activity. (see Fig.1 A-C; Gassen et al. MS-I). To evaluate the functional relevance of the 
complex formation between FKBP51 and Akt1, Western Blot analyses were performed to 
determine the levels of downstream proteins, mTOR substrates 4e-BP1 and p70-S6K and the 
autophagy markers Atg12, Beclin1 and LC3II/LC3I using FKBP51-/- and Akt1/2-/- MEFs. The 
results revealed a regulation of the marker proteins only in presence of FKBP51 and Akt1/2 
(Fig.2; Gassen et al. MS-I). In addition, the impact of the ADs AMI, FLX and paroxetine 
(PAR) on these pathways as well as on autophagosome formation was assessed. Western Blot 
analyses with lysates from rat cortical astrocytes ectopically expressing FKBP51 or empty 
vector were carried out. Since ADs had stimulatory effects on Akt1 (S473) dephosphorylation 
and on autophagy markers, ectopic FKBP51 amplified the effects of ADs on these molecules 
(Fig.3 B, C, E-I; Gassen et al. MS-I). FKBP51 deficient mice were evaluated in the FST to 
characterize the role of FKBP51 in AD response in vivo. Animals were treated for 45 min 
with PAR (10 mg/kg) and underwent behavioral testing. Subsequently, proteins were 
extracted from hippocampi and prefrontal cortices for Western blot analysis. The FST showed 
an effect of PAR in wild-type mice, but no significant change in behavior in FKBP51-/- mice. 
Protein analysis revealed that PAR triggered the elevation of pAkt (S473) levels and 
autophagy markers only in FKBP51+/+ but not FKBP51-/- mice (Fig.4; Gassen et al. MS-I). In 
collaboration, hippocampal slices of FKBP51+/+ and FKBP51-/- mice were used to assess 
neurotransmission in the CA1-CA3 regions. Neuronal activity of the CA1 area was measured 
by means of voltage-sensitive dye imaging (VSDI). PAR treatment (10 µM) of brain slices 
excitated neurotransmission in CA1. This was only observed in brain slices of FKBP51+/+ 
mice (Fig.5; Gassen et al. MS-I). In addition, levels of pAkt (S473) as well as autophagy 
markers were analyzed in PBMCs obtained from healthy male subjects. Protein expression 
levels of FKBP51 strongly correlated with the expression of the autophagy markers Beclin1, 
Atg12, and to a lesser extent with LC3B-II/LC3B-I; FKBP51 correlated negatively with pAkt 
(S473) (Fig.6; Gassen et al. MS-I). AD effects in human cells were measured by ex vivo 
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cultivation of PBMCs and treatment with ADs. Applied drug concentrations were based on 
standard therapeutic drug serum levels (Hiemke et al. 2011). The inducibility of autophagy 
markers by AMI, FLX and PAR correlated significantly with the FKBP51 expression level; 
Beclin1 and LC3B-II/LC3B-I and for Atg12 only when stimulated with PAR. Inducibility of 
pAkt (S473) by ADs negatively correlated with protein expression of FKBP51 (Fig.7; Gassen 
et al. MS-I). 
 
The forth manuscript by Gassen et al. FKBP51 inhibits GSK3β and amplifies the effects of 
distinct psychoactive drugs, (in the following referred to as MS-II) focused on the effect of 
FKBP51 on GSK3β and how this impacts on downstream pathways and the action of 
psychoactive drugs in cells, mice and humans. Most of methods were performed in analogy to 
MS-I. A detailed mapping and functional interaction analysis of FKBP51 with GSK3β 
preceded a detailed characterization of cellular and physiological effects by a multitude of in 
vitro and in vivo experiments. Interaction of FKBP51 with GSK3β was mediated 
predominantly by FKBP51’s FK1 domain, whereas FKBP51’s catalytical activity as well as 
binding to Hsp90 had no influence. Functional assays revealed that only mutants of FKBP51 
capable to bind GSK3β triggered increased pGSK3β (S9) levels. FKBP52 interacts with 
GSK3β, but induced no change in pGSK3β (S9) or TCF/LEF mediated transcription (Fig.1 A-
C; MS-II). The effect of FKBP51 and FKBP52 on pGSK3β (S9) and downstream targets 
pTau (S396; S622) and β-catenin was analyzed in HEK cells after ectopic expression of the 
immunophilins. FKBP51 overexpression resulted in the upregulation of pGSK3β (S9) and 
proteins downstream modulated by GSK3β like pTau (S396; S622) and β-catenin. FKBP52 
exerted no effect on the expression levels of the analyzed proteins apart from a significant 
decrease in pAkt (S473) when highly overexpressed (Fig.1; Gassen et al. MS-II). To analyze 
the effects of FKBP51/52, alone or in combination with psycho-active drugs, on GSK3β 
dependent transcription, TCF and LEF driven reporter gene assays were performed in HEK 
cells, rat primary cortical astrocytes, neurons, and in MEF cells lacking FKBP51 or GSK3β. 
FKBP51 overexpression produced stronger induction of reporter activity in combination to 
lithium, PAR or VPA than in the absence of drugs. The stimulatory effects of psycho-active 
drugs on TCF/LEF driven reporter genes were abolished upon deletion of FKBP51. As in 
HEK cells, FKBP52 also produced no effect on TCF/LEF signaling in cortical astrocytes 
(Fig.1 C, Fig.3 A,B; MS-II).  
Since the inhibitory effect of FKBP51 on Akt cannot explain the increase in pGSK3β, a 
possible interaction of FKBP51 with CDK5, another GSK3β regulating kinase, was 
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investigated. Co-immunoprecipitation experiments were carried out using HEK cells 
ectopically expressing FLAG-tagged FKBP51 that allowed precipitation of FKBP51 via anti-
FLAG conjugated magnetic beads. CDK5 was co-immunoprecipited with FKBP51. The role 
of CDK5 in regulating GSK3β activity was determined by the use of FKBP51-deficient MEF 
cells and ectopic expression as well as specific pharmacological inhibition of CDK5 by 
roscovitine. Inhibition by roscovitine resulted in markedly decreased levels of pGSK3β (S9). 
Ectopic expression of CDK5 led to an increase of pGSK3β (S9) levels in wild-type MEFs, but 
not in MEFs devoid of FKBP51 (Fig.2; MS-II). Effects of psycho-active drugs were observed 
also at the level of protein-protein interaction. Lithium and to lesser extent PAR enhanced the 
interaction between GSK3β and FKBP51 (Fig.4 F; MS-II). Measurements of the catalytical 
activity of GSK3β in a mass spectrometry based kinase assay (performed according to 
Bowley et al. 2005) revealed a decline of GSK3β’s kinase activity when the kinase reaction 
was complemented with lithium or PAR (Fig.4 G, H; MS-II). Effects of psycho-active drugs 
on pGSK3β (S9) phosphorylation as well as on TCF/LEF dependent transcription in wild-type 
MEF cells and in the absence of FKBP51 or GSK3β, showed that FKBP51 is crucial to 
mediate the effects on phosphorylation of pGSK3β (S9) and downstream events and GSK3β 
played an essential role in TCF/LEF signaling. Interestingly, VPA induced pGSK3β (S9) 
levels as well as improved TCF/LEF signaling even in absence of FKBP51 (Fig. 3B, Fig.4 A-
E; MS-II). In vivo experiments were performed in order to assess the response to lithium (85 
mg/kg) of mice in dependence of the FKBP51 expression status at the behavioral and protein 
expression level (refer to MS-I). In the FST, lithium exerted an AD-like effect in FKBP51+/+ 
animals, whereas FKBP51-/- mice displayed an impaired response to lithium. Western blot 
analyses performed with HIP, PFC and blood samples showed elevated pGSK3β (S9) levels 
after treatment with lithium or PAR only in FKBP51 wild-type animals (Fig.5; MS-II). 
Correlations of proteins expressed in PBMCs of healthy male subjects and ex vivo cultivation 
in addition to stimulation with psycho-active drugs were also performed. FKBP51 protein 
expression levels positively correlated with pGSK3β (S9) and β-catenin. The inducibility of 
pGSK3β (S9) after treatment with lithium or PAR, but not VPA, were correlated with 
FKBP51 expression (Fig.6 A-E; MS-II). PBMCs obtained from 56 patients with major 
depression, as a part of the MARS (Munich Antidepressant Response Signature) project, were 
analyzed for protein expression levels of pGSK3β (S9) and pTau (S622) by a commercial 
chip based protein-array. It showed that clinical response represented by the Hamilton score 
of depression (HMD) evaluated before and after AD therapy could be associated with 
increased pGSK3β (S9) and significantly with decreased pTau (S622) (Fig.7 A,B; MS-II). 
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4 Discussion 
FKBP51 emerged from genotype association studies as prominent factor in stress-related 
diseases such as depression and in the response to antidepressant treatment. It was included in 
candidate genotype studies originally because of its impact on GR (Wochnik 2005, Binder 
2004). Subsequent studies, to which this thesis contributed, provided further insight into 
FKBP51’s role in stress physiology and in the regulation of other signaling pathways (Binder 
et al. 2004; Jinwal et al. 2010; Klengel et al. 2013). 
Binder et al. reported that FKBP51 genotypes associated with higher levels of FKBP51 
proteins are also linked to improved clinical response to treatment with ADs (Binder et al. 
2004). Accordingly, results provided in MS-I and MS-II show that higher levels of FKBP51 
enhance the effect of psycho-active drugs such as ADs on Akt and GSK3β and downstream 
pathways. The protein kinases Akt and GSK3β have been reported as targets of ADs and 
mood stabilizers before (Beaulieu et al. 2009). Based on the findings of in vitro and in vivo 
experiments of MS-I and MS-II, the protein expression status of FKBP51 determines whether 
and how psycho-active substances alter Akt- and/or GSK3β-directed pathways. Thus, the 
FKBP51 expression level might determine cell-specific differences in drug effects on Akt 
phosphorylation described in literature (Beaulieu et al. 2009; Pei et al. 2009; Pei et al. 2010). 
Apart from FKBP51, Akt’s catalytic activity is orchestrated by multiple factors, the 
combination of which might be decisive determinants for ADs exerting either inhibitory or 
stimulatory effects on Akt kinases.  
Considering the drug relevant mechanism of action of FKBP51, the protein-protein 
interaction analyses described in MS-I support the role of FKBP51 as scaffolding protein that 
recruits the phosphatase PHLPP to Akt thereby facilitating Akt1 dephosphorylation. The FK1 
domain of FKBP51 interacted with both Akt and PHLPP. This interaction is independent of 
FKBP51’s PPIase activity and of binding to Hsp90. Although Akt and PHLPP were shown to 
be chaperoned by Hsp90 (Sinars et al. 2003; Sato et al. 2000), an Hsp90 independent 
interaction with FKBP51 is not unexpected, as intrinsic chaperone activity has been described 
for FKBP51 (Pirkl & Buchner 2001). Interaction analyses also revealed FKBP52 interacting 
with Akt, but not with PHLPP. Thus, FKBP52 did not directly affect pAkt (S472) levels. 
FKBP51 and FKBP52, although closely homologous, have divergent functions for neurite 
outgrowth (Quintá et al. 2010), regulation of microtubules (Jinwal et al. 2010), and the control 
of corticosteroid receptors (Wochnik et al. 2005; see also Schülke et al. 2010 and Touma et al. 
2011).  
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In MS-II, physical binding of FKBP51 and FKBP52 to GSK3β is presented for the first time. 
Even though both immunophilins bound to GSK3β, FKBP52 played a functionally 
antagonistic role to FKBP51. Binding of GSK3β to FKBP51 was shown to be also mediated 
largely via the FK1 domain of FKBP51; interestingly, binding was independent of Hsp90 
binding of FKBP51, although GSK3β is chaperoned by Hsp90 with the result of priming 
phosphorylation at Y216, necessary for GSK3β full catalytical activity (Lochhead et al. 
2006).  
By interacting with various protein phosphatases and kinases FKBP51 is capable to 
orchestrate posttranslational modifications at proteins and transcription factors of entire 
signaling networks. As presented in MS-I and MS-II, FKBP51 regulates promoters driven by 
the transcription factors FoxO3a and TCF/LEF via modulation of Akt1 and GSK3β activity. 
Originally, we hypothesized that the inhibitory effect of FKBP51 on Akt kinase should result 
in decreased pGSK3β (S9) levels, since GSK3β is an established substrate of Akt (Pei et al. 
2009). Phosphorylation of Akt at T308 is required for Akt-directed phosphorylation of 
pGSK3β (S9) (Pan et al. 2011). Unexpectedly, FKBP51 appeared to inhibit GSK3β by direct 
interaction resulting in elevated levels of pGSK3β (S9) in parallel to an inhibition of Akt1 as 
mirrored by reduced pAkt (S473) and no effect on phosphorylation at pAkt (T308). The 
inhibitory effect on GSK3β involves CDK5 as a regulator of GSK3β; CDK5 is presented here 
as a novel interaction partner of FKBP51. GSK3β and CDK5 were found to play 
complementary roles in diverse cellular processes and disorders such as neurodegenerative 
diseases (Maldonado et al. 2011). In Alzheimer’s disease, both kinases were identified as 
regulators of Tau phosphorylation and Tau clearance (Plattner et al. 2006). Jinwal et al. 
described that FKBP51 mediates phosphorylation of Tau, pointing to another mechanism that 
linked FKBP51 to CDK5 and GSK3β (Jinwal et al. 2010). 
The modulation of Akt1 activity through FKBP51 has an important impact on autophagy (see 
Fig. 4). Several studies linked autophagy to the pathology of diverse diseases. Furthermore, 
autophagy can be triggered by diverse therapeutics such as ADs (Zschocke & Rein 2011; 
Zschocke et al. 2011). FKBP51 might link stress physiology to autophagic processes. Laane 
et al. reported that treatment with the synthetic glucocorticoid dexamethasone induced the 
autophagic markers Beclin1 and Atg12 in vitro (Laane et al. 2009). It is well known that the 
manipulation of autophagy has far reaching consequences that ultimately precipitate in 
cellular and physiological events. Transgenic mice lacking Atg7, a crucial regulator in 
autophagosome formation, had a significant loss of body weight compared to wild-type 
animals (Zhang et al. 2009). This is in line with the observations that FKBP51-/- mice weighed 
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less compared to wild-type littermates (Hartmann et al. 2012). Thus, FKBP51 induced 
autophagy might at least partially account for the changes in mouse body weight in FKBP51-/- 
mice. 
 
 
 
Figure 4: FKBP51 regulates macroautophagy  
FKBP51 recruits Akt to PHLPP, which in turn inhibits Akt by dephosphorylation. 
Less efficient Akt kinase activity results in a decrease of activated mTOR; thereby, the 
two Beclin-inhibitors Akt and mTOR are inhibited. Beclin1 triggers membrane 
nucleation in concert with a series of Atgs. Sequestration of autophagosomes is 
facilitated by lipidation of LC3I to LC3II 
 
 
Akt and GSK3β activity is affected by mood stabilizers and ADs, although with different 
compound specific outcomes (Beaulieu et al. 2009). In MS-I and MS-II the effects of diverse 
psycho-active drugs on Akt and GSK3β phosphorylation and activity as well as on 
downstream targets were abolished in FKBP51-deficient mice and cell-lines. For instance, 
treatment with the AD PAR resulted in the regulation of Akt- and GSK3β-dependent 
pathways in vitro and in vivo, in dependence of FKBP51. For the first time it was shown that 
PAR directly inhibited GSK3β, suggesting that this enzyme is a potential mediator of PAR’s 
therapeutic actions (see Fig. 5).  
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This thesis presents FKBP51 as a novel regulator of autophagy and GSK3β, and links 
FKBP51 expression to AD/ mood stabilizer response. Analysis of clinical samples confirmed 
that FKBP51 as well as GSK3β and its substrate Tau might serve as predictive markers for 
AD response.  
The results of this thesis put forward that FKBP51 determines response to ADs and mood 
stabilizers by shaping cellular pathways like Akt1 and GSK3β signaling; inhibition of GSK3β 
or Akt improved AD effects. This thesis could show both proteins to be regulated by 
FKBP51, thereby promoting FKBP51 as a pivotal determinant in therapeutic effects through 
ADs. The here established impact of FKBP51 on protein kinases, signal transduction and 
autophagic processes significantly expands the range of actions of this versatile protein.  
 
 
 
 
 
Figure 5: Model of the multifarious ways to inhibit GSK3β pathways 
orchestrated by FKBP51 
FKBP51 governs inhibition of GSK3β by enabling CDK5 to block phosphatases PP2A 
and PP1. This results in decrease of depohsphorylation which shifts the equilibrium to 
more ihnhibitory phosphorylation of GSK3β at S9. Less β-catenin will be 
phosphorylated and therefore will not undergo proteasomal degradation. β-catenin 
binds TCF/LEF and activates promoters driven by these transcription factors. 
Inhibition of GSK3β by psychoactive drugs can be direct, but is significantly enhanced 
through strengthening the interaction of FKBP51 with GSK3β leading to increased 
phosphorylation at S9 and stronger inhibition. 
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Abstract 
Psychoactive drugs such as lithium and antidepressants target glycogen synthase kinase 3β 
(GSK3β). However, the functional integration with other factors relevant to drug action is 
poorly understood. We here show protein interaction between GSK3β and FK506 binding 
protein (FKBP) 51, which has been genetically linked to the actions of antidepressants. This 
interaction is accompanied by increased phosphorylation of GSK3β at serine 9 (pGSK3β) and 
downstream effects on beta catenin, tau phosphorylation and transcriptional activity of 
TCF/LEF. Deletion of GSK3β abolished the effect of FKBP51 on TCF/LEF. Lithium 
enhanced the interaction between FKBP51 and GSK3β and reporter gene assays revealed a 
synergistic effect of lithium or the antidepressant paroxetine with FKBP51 on TCF/LEF. 
Kinase activity assays revealed also a direct inhibition of GSK3β by paroxetine. The increase 
in pGSK3β observed in cells and mice after exposure to paroxetine or lithium was blunted 
upon deletion of FKBP51; deletion of FKBP51 also attenuated the effect of lithium in the 
forced swim test. In ex vivo cultivated human peripheral blood mononuclear cells (PBMCs) 
from healthy volunteers, the increase of pGSK3β upon treatment with lithium or paroxetine 
correlated with FKBP51 expression. Clinical improvement of drug-treated depressive patients 
correlated with protein markers of GSK3β pathway activity in their PBMCs. These data link 
FKBP51 to GSK3β and drug activity in health and disease.  
  
Introduction 
Glycogen synthase kinase 3β (GSK3β) is a serine-threonine kinase that was first associated 
with control of energy homeostasis1-3; it is now also known for its prominent role in 
developmental processes including neurogenesis, neuronal polarization and axon growth 
during brain morphogenesis4.  
The constitutively active form of GSK3β  inhibits several signaling pathways, for example 
through phosphorylation of transcription factors1, 5. These signaling pathways are generally 
activated through phosphorylation of GSK3β at serine 9 which inhibits GSK3β’s enzymatic 
activity6. Prominent kinases phosphorylating serine 9 of GSK3β are Akt, also known as 
protein kinase B, protein kinase A and protein kinase C7-9. Cyclin-dependent kinase 5 (CDK5) 
increases phosphorylation of GSK3β apparently in an indirect manner by inhibiting protein 
phosphatase 2A and protein phosphatase 110, 11. 
Several lines of evidence suggest a key role of GSK3β activity in the development as well as 
treatment of major depressive disorder. Increased activity of GSK3β, along with decreased 
activity of Akt, has been found post mortem in the ventral prefrontal cortex of individuals 
with major depression12.  In mice, decreasing the levels of GSK3β by deleting one allele of 
the gsk3β gene resulted in decreased depressive-like behavior13, 14. Similarly, reduction of 
GSK3β levels by injection of lentivirus expressing small hairpin RNA targeting GSK3β into 
the hippocampal dentate gyrus produced antidepressant-like effects in chronically stressed 
mice15. On the other hand, increasing the levels of GSK3β in mice by knock-in resulted in 
increased depressive-like behavior16.  
GSK3β can be targeted by lithium and by antidepressants which inhibit GSK3β activity17, 18. 
Lithium is a frequently prescribed mood stabilizer that also amplifies the effect of 
antidepressants19. Lithium inhibits GSK3β both directly and indirectly through 
phosphorylation at serine 9, while only an indirect mode of action has been reported for 
antidepressants so far17, 20. Newly developed inhibitors of GSK3β also display antidepressant-
like effects in mice21. 
Hence, the question arises whether and how other factors known to influence and mediate 
antidepressant action may link to GSK3β as important relay linked to several upstream and 
downstream pathways4. FK506 binding protein 51 (FKBP51) has been genetically associated 
with antidepressant response in several studies22, 23. FKBP51 is one of the Hsp90 
cochaperones and has originally been characterized as regulator of steroid receptor function, 
and in particular of the glucocorticoid receptor24, 25. More recently, FKBP51 has been 
discovered as inhibitor of Akt by recruitment of the phosphatase PHLPP26. Thus, the genetic 
link to antidepressant response in depressed patients and the effect on the GSK3β-inhibitory 
kinase Akt prompted us to test whether FKBP51 impacts on GSK3β activity, thereby 
modulating the actions of psychoactive drugs. We also included the close homologue 
FKBP52 it frequently acts as functional antagonist of FKBP5124, 26-29. 
 
  
Results 
FKBP51 binds to and inhibits GSK3β, thereby relieving the suppressive effect of GSK3β on 
downstream targets. 
To test the hypothesis that FKBP51 changes GSK3β activity, phosphorylation of GSK3β at 
serine 9 (pGSK3β) was determined after transient overexpression of FKBP52, FKBP51 and a 
series of mutants of FKBP51 into HEK cells. FKBP51 caused increased pGSK3, while the 
closely related FKBP52 showed no effect (Fig. 1A, suppl. Fig. 1A). The N-terminal FK1 
domain harboring the peptidylprolyl-ismoerase (PPIase) activity was required for increasing 
pGSK3β levels, while the enzymatic PPIase activity per se was dispensable. The effect of 
FKBP51 on GSK3β was also independent of Hsp90 interaction (Fig. 1A, suppl. Fig. 1A). 
All mutants that inhibited Akt1 (Gassen et al., submitted) also triggered the elevation of 
pGSK3β levels. Thus, the increase of pGSK3β levels by FKBP51 cannot be explained by the 
observation of FKBP51 inhibiting Akt1 kinase activity. Therefore, we first verified that 
indeed FKBP51 inhibited Akt1 by reducing pAkt1 levels also in the chosen cellular paradigm 
(suppl. Fig. 1B and D). We then evaluated whether FKBP51 may act directly on GSK3β. Co-
immunoprecipitation revealed that FKBP51 binds to GSK3β (Fig. 1B). FKBP51 constructs 
lacking the N-terminal FK1 domain did not interact with GSK3β, corresponding to their 
inability to increase pGSK3β levels. Neither binding to Hsp90 nor PPIase activity of FKBP51 
were required for interaction with GSK3β. FKBP52 also bound to GSK3β, indicating that 
binding alone is not sufficient to change the phosphorylation status of GSK3β.   
To monitor effects of FKBP51 downstream of GSK3β we measured TCF/LEF driven reporter 
gene activity. Increasing the levels of FKBP51 enhanced TCF/LEF-dependent transcriptional 
activity, in contrast to FKBP52 and consistent with FKBP51’s inhibitory action on GSK3β 
(Fig. 1C, suppl. Figs 1 B and C). Further, we compared the effects of FKBP51 and FKBP52 
on the GSK3β targets tau and β-catenin. The dose-dependent increase of pGSK3β by 
FKBP51 was accompanied by decreased phosphorylation of tau (serines 396 and 622) and by 
increased levels of GSK3β-controlled β-catenin (Figs. 1 D-F, suppl. Figs. 1 B and C). The 
stark difference between FKBP52 and FKBP51 in affecting GSK3β phosphorylation was also 
reflected on the level of GSK3β targets.  
 
Change of GSK3β phosphorylation by CDK5 depends on FKBP51 
Since the inhibitory effect of FKBP51 on Akt cannot explain the observed FKBP51-induced 
inhibition of GSK3β, we tested whether FKBP51 influences the ability of CDK5 to enhance 
phosphorylation of GSK3β. We found that FKBP51 interacts with CDK5 (Fig. 2A). We next 
assessed whether pGSK3β levels depend on CDK5 in cells differing in their FKB51 status: 
we made use of the CDK5 inhibitor roscovitine in wild-type (FKBP51+/+) mouse embryonic 
fibroblast cells (MEFs), FKBP51-/- MEFs and FKBP51-/- MEFs reconstituted by ectopically 
expressed FKBP51. Phosphorylation of GSK3β was dependent on CDK5 in all three cell 
systems, as indicated by reduced pGSK3β levels upon application of the CDK5 inhibitor 
(Fig. 2B). Ectopic expression of CDK5 increased pGSK3β levels in FKBP+/+ cells, but not in 
FKBP-/- cells; reconstituting FKBP51 in FKBP51-/- cells by ectopic expression largely 
restored the effect of CDK5 on pGSK3β levels (Fig. 2B). This supports the conclusion that 
FKBP51 promotes phosphorylation of GSK3β through CDK5. 
 
FKBP51 amplifies the effects of lithium and antidepressants on GSK3β and downstream 
targets 
GSK3β is as target of the mood stabilizer lithium and of several antidepressants17, 18. 
Therefore, we tested whether FKBP51 influences the effects of psycho-active drugs on 
GSK3β and its downstream targets. Reporter gene assays in rat primary cortical astrocytes 
evidenced a dose-dependent increase of TCF/LEF activity upon exposure to lithium (Fig. 3A). 
Coexpression of FKBP51 greatly amplified the effect of lithium, while FKBP52 had no effect. 
FKBP51 also enhanced the effects of lithium on TCF/LEF in rat primary cortical neurons 
(Fig. 3A). A synergistic effect on TCF/LEF-driven reporter activity was also observed in 
cortical astrocytes and neurons for FKBP51 in combination with the antidepressant paroxetine 
(PAR), and to a somewhat lesser extend for FKBP51 and valproic acid (VPA)(Fig. 3B). 
To test whether the observed synergy between FKBP51 and lithium, PAR and VPA on 
TCF/LEF depends on GSK3β, we compared the effects in GSK3β+/+ and GSK3β-/- MEFs. In 
GSK3β-/- MEFs, TCF/LEF activity was higher than in GSK3β+/+ cells and did not respond to 
lithium, PAR, VPA or FKBP51 (Fig. 4A). However, in GSK3β+/+ MEFs, coexpression of 
FKBP51 enhanced the stimulatory effect of lithium and PAR on TCF/LEF-dependent 
transcription. This effect was much less pronounced in the case of VPA treatment. The drugs 
also elevated the levels of pGSK3β (Fig. 4B). 
To further substantiate the conclusion that the action of psycho-active drugs depend on 
FKBP51, we made use of the FKBP51+/+ and FKBP51-/- MEFs. Lithium and PAR increased 
pGSK3β in FKBP51+/+, but not in FKBP51-/- MEFs (Figs. 4C and D). In contrast, VPA 
increased pGSK3β irrespectively of the FKBP51 gene status (Figs. 4C and D). Reporter gene 
assays measuring TCF/LEF-dependent transcription showed similar TCF/LEF activity in 
untreated FKBP51+/+ and FKBP51-/- MEFs. However, only FKBP51+/+ MEFs displayed a 
stimulation of TCF/LEF upon exposure to lithium and PAR, while VPA activated TCF/LEF 
irrespectively of the FKBP51 status (Fig. 4E).  
To further characterize the synergism of FKBP51 and psycho-active drugs on GSK3β we 
tested whether lithium alters binding of FKBP51 to GSK3β. Treatment of HEK cells with 
lithium increased the interaction between FKBP51 and GSK3β, while PAR had only a minor 
and VPA no effect (Fig. 4F). Addition of lithium to cell extracts in the coimmunoprecipitation 
reaction also yielded a higher interaction of FKBP51 and GSK3β. The effects of lithium on 
GSK3β phosphorylation have been found to be both directly and indirectly, while only 
indirect effects have been reported for antidepressants17, 20. Using kinase activity assays we 
confirmed a direct inhibition of GSK3β by lithium; we found in addition that paroxetine also 
inhibits GSK3β directly, albeit only to a minor extent at a concentration of 20 µM (Figs. 4G 
and H).  
 
FKBP51 and psycho-active drugs in mice and human 
To test whether FKBP51 is linked to the actions of psychoactive drugs also in vivo, we treated 
FKBP51+/+ and FKBP51-/- mice with lithium. The animals were assessed in the forced swim 
test, a widely used paradigm to measure depression-like behavior in mice. While the animals 
treated with vehicle did not display significant differences between FKBP51 genotypes, after 
lithium treatment, FKBP51+/+ mice struggled longer and floated shorter times compared to 
FKBP51-/- mice (Fig. 5). In addition, lithium prolonged the latency to first floating in 
FKBP51+/+, but not in FKBP51-/- mice. We also determined the pGSK3β/GSK3β ratio in the 
hippocampus, prefrontal cortex and peripheral blood of lithium or PAR treated FKBP51+/+ 
and FKBP51-/- mice. In all three tissues, both drugs increased pGSK3β in FKBP51+/+, but not 
in FKBP51-/- mice (Fig. 5). 
To translate these findings to human, we first determined the expression levels of FKBP51, 
pGSK3β/GSK3β and beta-catenin in peripheral blood mononuclear lymphocytes (PBMCs) of 
healthy volunteers. A highly significant correlation between FKBP51 expression and 
pGSK3β/GSK3β was observed (Fig. 6). To evaluate the link to the action of psychoactive 
drugs, PBMCs were cultivated ex vivo and treated with lithium, PAR or VPA. To more 
closely mimic the clinically relevant in vivo conditions, drug concentrations were chosen 
according to the results of therapeutic drug monitoring in psychiatry30. The effect of lithium 
and PAR on pGSK3β/GSK3β significantly correlated with the expression of FKBP51, while 
the effect of VPA was independent of the FKBP51 expression status (Fig. 6).  
To further test the physiological relevance of the FKBP51-dependent actions of psychoactive 
drugs on GSK3β and downstream targets, we measured protein levels in PBMCs from 56 
patients using a protein array and related them to clinical treatment response. We observed a 
significant negative correlation of the GSK3β target pTau (S622) with clinical treatment 
response (Fig. 7); a trend was received for pGSK3β/GSK3β. 
 
  
Discussion 
The use of recent high-throughput technologies for genome-wide genotyping has spawn a 
wealth of association data in complex diseases; this progress entailed the need to apply 
complementary approaches to shed light on the identity and operation of the underlying 
signaling pathways and molecular networks31, 32. The results of this study suggest that the 
genetic association of FKBP51 with clinical response to antidepressant treatment is linked to 
FKBP51’s action on GSK3β, which amplifies the impact of psycho-active drugs on this 
kinase.  
Originally, we hypothesized that the known inhibitory effect of FKBP51 on Akt26 increases 
GSK3β activity through decreased Akt-dependent phosphorylation of GSK3β at serine 9. It 
appears that the here presented direct interaction of FKBP51 with GSK3β is responsible for 
inhibition of GSK3β by increased phosphorylation, even though Akt is inhibited at the same 
time. Phosphorylation of Akt at serine 473 is required for enhanced kinase activity33, 34 and 
has also been reported to enhance Akt-directed phosphorylation of GSK3β. However, others 
have found that phosphorylation of GSK3β by Akt is independent of serine 473 
phosphorylation and only requires phosphorylation at threonine 308 for basal Akt activity35. 
Since FKBP51 only alters phosphorylation at serine 473, but not at threonine 308, there might 
be no consequence for GSK3β through FKBP51’s effect on Akt in our experimental set-up. 
The effect of FKBP51 on GSK3β likely involves CDK5, a regulator of GSK3β activity10, 11, 
which we report here as a newly identified FKBP51 interaction partner. These findings, 
together with FKBP51’s impact on Akt and other signaling molecules lead us to propose that 
FKBP51 re-sets molecular pathways and networks by direct interaction with pivotal pathway 
elements. Since FKBP51 is a strongly stress-induced gene, this mechanism also efficiently 
links stress response to several pathways. 
In contrast to FKBP51, the highly homologous FKBP52 displayed no effect on GSK3β, 
downstream targets and the effect of lithium. Differential outcomes between FKBP51 and 
FKBP52 are also known for their effects on corticosteroid receptors24, 25, microtubules27, 28, 
neurite outgrowth29 and Akt26 (Gassen et al. submitted). Functional domain mapping revealed 
the N-terminal FK1 domain as essential for the effect of FKBP51 on GSK3β; the enzymatic 
activity of the PPIase situated in this region was not required. Similarly, the FK1 domain of 
FKBP51 was indispensable for its effect on the glucocorticoid receptor24, 25, as well as on 
Akt26 (Gassen et al. submitted), but the PPIase activity was dispensable in both cases. 
Collectively, these data support the notion that the most important function of FKBP51’s FK1 
domain is not the isomerization of peptidylprolyl-bonds, but the assembly of protein 
complexes. 
GSK3β has been extensively discussed as promising target of new psycho-active drugs36, 37. 
The results presented here add with FKBP51 a novel regulator of GSK3β, which at the same 
time has been linked to clinical AD response. The physiological relevance of this FKBP51-
governed GSK3β pathway is further substantiated by in vivo experiments in mice and by 
providing strong evidence for a functional link of the GSK3β pathway to treatment response 
of depressed patients. The demonstration of the functionality of this pathway in a drug- and 
FKBP51-dependent manner in cultivated PBMCs opens the prospect for developing highly 
informative biomarkers. These may not only be derived from determination of pathway 
components in PBMCs from patients, but also from treatment of the ex vivo cultivated 
PBMCs with diverse antidepressants to monitor pathway response. These dynamic 
biomarkers would constitute a major advance towards implementing the concept of 
personalized medicine38. 
 
Experimental Procedures. Details of the experimental methods can be found in the 
supplemental material. 
  
Figure Legends 
 
Figure 1. Functional interaction of FKBP51 with GSK3β. A, constructs used in the 
interaction analyses and their effect on phosphorylation of GSK3β (S9). FK, FK506 binding 
domain; FL, full length. “PPIaseMut” denotes the F67V/D68V mutation abolishing PPIase 
activity; “Hsp90Mut” carries the K352A/R356A mutation disrupting interaction with Hsp90. 
HEK cells were transiently transfected with the plasmids encoding the listed FKBP 
constructs, all fused to a Flag-tag. The levels of GSK3β and pGSK3β were determined by 
Western blot and quantified (right panel). * p<0.05, ** p<0.01, difference compared to FL 
Fkbp51. B, representative Western blots of the FKBP-GSK3β interaction analyses. Numbers 
on top of the panel correspond to the constructs listed in A. Plasmids were transfected into 
HEK cells and precipitation of protein complexes was performed using magnetic protein G 
beads conjugated to a Flag-antibody; (co)precipitated proteins were visualized by Western 
blot and quantified. Numbers at the bottom of the panel summarize the results of 3 
independent experiments (3 technical replicates of the Western blots of each experiment) 
analyzing the interaction of the FKBPs with GSK3β. C, The functional effect of FKBP-
governed differential GSK3β phosphorylation was assessed by TCF/LEF-driven reporter gene 
analysis in HEK cells transiently overexpressing increasing amounts of full-length FKBP51 or 
52. Expression efficiency was controlled by Western blot analysis (right panel). Relative 
reporter activity is given in arbitrary units reflecting the mean +/- SEM of three independent 
experiments performed in triplicate. D-F, HEK cells were transfected with either control 
plasmid or two different amounts of FKBP51 or FKBP52 expressing plasmid (1.5 or 3 µg 
plasmid/ 107 cells), and the protein parameters were determined by Western blot. Graphs 
display the difference of protein phosphorylation or abundance in comparison to vector 
control as the relative mean expression + SEM of 3 different experiments.  * p<0.05; ** 
p<0.01; *** p<0.001. 
 Figure 2. FKBP51 interacts with CDK5 that changes GSK3β phosphorylation. A, HEK cells 
were transfected with FLAG-tagged FKBP51 expressing plasmid or control vector and 
interaction of FKBP51 and CDK5 was evaluated by co-immunoprecipitation as indicated. 
Representative Western blot is shown. B, comparison of pGSK3β in FKBP51+/+, FKBP51-/-, 
and FKBP51-/- MEFs reconstituted by ectopic expression of FKBP51. Cells were 
(co)transfected with a CDK5 expressing plasmid or treated with the CDK5 inhibitor 
Roscovitine (0.3 µM) as indicated. Phosphorylation of GSK3β was determined by Western 
blot. Representative blot and quantification of pGSK3b as mean + SEM of three different 
experiments (each analyzed in three technical replicates) are displayed. * p<0.05; ** p<0.01; 
*** p<0.001.  
 
Figure 3. FKBP51 amplifies the effects of lithium and paroxetine on GSK3β. TCF/LEF 
reporter gene assays were used as read out of the ability of GSK3β to suppress downstream 
targets.  Primary cortical astrocytes (A and B) or primary cortical neurons (A and B) were 
transfected with reporter and FKBP51 or FKBP52 expressing plasmids and treated with the 
drugs as indicated for 48h. Reporter activity in vehicle-treated and vector-transfected cells 
was set to 1. Data represent results from 3 independent experiments performed in triplicate. 
Drug concentrations were: PAR 10µM, VPA 10mM, Li 10mM unless indicated otherwise. * 
p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 4. FKBP51-dependent and –independent effects of lithium and paroxetine on GSK3β. 
A,E, GSK3β-/- and GSK3β+/+ MEFS (A) or FKBP51+/+ and FKBP51-/- MEFs (E) were 
transfected with TCF/LEF-reporter and FKBP51 or FKBP52 expressing plasmids and treated 
with the drugs as indicated for 48h. Reporter activity in vehicle-treated and vector-transfected 
cells was set to 1. B-D, the ratios of pGSK3β to GSK3β were determined in the indicated 
MEFs after drug treatment. Drug concentrations in A-E: PAR 10µM, VPA 10mM, Li 10mM. 
F, interaction analysis of FKBP51 and GSK3β by coimmunoprecipitation. HEK cells were 
transfected with FKBP51-FLAG and GSK3β expressing plasmids, treated with drugs as 
indicated for 48h, and precipitation of protein complexes was performed using magnetic 
protein G beads conjugated to a Flag-antibody; (co)precipitated proteins were visualized by 
Western blot and quantified. G, H, effect of lithium and PAR on kinase activity of purified 
GSK3β. GSK3β was exposed to drug as indicated and kinase reaction was started by adding 
biotinylated substrate and ATP. Substrate phosphorylation was determined by mass 
spectrometry. All data represent results from 3 independent experiments performed in 
triplicate. * p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 5. FKBP51 determines the effect of lithium and PAR in mice. FKBP51-/- and 
FKBP51+/+ mice were treated with lithium or vehicle and subjected to the forced swim test 
(N = 7-9 per group). Graphs show the times of struggling, swimming, floating and latency to 
first floating. For determining FKBP51-dependency of drug effects on pGSK3β in mice, 
FKBP51-/- and FKBP51+/+ mice were treated with lithium (50 mg kg-1), PAR (10 mg kg-1) or 
the respective vehicle and sacrificed 45 mins later. Levels of the indicated proteins were 
determined by Western blotting in extracts of the hippocampus, prefrontal cortex and blood 
from 9-10 animals in technical triplicates. * p<0.05; ** p<0.01; *** p<0.001.  
 
Figure 6. Expression of FKBP51 in human peripheral blood lymphocytes correlates with 
pGSK3β and the effects of lithium and PAR. PBMCs were collected from healthy male 
volunteers (N=20) and protein levels were determined in cell extracts by Western blotting. 
PBMCs were also cultivated ex vivo and treated with lithium (1mM), PAR (0.365 µM), VPA 
(1mM) or vehicle for 48 h and protein levels were determined in cell extracts by Western 
blotting. Change of pGSK3β/GSK3β was calculated from the comparison of drug treated cells 
with vehicle treated cells. Each dot represents the levels of the respective proteins in PBMCs 
from one individual. Average expression levels were set to 1. 
 
Figure 7. Correlation analysis of pGSK3β and its target tau with clinical treatment response. 
PBMCs were collected from depressive patients at the day of admission to the clinic (N=54). 
Protein concentrations in extracts were determined on a protein array and correlated to the 
change in Hamilton Depression Score.   
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Supplemental Material to Gassen et al., 
FKBP51 inhibits GSK3β and amplifies the effects of distinct psychoactive drugs 
 
LEGENDS TO SUPPLEMENTAL FIGURES 
Supplementary Figure 1. FKBP51 dependency of GSK3β pathways. The impact of FKBP51 
expression on pGSK3β, phosphorylation of the GSK3β target tau and level of the GSK3β 
target β-catenin. HEK cells were transfected with either control plasmid or two different 
amounts of FKBP51 or FKBP52 expressing plasmid (1.5 or 3 µg plasmid/ 107 cells), and the 
protein parameters were determined by Western blot. A, representative Western blots; B-E, 
graphs display the difference of protein phosphorylation or abundance in comparison to 
vector control as the relative mean expression + SEM of 3 different experiments. * p<0.05; ** 
p<0.01; *** p<0.001.  
 
 
 
MATERIALS AND METHODS 
Cell lines - Human embryonic kidney cells (HEK-293, ATCC CRL-1573) and mouse 
embryonic fibroblasts (MEFs) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco) supplemented with 10% FCS and 100 units/ml penicillin and streptomycin, 
respectively. FKBP51-/-, GSK3β-/-(kind gift of James Woodgett, Ontario Cancer Institute, 
Toronto, Canda) and Akt1/2-/- MEFs (kind gift of Nissim Hay, University of Illinois, Chicago, 
Illinois) have been described before1-3.   
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Primary cultures of rat astrocytes and neurons - Enriched astroglial cultures were prepared 
from postnatal day 1 rat pups (Sprague-Dawley, Charles River, Sulzfeld, Germany) and 
handled as described4-6.  
 
Transfection in MEF Fkbp51-/- cells, rat primary astrocytes and neurons – Afore 
detached MEF cells (2 x 106) were re-suspended in 100 µl transfection buffer (50 mM HEPES 
pH 7.3, 90 mM NaCl, 5 mM KCl, 0.15 mM CaCl2)7. A maximal amount of 5 µg plasmid 
DNA was added to the cell suspension, and electroporation was carried out using the Amaxa 
Nucleofactor system (program # T-020). For neurons, the rat neuron nucleofector kit was used 
(#VDP-1003). Cells were re-plated at a density of 105/cm2 and further processed for Western 
blot analysis.  
 
Preparation of human PBMCs – Blood of healthy male volunteers was collected via 
venipuncture, diluted with PBS and carefully loaded on Biocoll solution (1BioChrom AG, 
L6113) and centrifuged at 800 x g for 20 min (brakeless running down). PBMCs were 
enriched by selecting the interphase of the Biocoll gradient. PBMCs of the interphase were 
washed two times with ice-cold PBS. PBMCs were re-suspended in RPMI and plated at 
4x105/cm2. After recovery for 6 h, cells were treated with either, 190 µM (8 µg ml-1) lithium 
chloride, 694 µM (100 ng ml-1) VPA, 365 nM (120 ng ml-1) PAR. Concentrations had been 
chosen to match therapeutic concentrations in the serum according to the consensus 
guidelines for therapeutic drug monitoring in psychiatry8. 
 
Plasmids – FKBP51 deletion mutants were constructed using the pRK5-FKBP51 plasmid as 
template9. PCR was performed as described before9 with the following combination of 
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primers; dFK1,fwd5'-TCTCTCCACTCGAGATA TGAAAGGAGAGGATTTATTTG-3, rev 
5'-CTCTTCTTGCGGCCGCTCACTTGTCA 
TCGTCGTCCTTGTAGTCTACGTGGCCCTCAGGTTTCTC-3'; dFK1+FK2, fwd5'-
TCTCTCCA CTCGAGATA TGAAGGCCAAAGAATCCTGGG-3', rev 5'-
CTCTTCTTGCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTACGTGGCCC 
TCAGGTTTCTC-3'; FK1+FK2, fwd5'-TTCTTTCCA CTCGAGATA TGA CTA CTG ATG AAG 
G-3', rev. 5'-CTCTTCTT 
GCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTTCGAAGCTCTTAAGTGTAAC-3'; FK2, 
fwd5'-TCTCTCCACTCGAGATA TGAAAGGAGAGGATTTATTTG-3, rev 5'-CTCTTCTT 
GCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTTCGAAGCTCTTAAGTGTAAC-3'. All 
clones were checked by Sanger sequencing.  
Plasmids expressing TCF/LEF-Luc, CDK5-HAand FKBP52 have been described9-11.  
 
Reporter gene assays - Reporter gene experiments were carried out in 96-well formats. 
2*106cells were transfected with 1000 ng TCF/LEF-Luc, 100 ng pCMV-Gaussia-Luc and 
1000 ng pRK5-FKBP51/52-Flag -plasmid using Amaxa Nucleofactor system as described 
above. Drug treatment was usually for 48h as specified in the figure legends. To determine 
Firefly luciferase activity, cells were lysed in 50 µL passive lysis buffer (0.1 M KPO4 pH 7.8, 
0.2% Triton); addition of 50 µL of luciferase reaction buffer to a fraction of 10 µL of cell 
lysate (33 mM KHPO4, pH 7.8, 1.7 mM ATP, 3.3 mM MgCl2, and 13 mM luciferin) and 
luminometric readings were performed with an automatic counter (Tristar, Berthold). Activity 
of secretory Gaussia luciferase12 was measured after addition of  50 µL of substrate/buffer 
(1.1 M NaCl, 2.2 mM EDTA, 0.22 M KPO4 pH 5.1, 0.44 mg ml-1 BSA, and 0.5 mg ml-1 
coelenterazine). 
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Co-Immunoprecipitation(CoIP) - CoIP of FLAG-tagged FKBP51/52 mutants with endogenous 
GSK3β or endogenous CDK5 witwere performed in HEK-293 cells. 5×106 cells were electroporated 
with 5 µg of the respective expression plasmids using a GenePulser (Bio-Rad, USA) at 350 V/700 µF 
in 400 µl of electroporation buffer (50 mM K2HPO4/KH2PO4, 20 mM KAc, pH 7.35, 25 mM MgSO4). 
After three days of cultivation in DMEM/10% FCS, cells were lysed in CoIP-buffer containing 20 mM 
Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Igepal complemented with protease inhibitor 
cocktail (Sigma, P2714). This was followed by incubation on an overhead shaker for 20 min at 4 °C. 
The lysate was cleared by centrifugation, the protein concentration was determined, and 1.2 mg of 
lysate was incubated with 2.5 µg FLAG antibody overnight at 4 °C. 20 µl of BSA-blocked Protein G 
Dynabeads (Invitrogen, 100-03D) were added to the lysate–antibody mix followed by 3 h incubation 
at 4 °C. The beads were washed 3 times with PBS and protein-antibody complexes were eluted with 
100 µl of 1× FLAG-peptide solution (Sigma, 100–200 µg ml-1, F3290) in CoIP buffer for 30 min at 
4 °C. 5–15 µg of the cell lysates or 2.5 µl of the immunoprecipitates were separated by SDS-PAGE. 
 
Western Blot analysis – Protein extracts were obtained by lysing cells in 62.5 mM Tris, 2% 
SDS and 10% sucrose, supplemented with protease (Sigma , P2714) and phosphatase (Roche, 
04906837001) inhibitor cocktail. Samples were sonicated and heated at 95 ºC for 5 min. 
Proteins were separated by SDS-PAGE and electro-transferred onto nitrocellulose 
membranes. Blots were placed in Tris-buffered saline, supplemented with 0.05% Tween 
(Sigma, P2287) and 5% non-fat milk for 1 h at room temperature and then incubated with 
primary antibody (diluted in TBS/0.05% Tween) overnight at 4 ºC. The following primary 
antibodies were used: Beclin1 (1:1000, Cell Signaling, #3495), GSK3β (1:1000, Cell 
Signaling, #9315), LC3B-I/II (1:1000, Cell Signaling, #2775), FLAG (1:7000, Rockland, 
600-401-383), HA-HRP conjugated (1:25000, Roche, 11667475001), FKBP51 (1:1000, 
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Bethyl, A301-430A ), FKBP52 (1:2000, Bethyl, A301-427A), Akt (1:1000, Cell Signaling, 
#4691), pAkt (1:1000, Ser472, T308, 1:1000, Cell Signaling, #4058, #9275), pGSK3β 
(1:1000, Cell Signaling, #9323), PI3K Class III (Vps34, 1:1000, Cell Signaling, #4263), ptau 
(SS396; Abcam, #ab109390), ptau (S622; SCBT, #sc-16938), Actin (1:5000, Santa Cruz 
Biotechnologies, sc-1616). 
Subsequently, blots were washed and probed with the respective horseradish peroxidase- or 
fluorophore-conjugated secondary antibody for 1 h at room temperature. The immuno-
reactive bands were visualized either using ECL detection reagent (Millipore, Billerica, MA, 
USA, WBKL0500) or directly by excitation of the respective fluorophore. Determination of 
the band intensities were performed with BioRad, ChemiDoc MP, or X-ray-films 
 
Animals and animal housing – The Fkbp51 knockout (Fkbp51-/-) mouse line was previously 
generated1, 13 and fully backcrossed to C57/Bl6. Genotypes were verified by PCR of tail 
DNA. Only male mice were used for the experiment, obtained from heterozygous breeding 
pairs. Animals were between 10 and 16 weeks old at the start of the experiment. Mice were 
held under standard conditions (12L: 12D light cycle, lights on at 08:00 am, temperature 
23±2°C), were singly housed and acclimated to the room for one week before the beginning 
of the experiments. Food (Altromin 1314, Altromin GmbH, Germany) and tap water were 
available ad libitum.  
All experiments were carried out in the animal facilities of the Max Planck Institute of 
Psychiatry in Munich, Germany. The experiments were carried out in accordance with the 
European Communities' Council Directive 86/609/EEC. All efforts were made to minimize 
animal suffering during the experiments. The protocols were approved by the committee for 
the Care and Use of Laboratory animals of the Government of Upper Bavaria, Germany. 
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Animal treatments and behavioral experiments – All mice were injected intraperitoneally 
either with a single dose of lithium (85 mg kg-1; dissolved in saline; Sigma-Aldrich, 
Germany), paroxetine (10 mg kg-1; dissolved in saline; Sigma-Aldrich, Germany) or saline 
vehicle solution. The injection volume was 5 ml kg-1 body weight. 45 min after the injection, 
two subgroups of mice (first group: WT vehicle, n = 10; Fkbp51-/- vehicle, n = 9; WT lithium, 
n = 10; Fkbp51-/- lithium, n = 10; WT; second group: WT vehicle, n = 10; Fkbp51-/- vehicle, n 
= 9; WT paroxetine, n = 10; Fkbp51-/- paroxetine, n = 10; WT) were sacrificed by decapitation 
following quick anesthesia by isoflurane. Trunk blood was collected in 1.5 ml EDTA-coated 
microcentrifuge tubes (KabeLabortechnik, Germany) and kept on ice until further processing. 
Furthermore, brains were removed; hippocampus and prefrontal cortex were extracted and 
stored on dry ice until further processing. 
Another subgroup of mice (WT vehicle, n = 8; Fkbp51-/- vehicle, n = 8; WT lithium, n = 9; 
Fkbp51-/- lithium, n = 7) was subjected to a forced swim test (FST) 45 min after the injection. 
The FST was carried out between 9:00 am and 10:30 am in the same room in which the mice 
were housed and was analyzed using an automated video-tracking system (Anymaze 4.20, 
Stoelting, IL; USA). In the FST, each mouse was put into a 2 l glass beaker (diameter: 13 cm, 
height: 24 cm) filled with tap water (21 ± 1 °C) to a height of 15 cm, so that the mouse could 
not touch the bottom with its hind paws or tail. Testing duration was 6 min. Time spent 
immobile and time spent struggling was scored by an experienced observer, blind to genotype 
or treatment of the animals. 
 
GSK3β kinase activity 
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Determination of GSK3b kinase activity in the presence of lithium, paroxetine or vehicle was 
performed following a published protocol14.    
 
Statistical analysis 
All statistical analyses were performed with SPSS 16.0. When two groups were compared, the 
student’s t-test was applied. For three or more group comparisons, one-way or two-way 
analysis of variance (ANOVA) was performed, followed by Tukey’s post-hoc test, as 
appropriate. All ANOVA F and p values are reported in supplementary table 1; significant 
results of the contrast tests are indicated by asterisks in the graphs. Protein-protein 
associations were analyzed using the Pearson correlation coefficient. P values of less than 
0.05 were considered significant. 
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Abstract 
 
Clinical studies established a genetic link between the cochaperone FKBP51 and 
antidepressant (AD) response in mood disorders while the underlying mechanisms remain 
elusive. We provide first in vitro and in vivo evidence for a role of FKBP51 in priming Akt-
dependent pathways for AD action on neuronal function and behavior. We found that 
inhibition of Akt by FKBP51 is followed by Akt-downstream cascades triggering activation 
of FoxO3a, inhibition of mTOR, and induction of autophagy markers. ADs modulate these 
pathways in a similar fashion; intriguingly, these AD effects are blunted in Fkbp51-/- cells and 
mice. Likewise, ADs’ impact on neuronal function and on behavior is abolished in Fkbp51-/- 
mice. In human blood cells, the FKBP51 expression status strongly correlates with the 
potential of ADs to act on the respective pathways. Together, these findings provide a 
functional link between ADs and FKBP51, the latter sensitizing the organism for AD actions.  
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Introduction 
FK506 binding protein 51 (FKBP51) is a regulator of the glucocorticoid receptor, and 
consequently of the stress hormone axis and stress physiology 1-5. In addition, human genetic 
studies link FKBP51 to the antidepressant response rate 6-9. Despite the intimate connection of 
stress physiology to pathophysiology and treatment of depression10, 11, the mechanistic role of 
FKBP51for antidepressant response has remained enigmatic.  
Convergent molecular pathways addressed by both FKBP51 and antidepressants could 
explain the impact of FKBP51 on antidepressant response; modulation of these pathways by 
FKBP51 could thus influence their reactivity towards antidepressants. The hypothesis that 
these pathways involve Akt and downstream autophagic events is derived from two 
observations: some antidepressants modulate Akt12, 13 as well as autophagy14-17 and FKBP51 
inhibits Akt18. This protein kinase exhibits interdependency with mTOR (mammalian target 
of rapamycin) and thereby affects autophagy19-24. Very recently, also an mTOR-independent 
effect of Akt on autophagy has been found by direct phosphorylation of Beclin125. 
Autophagy is a conserved cellular degradation process ensuring continuous removal of 
damaged macromolecules and thus functional integrity of cells and tissues26. Different types 
of autophagy are described in the literature27. Macroautophagy involves the step-wise 
formation of an autophagosome engulfing damaged organelles or proteins and subsequent 
fusion with a lysosome yielding the autolysosome. This process is orchestrated by a series of 
autophagy-related genes (Atg) and is regulated by complex pathways, which are partly under 
control of the mTOR kinase28, 29. Corresponding to this multitude of involved factors, 
experimental evaluation of autophagy is usually based on the determination of several 
markers. These include, but are not limited to, lipidation of LC3B-I (yielding LC3B-II), 
Atg12, Beclin1 and Vps34 (class III phosphatidylinositol-3-kinase). Chaperone-mediated 
autophagy is a more recently characterized selective type of autophagy; distinct proteins are 
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identified by chaperones, directed to lysosomes, unfolded and translocated to the inside of 
lysosomes30. 
As guardian of cellular homeostasis, autophagy is a pivotal process in a range of (patho-) 
physiological conditions including infectious diseases, cancer, and diabetes, and recently also 
neurotransmission and neurodegeneration31-34. Indirect evidence has been provided for a role 
of autophagy in depression: some antidepressants change the autophagic flux and the 
expression of autophagy markers14-17. Moreover, induction of autophagy by the mTOR 
inhibitor rapamycin was reported to exert antidepressant-like effects in mice35.  
In this study, we characterized the physical and functional interaction of FKBP51 with Akt, 
tested whether this interaction impacts on downstream signaling events and markers of 
autophagy, and evaluated convergent, FKBP51-dependent molecular actions of 
antidepressants on signaling pathways, neuronal function and behavior in life cells, mice and 
humans.  
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Results 
Identification of FKBP51-Akt directed pathways and downstream autophagy 
As candidate mechanism for convergent actions of antidepressants and FKBP51, we first 
characterized the reported effect FKBP51 on the protein kinase Akt18. A series of FKBP51 
deletion and point mutant constructs as well as the close homologue FKBP52 were expressed 
in HEK cells to assess their interaction with Akt or the Akt-targeting phosphatase PHLPP by 
co-immunoprecipitation (Fig. 1A and B, suppl. Fig. 1A). While FKBP51 interacted with both 
Akt and PHLPP18, FKBP52 only coprecipitated Akt. The interaction of FKBP51 with both 
Akt1 and PHLPP required the peptidylprolylisomerase (PPIase) domain (FK1) of FKBP51, 
but not the enzymatic PPIase activity of this domain (“51PPImut”). These protein interactions 
did also not require Hsp90 binding of FKBP51 (“Hsp90mut”, Fig. 1A and B, suppl. Fig. 1A).  
To monitor potential functional consequences of these interactions between FKBP51/52 and 
Akt, we first determined two indicators of Akt activity, i.e. phosphorylation of Akt (S473 on 
Akt1) and transcriptional activity of FoxO3a. Phosphorylation of Akt at S473 is required for 
enhanced kinase activity, while phosphorylation at threonine 308 is needed for basal activity. 
FoxO3a is a forkhead transcription factor which is inhibited by phosphorylation through Akt 
at serine 31836. De-phosphorylation of Akt (S473 on Akt1) was only induced by ectopic 
expression of FKBP51, but not by FKBP52 (Fig. 1A, suppl. Fig. 1B and C). Phosphorylation 
of Akt at threonine 308, which is not known as target of PHLPP, remained unchanged under 
all conditions (suppl. Fig. 1C). The decrease of pFoxO3a paralleled the decrease of pAkt 
(S473). In addition, only those mutants of FKBP51 that interacted with both Akt and PHLPP 
also affected phosphorylation of Akt (S473) and FoxO3a (Fig. 1A). These findings support 
the model that FKBP51, but not FKBP52, recruits PHLPP to Akt through its PPIase domain 
leading to PHLPP-catalyzed de-phosphorylation of Akt (cf. also Fig. 8).  
To assess whether the FKBP51-induced decrease of FoxO3a phosphorylation goes along with 
altered transcriptional activity of FoxO3a, we performed reporter gene assays in HEK cells. 
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Transient transfection of either FKBP51 or FKBP52 encoding plasmids in HEK cells revealed 
a dose-dependent stimulation of FoxO3a-driven reporter gene activity by FKBP51, whereas 
FKBP52 exerted no or even a mild inhibitory effect (Fig. 1C, suppl. Fig. 1D). 
As potential further consequences of FKBP51-triggered inhibition of Akt we analyzed the 
impact of FKBP51 on autophagic pathways; Akt and the linked mTOR kinase are key 
regulators of genes involved in autophagy37, 38. Comparing FKBP51-/- and wild-type 
(FKBP51+/+) mouse embryonic fibroblasts (MEFs), we found that MEFs lacking FKBP51 not 
only displayed higher levels of Akt phosphorylation (S473), but also higher phosphorylation 
levels of two downstream targets of mTOR (pp70S6K, p4E-BP1, Fig. 2A and suppl. Fig. 2A). 
This indicates an overall increased mTOR activity in FKBP51-deficient MEFs. Since mTOR 
inhibits autophagy pathways, we also determined the expression of three major markers of 
autophagy. Protein levels of Beclin1, LC3B-II/I and Atg12 were indeed reduced in FKBP51-/- 
MEFs (Fig. 2A). These effects of FKBP51 gene deletion were attenuated by ectopic 
expression of FKBP51 in FKBP51-/- MEFs (Fig. 2A and suppl. Fig. 2A). Together, the data 
corroborate a stimulatory role of FKBP51 on autophagy pathways.  
Given that FKBP51 acts on a variety of intracellular proteins, it was important to test whether 
the effects of FKBP51 on autophagy pathways require Akt. We used Akt1/2-/- MEFs to 
evaluate FKBP51’s ability to affect expression of autophagy markers. In wild-type MEFs, 
transfection of FKBP51 decreased the phosphorylation levels of the two downstream targets 
of the Akt-mTOR pathway, pp70S6K and p4E-BP1, and increased the levels of the autophagy 
markers Beclin1 and LC3B-II/I (Fig. 2B and suppl. Fig. 2B). These effects of FKBP51 were 
not observed in Akt1/2-/- MEFs, but were restored after reintroducing Akt1 and Akt2 into 
Akt1/2-/- by transient transfection (Fig. 2B and suppl. Fig. 2B). We conclude that the impact 
of FKBP51 on autophagy markers requires Akt1 and/or Akt2 (cf. also Fig. 8).   
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Cellular effects of antidepressants depend on FKBP51 
Since FKBP51 has been linked to the pharmacological responsiveness to antidepressants 
(ADs) in clinical genetic studies6, 39, potential convergent effects of ADs and FKBP51 were 
analyzed. Both, decrease and increase of pAkt by ADs has been reported to date12, 13, and 
modulation of autophagy pathways has been found for several ADs14-17. We used reporter 
gene assays recording the transcriptional activity of the Akt target FoxO3a in primary rat 
astrocytes. As observed in HEK cells (Fig. 1C), cotransfection of FKBP51 increased the 
activity of FoxO3a (Fig. 3A, suppl. Fig. 3A). Treatment with the ADs paroxetine (PAR), 
amitriptyline (AMI) or fluoxetine (FLX, all at 10 µM that proved sufficient for induction of 
autophagy markers15) stimulated reporter gene activity by a factor of ~1.5; concomitant 
overexpression of FKBP51 augmented reporter activity by ~2-fold (Fig. 3A, suppl. Figs 3 A 
and B). Analysis of the phosphorylation status of Akt indicated that FKBP51 and ADs act 
synergistically to reduce pAkt in primary astrocytes (Fig. 3B, suppl.  Figs. 3C and D). 
The importance of FKBP51 for AD effects on the Akt-autophagy pathway was further 
evaluated in FKBP51-/- and Akt1/2-/- MEFs. The ADs PAR, AMI and FLX reduced 
phosphorylation of Akt in FKBP51+/+, but not in FKBP51-/- MEFs; ectopic expression of 
FKBP51 in FKBP51-/- MEFs restored the effect of ADs on Akt phosphorylation (Fig. 3C, 
suppl. Figs 3E and F). The autophagy marker LC3BII/I was elevated upon AD treatment in 
FKBP51+/+ MEF cells (Fig. 3D, suppl. Figs. 3E and G), as reported previously for astrocytes15. 
This AD effect was blunted in FKBP51-/- MEFs, and restored when FKBP51 was ectopically 
expressed in these cells (Fig. 3D, suppl. Figs. 3E and G). In Akt1/2-/- MEFs, AD exposure did 
not induce changes in LC3B-II/I levels (suppl. Figs. 3H and I). When Akt1 and Akt2 were re-
introduced by ectopic expression, the effects of ADs re-emerged.  
In addition to the conversion of LC3B-I to LC3B-II, the shift of LC3B-II from cytoskeletal to 
autophagosomal compartments is also a major hallmark of autophagy induction. Therefore, 
the influence of FKBP51 on the capability of ADs to change the distribution of recombinant 
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GFP-LC3B was monitored in primary cortical astrocytes. Ectopically expressed FKBP51 
enhanced AD-induced clustering of GFP-LC3B (Fig. 3E and F, suppl. Figs. 3J and K). Also 
in the absence of ADs, FKBP51 triggered the formation of GFP-LC3B positive puncta, 
although to a lesser extent. FKBP51 also enhanced the ability of ADs to induce conversion 
from LC3B-I to LC3B-II and to elevate Beclin1 and ATG12 levels in astrocytes (Figs. 3G-I, 
suppl. Figs. 3C and L-N). Collectively, these data support the conclusion that cellular AD 
effects on autophagy pathways depend on FKBP51. 
 
Effects of paroxetine in mice depend on FKBP51 
To assess whether FKBP51 also modulates AD response in vivo, we treated FKBP51+/+ and 
FKBP51-/- mice with PAR. Protein extracts from hippocampus and prefrontal cortex showed 
brain region and genotype dependent responses to PAR. In FKBP51+/+ mice, PAR treatment 
(10 mg kg-1) evoked de-phosphorylation of Akt, and increased the levels of Beclin1, LC3B-
II/I, Atg12 and Vps34. In contrast, FKBP51-/- mice revealed no alterations in protein levels of 
phosphorylated Akt and autophagy markers in either brain region after PAR treatment (Fig. 
4A-E, suppl. Figs. 4A and B).  
To test whether also the behavioral efficacy of ADs depends on the FKBP51 expression status, 
we employed a well-established test for AD action; FKBP51-/- mice were subjected to a 
forced swim test to monitor the animals’ response to an acute PAR injection. PAR-treated 
FKBP51+/+ mice spent less time floating (immobility) compared to vehicle-treated FKBP51+/+ 
mice, thus exhibiting the expected response to ADs. In contrast, the effect of PAR was 
significantly less pronounced in FKBP51-/- mice (Fig. 4F right). Similarly, PAR treatment led 
to an increase in the time spent struggling in FKBP51+/+ mice compared to vehicle-treated 
FKBP51+/+ mice, while this effect of PAR was again significantly attenuated in FKBP51-/- 
mice (Fig. 4F left).  
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Since autophagy has been linked to neurotransmission, we also tested whether FKBP51 
changes the effect of PAR on neuronal function as a physiological correlate of behavior40. We 
electrically stimulated hippocampal CA3-CA1 synapses in brain slices from FKBP51+/+ and 
FKBP51-/- mice and monitored CA1 neuronal activity by means of voltage-sensitive dye 
imaging (VSDI)41-43. This approach was chosen for two reasons: first, the CA1 area is an 
important output subfield of the hippocampus, which has been implicated in the 
pathophysiology of depression and in antidepressant action44, 45. Second, we considered 
potential heterogeneity of the PAR effect at CA3-CA1 synapses; thus, VSDI measurement of 
neuronal activity in a larger portion of CA1 appeared more promising than the typically more 
restricted electrode recording techniques. In slices from FKBP51+/+ mice, bath application of 
PAR (10 µM) enhanced ‘region of interest’ (ROI)-extracted fast, depolarization-mediated 
imaging signals (FDSs), which reflect excitatory postsynaptic potentials as well as neuronal 
action potentials42, 43. This effect was not observed in slices from FKBP51-/- animals (Fig. 5). 
 
Effects of antidepressants in human blood cells depend on FKBP51 
Finally, we tested whether the link between FKBP51 expression status and AD response of 
autophagy markers also exists in human peripheral blood mononuclear cells (PBMCs). 
PBMCs derived from healthy male volunteers showed marked variations in basal FKBP51 
expression (Fig. 6). The FKBP51 expression level was negatively correlated with the 
phosphorylation status of Akt and positively correlated with the autophagy markers Beclin1 
and Atg12 (Figs. 6B, C and E); LC3B-II/I displayed a weak correlation with FKBP51 protein 
levels, while no significant correlation was found for Vps34 (Figs. 6D and F).  
In addition, PBMCs derived from healthy male volunteers were also cultivated ex vivo and 
treated with the ADs AMI, FLX and PAR for 72 h. To more closely mimic the clinically 
relevant in vivo conditions, drug concentrations were chosen according to the results of 
therapeutic drug monitoring in psychiatry46. The extent of de-phosphorylation of Akt and 
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change of LC3B-II/I ratio and levels of Beclin1 in response to ADs correlated with the 
expression level of FKBP51 (Fig. 7, suppl. Fig. 5). Higher expression of FKBP51 was 
associated with AD-induced de-phosphorylation of Akt, while low expression of FKBP51 
was associated with AD-induced Akt phosphorylation. For Beclin1, a gradual shift from 
slightly inhibitory to stimulatory effects of ADs was observed with increasing FKBP51 levels. 
AD-triggered lipidation of LC3B-I was positively correlated with the FKBP51 expression 
status. Atg12 expression was not significantly changed by AMI and FLX, while PAR affected 
Atg12 expression in an FKBP51-dependent fashion similarly to Beclin1.  
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Discussion 
FKBP51 has originally been selected as candidate for genetic analyses in depression and AD 
responsiveness6, because it is involved in the regulation of the glucocorticoid receptor5, and 
thereby the stress hormone axis47. Our study brings novel FKBP51-directed pathways to the 
fore (summarized in Fig. 8) and establishes the importance of FKBP51 in AD action on the 
molecular, cellular and organismic level. Our data are in line with the observation that the 
FKBP51 genotype associated with faster AD treatment response is also linked to higher 
expression levels of FKBP516. 
Akt has been reported as target of AD action before, and both positive and negative changes 
of pAkt levels have been found for different ADs in different cellular systems12, 13, 48-54. Based 
on our in vitro and in vivo findings, we propose that the FKBP51 expression status determines 
whether and how antidepressants alter Akt phosphorylation; thus, variations in FKBP51 
expression might be the underlying cause for the differences in AD effects on Akt.  In general, 
phosphorylation of Akt is under multifactorial control55 that could be the basis for both 
inhibitory and FKBP51-dependent stimulatory actions of antidepressants. 
Considering the AD relevant mechanism of action of FKBP51, our protein interaction 
analyses support the concept of FKBP51 as scaffolding protein that recruits PHLPP to Akt18. 
Mapping of the interaction revealed the FK1 domain as major mediator of the interaction to 
both Akt and PHLPP. Thus, the impact of FKBP51 on Akt constitutes an Hsp90-independent 
activity. Hsp90-independent actions of FKBP51 are not without precedence, as intrinsic 
chaperone activity has been ascribed to FKBP5156. Of note, Hsp90 itself is also involved in 
the regulation of Akt phosphorylation; inhibition of complex formation between Akt and 
Hsp90 has been shown to promote de-phosphorylation of Akt through PP2A57 that acts on 
threonine 30858. Our analyses also showed that FKBP52 is interacting with Akt, but not with 
PHLPP2; accordingly, FKBP52 did not change Akt phosphorylation. Divergent actions of 
FKBP51 and FKBP52 have also been observed for neurite outgrowth59, regulation of 
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microtubules60, 61 and control of the corticosteroid receptors5, 62. Intriguingly, the FK1 domain 
has been identified to be crucial for the differential effects on the glucocorticoid receptor5, 63, 
while the enzymatic PPIase activity of FKBP51 was not required for the inhibitory effect5. 
These data collectively raise the possibility that the most relevant function of the FK1 domain 
of FKBP51, and potentially other PPIase domains, is the establishment of protein-protein 
interactions, rather than execution of isomerization of peptidylprolyl bonds.  
The here established impact of FKBP51 on markers of autophagy significantly expands the 
range of actions of this versatile protein. Since FKBP51 is regulated by glucocorticoids64,65, 
this pathway might link physiological stress to autophagy. In fact, it has been reported that the 
synthetic glucocorticoid dexamethasone induces de-phosphorylation of Akt (serine 473 in 
Akt1) and autophagy66, 67. Impacting autophagy potentially has far reaching cellular and 
physiological consequences26. For example, lower body mass has been reported as one of the 
consequences of genetically blocking autophagy68, 69. Thus, it is possible that the lack of 
autophagy-promoting actions of FKBP51 in FKBP51-/- mice at least partially accounts for the 
lower body weight of the FKBP51-/- versus FKBP51+/+ animals4.   
In light of the still unknown molecular mechanism by which ADs exactly act, our results 
strengthen the view that the achievement of a complete understanding requires the 
investigation of intracellular AD effects to complement the known actions on mono-aminergic 
neurotransmitter systems70. In general, it is not possible to unequivocally predict complex 
behavior from distinct cellular events. Nevertheless, a link has been discovered from 
autophagy to neurotransmission71. Thus, it is plausible that FKBP51-governed autophagy 
pathways underlie also the here described FKBP51 dependency of PAR’s effect on neuronal 
activity in the hippocampus. Furthermore, neuronal circuit dynamics in the hippocampus are 
linked to behavior in an animal model of depression45. This provides supporting evidence that 
the FKBP51 dependency of PAR’s impact on behavior is related to effects on the 
electrophysiological level and the underlying pathways.  
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While genetic studies of complex diseases, including studies on respective drug actions, have 
significantly benefitted from the advanced technologies of genome-wide genotyping, the 
necessity of complementary approaches such as molecular pathway and network analyses to 
move from genomic localization to mechanistic insight has come into focus more recently72, 73. 
Our finding of FKBP51-dependent effects of ADs on intracellular pathways strengthens the 
relevance of the genetic association of FKBP51 with AD response and provides substantial 
information for more targeted genetic studies. In addition, our results suggest considering 
autophagy mechanisms as pharmacological target to improve treatment of depression, as 
discussed for other diseases very recently31 .  
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Figure Legends 
 
Figure 1. Functional interaction of Akt and PHLPP with FKBP51. A, constructs used in the 
interaction analyses. FK, FK506 binding domain; FL, full length. “PPIaseMut” denotes the 
F67V/D68V mutation destroying PPIase activity; “Hsp90Mut” denotes the K352A/R356A 
mutation in the tetratricopeptide repeat (TPR) domain abolishing interaction with Hsp90. 
HEK cells were transiently transfected with the plasmids encoding the listed FKBP constructs, 
all fused to a Flag-tag. Precipitation of protein complexes was performed using magnetic 
protein G beads conjugated ta a Flag-antibody and (co)precipitated proteins were visualized 
by Western blot and quantified (details in Suppl. Fig. 1). Tables summarize the results of 3 
independent experiments (3 technical replicates of the Western blots of each experiment) 
analyzing the interaction of the FKBPs with Akt1 and PHLPP2 (left) and the change of 
phosphorylation of Akt (S473 in Akt1) and the Akt target FoxO3a (S318) (right). ++ strong 
interaction, + weak interaction, - interaction not detectable. ↓↓ strong decrease, ↓ weak 
decrease, - no change. B, representative Western blots of the interaction analyses. Numbers 
correspond to the constructs listed in A. C, The functional effect of FKBP-governed 
differential FoxO3a phosphorylation was assessed by FoxO3a-driven reporter gene analysis in 
HEK cells transiently overexpressing increasing amounts of full-length FKBP51 or 52. 
Expression efficiency was controlled by Western blot analysis (right panel). Relative reporter 
activity is given in arbitrary units reflecting the mean +/- SEM of three independent 
experiments performed in triplicate. * p<0.05; *** p<0.001, statistical details in suppl. Fig. 1. 
 
Figure 2. FKBP51 dependency of Akt pathways. A, The impact of the FKBP51 expression 
status on the levels of pp70S6K, p4E-BP1, pAKT1 (S473), Beclin1, LC3B-II/I, and Atg12 
was assessed by Western blot analysis in FKBP51+/+ MEFs, FKBP51-/- MEFs, and FKBP51-/- 
MEFs transfected with an FKBP51 expressing plasmid. Graphs show the relative mean 
expression + SEM of 4 different experiments; expression in FKBP51+/+ MEFs was set to 1. B, 
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the dependency of FKBP51’s impact on the expression of pp70S6K, p4W-BP1, Beclin1, and 
LC3B-II/I was evaluated in Akt1/2+/+ MEFs, Akt1/2-/- MEFs and in Akt1/2-/- MEFs 
transfected with Akt1 and Akt2 expressing plasmids. Graphs display pairwise comparisons of 
cells cotransfected with vector or FKBP51 expressing plasmid and represent the relative mean 
expression + SEM of 3 different experiments; expression in Akt1/2+/+, vector-transfected 
MEFs was set to 1. * p<0.05; ** p<0.01; *** p<0.001. See suppl. Table 1 for all statistical 
parameters.  
 
Figure 3. FKBP51 enhances antidepressants’ effects in cells. A, primary rat cortical 
astrocytes were transfected with a FoxO3a-driven reporter plasmid in combination with an 
FKBP51 expressing vector or control vector. Treatment with PAR (10 µM) was for 48 h. Bars 
represent the mean + SEM of 3 independent experiments performed in triplicate; reporter 
activity in untreated, control-transfected cells was set to 1. B, primary rat astrocytes were 
transfected with an FKBP51 expressing vector or control vector, treated with PAR (10 µM) 
for 48 h, and the pAkt/Akt ratio was determined by Western blot. Bars represent the mean + 
SEM of 3 independent experiments performed in triplicate. pAkt/Akt in untreated, control-
transfected cells was set to 1. C, D, FKBP51+/+, FKBP51-/- and FKBP51-/- MEFs transfected 
with an FKBP51 expressing plasmid were treated with PAR (10 µM) for 48 h, and the 
pAkt/Akt (C) and LC3B-II/I (D) ratios were determined by Western blot. Bars represent the 
mean + SEM of 3 independent experiments performed in triplicate. Protein levels in 
FKBP51+/+, untreated cells were set to 1. E, primary rat cortical astrocytes were transfected 
with a vector expressing GFP-LC3B, in combination with an FKBP51 expressing vector or 
cloning vector, and treated with PAR (10 µM) for 48 h. The number of GFP-LC3B positive 
puncta was determined per cell. 15-25 randomly selected cells were evaluated for each 
condition. F, representative fluorescence images of E. G-I, cortical astrocytes were 
transfected and treated as in B and LC3B-II/I Beclin1 levels were determined by Western 
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blotting. Bars represent the mean + SEM of 3 independent experiments performed in triplicate. 
Protein levels in wild-type, untreated cells were set to 1. * p<0.05; ** p<0.01; *** p<0.001. 
See suppl. Table 1 for all statistical parameters. 
 
Figure 4. FKBP51 determines the effect of PAR in mice. A-E, FKBP51-/- and FKBP51+/+ 
mice were treated with PAR (10 mg kg-1) or vehicle and sacrificed 45 mins later. Levels of 
the indicated proteins were determined by Western blotting in extracts of the hippocampus 
and the prefrontal cortex from 9-10 animals in technical triplicates. F, FKBP51-/- and 
FKBP51+/+ mice were treated with PAR or vehicle and subjected to the forced swim test 
(N = 7-9 per group). Graphs show the times of immobility and struggling. See suppl. Table 1 
for all statistical parameters. * p<0.05; ** p<0.01; *** p<0.001. See suppl. Table 1 for all 
statistical parameters. 
 
Figure 5. The effect of PAR on evoked CA1 neuronal activity depends on FKBP51. A, Left, 
illustration of the position of the stimulation electrode (Stim) and ROI used for the calculation 
of CA1 neuronal population activity. Right, depolarization-mediated VSDI signal recorded 
11 ms after the electrical stimulation pulse. Warmer colors represent higher values of the 
fractional change in fluorescence (ΔF/F) and, thus, stronger neuronal activity. B, Left, 
quantification of PAR’s effects on CA1 FDSs (N= 10 slices from 4 mice for each group). *  
p = 0.032 (paired t-test); n.s., p = 0.912 (paired t-test); data are given as mean ± SEM. Right, 
representative recording traces illustrating the PAR effects on CA1 FDSs.  
 
Figure 6. Expression of FKBP51 in human peripheral blood lymphocytes varies and 
correlates with pAkt-autophagy pathway components. Peripheral blood mononuclear 
lymphocytes were collected from healthy male volunteers (N=20) and protein levels were 
determined in cell extracts by Western blotting (example blot shown in A). Plots display the 
17 
 
correlation between the levels of FKBP51 and pAkt (S473), Beclin1, LC3B-II/I, Atg12 or 
Vps34. Each dot represents the levels of FKBP51 and the respective protein in PBMCs from 
one individual. Average expression levels were set to 1. 
 
Figure 7. The effects of antidepressants in human peripheral blood lymphocytes correlate 
with the expression level of FKBP51. Peripheral blood mononuclear cells were collected from 
healthy male volunteers (N=20), cultivated ex vivo and treated with AMI (0.888 µM), FLX 
(1.695 µM) or PAR (0.365 µM) for 48 h. The levels of FKBP51, pAkt (S473), Beclin1, 
LC3B-II/I, and Atg12 were determined by Western blots. Plots depict the change in protein 
levels upon treatment with AD compared to vehicle-treated cells in correlation to the 
expression level of FKBP51. Each dot represents the levels of FKBP51 and the change of the 
levels of the respective protein in PBMCs from one individual determined in treated and 
untreated cells. 
 
Figure 8. Model of FKBP51‘s impact on Akt, mTOR and autophagy pathways. A, through its 
PPIase domain (FK1), FKBP51, but not FKBP52, recruits PHLPP to Akt, thereby inactivating 
Akt through de-phosphorylation (S473 in Akt1). Inhibition of Akt removes its inhibitory 
action on FoxO3a (B) and abolishes the stimulatory effect on mTOR (C). The resulting loss 
of mTOR activity leads to reduced phosphorylation of p70S6K (D) or 4E-BP1 (E), 
respectively; it also removes the suppressive effect of mTOR on autophagy (F), indicated by 
the increase of several markers. Antidepressants act on the same pathways in an FKBP51-
dependent manner.  
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LEGENDS TO SUPPLEMENTAL FIGURES 
Suppl. Figure 1. Summary of data of the functional interaction of Akt and PHLPP with 
FKBP51. A, HEK cells were transiently transfected with the plasmids encoding the FKBP 
constructs listed in figure 1 and analyses of interaction with Akt, PHLPP, and Hsp90 were 
performed by co-immunoprecipitation and Western blot analysis. Interaction with wild-type 
full-length FKBP51 was set to 1 for all interactions and served as reference for interaction 
with the other FKBP isoforms. The table summarizes the results of 3 independent co-
immunoprecipitations with 3 technical replicates of the respective Western blots. Numbers 
indicate relative intensity of interacting proteins, including p-values of interaction differences 
(compared to full-length wt FKBP51). B, representative Western blots for Figure 1A, change 
of pAkt and pFoxO3a. The FKBP proteins were detected by an antibody directed against their 
FLAG tags. C, summary of the numeric results of the effect of FKBP51 expression in HEK 
cells on the phosphorylation status of Akt1 and FoxO3a (corresponding to Fig. 1A). Numbers 
reflect the results of 3 independent experiments with 3 technical replicates of the respective 
Western blots. Numbers indicate the phosphorylation level of Akt1 or FoxO3a (normalized to 
the Western signal of the respective total protein), with the level of vector-transfected cells 
(mutant “-”) set to 1, including p-values of phosphorylation changes. p-values < 0.05 are 
underlined in A and C. D, List of p-values corresponding to Fig. 1C. 
 
Suppl. Figure 2 Cellular effects of FKBP51 require Akt1 or Akt2. Representative Western 
blots documenting the impact of FKBP51 on pp70S6K, p4W-BP1, pAKT (S473), Beclin1, 
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LC3B-II/I, and Atg12. Examples correspond to figures 2A and B of the main text. See suppl. 
Table 1 for all statistical parameters. 
 
Suppl. Figure 3. Convergent effects of FKBP51 and antidepressants. A and B, primary rat 
cortical astrocytes were transfected with a FoxO3a-driven reporter plasmid in combination 
with an FKBP51 expressing vector or control vector and treated with AMI, FLX or PAR 
(10 µM each) for 48 h. Representative Western is shown (A). Bars represent the mean + SEM 
of 3 independent experiments performed in triplicate (B); reporter activity in untreated, 
control-transfected cells was set to 1. C, D, L-N, cortical astrocytes were transfected and 
treated as in A,B and levels of pAkt/Akt (D), Beclin1 (L), LC3B-II/I (M) and Atg12 (N) were 
determined by Western blotting (representative blot in C). Bars represent the mean + SEM of 
3 independent experiments performed in triplicate. Protein levels in wild-type, untreated cells 
were set to 1. E-G, FKBP51+/+, FKBP51-/- and FKBP51-/- MEFs transfected with an FKBP51 
expressing plasmid were treated AMI, FLX or PAR (10 µM each) for 48 h, and the 
pAkt1(S473)/Akt1 (F) and LC3B-II/I (G) ratios were determined by Western blot 
(representative blot shown in E). Bars represent the mean + SEM of 3 independent 
experiments performed in triplicate. Protein levels in FKBP51+/+, untreated cells were set to 1. 
H-I, Akt1/2+/+ MEFs, Akt1/2-/- MEFs and in Akt1/2-/- MEFs transfected with Akt1 and Akt2 
expressing plasmids were treated with AMI, FLX or PAR (10 µM each) for 48 h. The ratio of 
LC3B-II/I was determined by Western blot (representative example in H). Bars represent the 
mean + SEM of 3 independent experiments performed in triplicate. LC3B-II/I in the 
respective untreated cells was set to 1 (dotted line). J and K, primary rat cortical astrocytes 
were transfected with a vector expressing GFP-LC3B, in combination with an FKBP51 
expressing vector or cloning vector, and treated with AMI or FLX (10 µM each)  for 48 h. 
The number of GFP-LC3B positive puncta was determined per cell. 15-25 randomly selected 
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cells were evaluated for each condition. K, representative fluorescence images of J. * p<0.05; 
** p<0.01; *** p<0.001. See suppl. Table 1 for all statistical parameters. 
 
Suppl. Figure 4. The effect of paroxetine in mice depends on FKBP51. FKBP51-/- and wild-
type mice were treated with PAR or vehicle and sacrificed 45 mins later. A, B, representative 
Western blots to figure 4 of the main text.  
 
Suppl. Figure 5. Representative Western of extracts from antidepressant-treated peripheral 
blood mononuclear lymphocytes (corresponding to figure 7 of the main text).  
 
Suppl. Table. Details of results of statistical analyses. NS, non significant.  
 
 
 
MATERIALS AND METHODS 
Cell lines - Human embryonic kidney cells (HEK-293, ATCC CRL-1573) and mouse 
embryonic fibroblasts (MEFs) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco) supplemented with 10% FCS and 100 units/ml penicillin and streptomycin, 
respectively. FKBP51-/- and Akt1/2-/- MEFs (kind gift of Nissim Hay, University of Illinois, 
Chicago, Illinois) have been described before1, 2.   
 
4 
 
Primary cultures of murine astrocytes - Enriched astroglial cultures were prepared from 
postnatal day 1 rat pups (Sprague-Dawley, Charles River, Sulzfeld, Germany) and handled as 
described3, 4.  
 
FKBP51 Rescue in MEF Fkbp51-/- cells – Afore detached MEF cells (2 x 106) were re-
suspended in 100 µl transfection buffer (50 mM HEPES pH 7.3, 90 mM NaCl, 5 mM KCl, 
0.15 mM CaCl2)5. A maximal amount of 5 µg plasmid DNA was added to the cell suspension, 
and electroporation was carried out using the Amaxa Nucleofactor system (program # T-020). 
Cells were re-plated at a density of 105/cm2 and further processed for Western blot analysis.  
Analysis of GFP-LC3 in astrocytes - 2*106cells were transfected with 2 ng GFP-LC3 
expressing plasmid or the respective cloning vector using Amaxa Nucleofactor system as 
described above. Cells were grown for 48h and analyzed by fluorescence microscopy.  At 
least 20 cells were counted. 
Preparation of human PBMCs – Blood of healthy male volunteers was collected via 
venipuncture, diluted with PBS and carefully loaded on Biocoll solution (1BioChrom AG, 
L6113) and centrifuged at 800 x g for 20 min (brakeless running down). PBMCs were 
enriched by selecting the interphase of the Biocoll gradient. PBMCs of the interphase were 
washed two times with ice-cold PBS. PBMCs were re-suspended in RPMI and plated at 
4x105/cm2. After recovery for 6 h, cells were treated with either 888 nM (120 ng ml-1) AMI, 
1695 nM (500 ng ml-1) FLX, 365 nM (120 ng ml-1) PAR. Concentrations had been chosen to 
match therapeutic concentrations in the serum according to the consensus guidelines for 
therapeutic drug monitoring in psychiatry6. 
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Plasmids – FKBP51 deletion mutants were constructed using the pRK5-FKBP51 plasmid as 
template7. PCR was performed as described before7 with the following combination of 
primers; dFK1,fwd5'-TCTCTCCACTCGAGATA TGAAAGGAGAGGATTTATTTG-3, rev 
5'-CTCTTCTTGCGGCCGCTCACTTGTCA 
TCGTCGTCCTTGTAGTCTACGTGGCCCTCAGGTTTCTC-3'; dFK1+FK2, fwd5'-
TCTCTCCA CTCGAGATA TGAAGGCCAAAGAATCCTGGG-3', rev 5'-
CTCTTCTTGCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTACGTGGCCC 
TCAGGTTTCTC-3'; FK1+FK2, fwd5'-TTCTTTCCA CTCGAGATA TGA CTA CTG ATG AAG 
G-3', rev. 5'-CTCTTCTT 
GCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTTCGAAGCTCTTAAGTGTAAC-3'; FK2, 
fwd5'-TCTCTCCACTCGAGATA TGAAAGGAGAGGATTTATTTG-3, rev 5'-CTCTTCTT 
GCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCTTCGAAGCTCTTAAGTGTAAC-3'. All 
clones were checked by Sanger sequencing.  
Plasmids expressing Akt1, Akt2, LC3B, FoxO3a-Luc, and PHLPP2-HA have been described 8-10. 
 
Reporter gene assays - Reporter gene experiments were carried out in 96-well formats. 
2*106cells were transfected with 1000 ng FoxO3a-Luc, 100 ng pCMV-Gaussia-Luc and 
1000 ng pRK5-FKBP51/52-Flag -plasmid using Amaxa Nucleofactor system as described 
above. To determine Firefly luciferase activity, cells were lysed in 50 µL passive lysis buffer 
(0.1 M KPO4 pH 7.8, 0.2% Triton); addition of 50 µL of luciferase reaction buffer to a 
fraction of 10 µL of cell lysate (33 mM KHPO4, pH 7.8, 1.7 mM ATP, 3.3 mM MgCl2, and 
13 mM luciferin) and luminometric readings were performed with an automatic counter 
(Tristar, Berthold). Activity of secretory Gaussia luciferase11 was measured after addition of  
50 µL of substrate/buffer (1.1 M NaCl, 2.2 mM EDTA, 0.22 M KPO4 pH 5.1, 0.44 mg ml-1 
BSA, and 0.5 mg ml-1 coelenterazine). 
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Co-Immunoprecipitation(CoIP) - CoIP of FLAG-tagged FKBP51 mutants with endogenous Akt1 
with FLAG-tagged FKBP51/52 were performed in HEK-293 cells. 5×106 cells were electroporated 
with 5 µg of the respective expression plasmids using a GenePulser (Bio-Rad, USA) at 350 V/700 µF 
in 400 µl of electroporation buffer (50 mM K2HPO4/KH2PO4, 20 mM KAc, pH 7.35, 25 mM MgSO4). 
After three days of cultivation in DMEM/10% FCS, cells were lysed in CoIP-buffer containing 20 mM 
Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Igepal complemented with protease inhibitor 
cocktail (Sigma, P2714). This was followed by incubation on an overhead shaker for 20 min at 4 °C. 
The lysate was cleared by centrifugation, the protein concentration was determined, and 1.2 mg of 
lysate was incubated with 2.5 µg FLAG antibody overnight at 4 °C. 20 µl of BSA-blocked Protein G 
Dynabeads (Invitrogen, 100-03D) were added to the lysate–antibody mix followed by 3 h incubation 
at 4 °C. The beads were washed 3 times with PBS and protein-antibody complexes were eluted with 
100 µl of 1× FLAG-peptide solution (Sigma, 100–200 µg ml-1, F3290) in CoIP buffer for 30 min at 
4 °C. 5–15 µg of the cell lysates or 2.5 µl of the immunoprecipitates were separated by SDS-PAGE. 
 
Western Blot analysis – Protein extracts were obtained by lysing cells in 62.5 mM Tris, 2% 
SDS and 10% sucrose, supplemented with protease (Sigma , P2714) and phosphatase (Roche, 
04906837001) inhibitor cocktail. Samples were sonicated and heated at 95 ºC for 5 min. 
Proteins were separated by SDS-PAGE and electro-transferred onto nitrocellulose 
membranes. Blots were placed in Tris-buffered saline, supplemented with 0.05% Tween 
(Sigma, P2287) and 5% non-fat milk for 1 h at room temperature and then incubated with 
primary antibody (diluted in TBS/0.05% Tween) overnight at 4 ºC. The following primary 
antibodies were used: Beclin1 (1:1000, Cell Signaling, #3495), Atg12 (1:1000, Cell Signaling 
#2010), LC3B-I/II (1:1000, Cell Signaling, #2775), FLAG (1:7000, Rockland, 600-401-383), 
HA-HRP conjugated (1:25000, Roche, 11667475001), FKBP51 (1:1000, Bethyl, A301-430A 
), FKBP52 (1:2000, Bethyl, A301-427A), Akt (1:1000, Cell Signaling, #4691), pAkt (1:1000, 
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Ser472, T308, 1:1000, Cell Signaling, #4058, #9275), pFoxO3a (1:1000, Cell 
Signaling,#9465), PI3K Class III (Vps34, 1:1000, Cell Signaling, #4263), p4E-BP1 
(Thr37/46, 1:1000, Cell Signaling, #2855), pp70S6K (Thr371, 1:1000, Cell Signaling, 
#9208), Actin (1:5000, Santa Cruz Biotechnologies, sc-1616). 
Subsequently, blots were washed and probed with the respective horseradish peroxidase- or 
fluorophore-conjugated secondary antibody for 1 h at room temperature. The immuno-
reactive bands were visualized either using ECL detection reagent (Millipore, Billerica, MA, 
USA, WBKL0500) or directly by excitation of the respective fluorophore. Determination of 
the band intensities were performed with BioRad, ChemiDoc MP, or X-ray-films 
 
Animals and animal housing – The Fkbp51 knockout (Fkbp51-/-) mouse line was previously 
generated1, 12 and fully backcrossed to C57/Bl6. Genotypes were verified by PCR of tail 
DNA. Only male mice were used for the experiment, obtained from heterozygous breeding 
pairs. Animals were between 10 and 16 weeks old at the start of the experiment. Mice were 
held under standard conditions (12L: 12D light cycle, lights on at 08:00 am, temperature 
23±2°C), were singly housed and acclimated to the room for one week before the beginning 
of the experiments. Food (Altromin 1314, Altromin GmbH, Germany) and tap water were 
available ad libitum.  
All experiments were carried out in the animal facilities of the Max Planck Institute of 
Psychiatry in Munich, Germany. The experiments were carried out in accordance with the 
European Communities' Council Directive 86/609/EEC. All efforts were made to minimize 
animal suffering during the experiments. The protocols were approved by the committee for 
the Care and Use of Laboratory animals of the Government of Upper Bavaria, Germany. 
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Animal treatments and behavioral experiments – All mice were injected intraperitoneally 
either with a single dose of paroxetine (10 mg kg-1; dissolved in saline; Sigma-Aldrich, 
Germany) or saline vehicle solution. The injection volume was 5 ml kg-1 body weight. 45 min 
after the injection, a subgroup of mice (WT vehicle, n = 10; Fkbp51-/- vehicle, n = 9; WT 
paroxetine, n = 10; Fkbp51-/- paroxetine, n = 10; WT) was sacrificed by decapitation 
following quick anesthesia by isoflurane. Trunk blood was collected in 1.5 ml EDTA-coated 
microcentrifuge tubes (KabeLabortechnik, Germany) and kept on ice until further processing. 
Furthermore, brains were removed; hippocampus and prefrontal cortex were extracted and 
stored on dry ice until further processing. 
Another subgroup of mice (WT vehicle, n = 8; Fkbp51-/- vehicle, n = 8; WT paroxetine, n = 9; 
Fkbp51-/- paroxetine, n = 7) was subjected to a forced swim test (FST) 45 min after the 
injection. The FST was carried out between 9:00 am and 10:30 am in the same room in which 
the mice were housed and was analyzed using an automated video-tracking system (Anymaze 
4.20, Stoelting, IL; USA). In the FST, each mouse was put into a 2 l glass beaker (diameter: 
13 cm, height: 24 cm) filled with tap water (21 ± 1 °C) to a height of 15 cm, so that the mouse 
could not touch the bottom with its hind paws or tail. Testing duration was 6 min. Time spent 
immobile and time spent struggling was scored by an experienced observer, blind to genotype 
or treatment of the animals. 
 
Electrophysiology - Brain slices were obtained from 11-18 week-old male FKBP51+/+ and 
FKBP51-/- mice. Preparation and staining of slices with the voltage-sensitive dye Di-4-
ANEPPS as well as VSDI and data analysis were performed as described13, 14, with the 
exception that ∆F/F values were smoothed using a 5 x 5 x 3 average filter. To reduce noise, 
four acquisitions subsequently recorded at intervals of 5 s were averaged. Neuronal activity 
was evoked by square pulse electrical stimuli (200 µs pulse width) delivered via a custom-
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made monopolar tungsten electrode (Teflon-insulated to the tip of 50 µm diameter) to the 
Schaffer collateral-commissural pathway15. The circular ROI (r = 4 pixels) was placed into 
the CA1 stratum radiatum near the stimulation electrode. The ROI also covered a part of the 
adjacent CA1 stratum pyramidale (Fig. 5A). The intensity of voltage stimulation was adjusted 
in a manner to produce FDSs with peak amplitudes of ~30% of the highest attainable value. 
 
Statistical analysis 
All statistical analyses were performed with SPSS 16.0. When two groups were compared, the 
student’s t-test was applied. For three or more group comparisons, one-way or two-way 
analysis of variance (ANOVA) was performed, followed by Tukey’s post-hoc test, as 
appropriate. All ANOVA F and p values are reported in supplementary table 1; significant 
results of the contrast tests are indicated by asterisks in the graphs. Protein-protein 
associations were analyzed using the Pearson correlation coefficient. P values of less than 
0.05 were considered significant. 
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figure parameter ANOVA variable 1 variable 2 variable 1 * variable 2
2A pp70S6K 
1 Way ANOVA 
variable 1 = 
genotype 
F2,8 = 
3.994 p = 0.079         
2A p4E-BP1 F2,8 = 17.859 p < 0.01         
2A pAkt (S473) / Akt 
F2,8 = 
267.265 p < 0.001         
2A Beclin 1 F2,8 = 32.996 p < 0.001         
2A LC3-II / LC3-I 
F2,8 = 
177.628 p < 0.001         
2A Atg12 F2,8 = 26.092 p < 0.001         
2B pp70S6K 
2 Way ANOVA 
variable 1 = 
treatment 
variable 2 = 
genotype 
F5,12 = 
4.298 p = 0.060 
F5,12 = 
13.870 p < 0.001 
F5,12 = 
30.737 p < 0.001 
2B p4E-BP1 F5,12 = 5.470 p < 0.05 
F5,12 = 
9.474 p < 0.01 
F5,12 = 
4.997 p < 0.05 
2B Beclin 1 F5,12 = 24.605 p < 0.001 
F5,12 = 
11.728 p < 0.01 
F5,12 = 
19.634 p < 0.001 
2B LC3B-II / LC3B-I 
F5,12 = 
105.288 p < 0.001 
F5,12 = 
11.107 p < 0.01 
F5,12 = 
13.721 p < 0.001 
3A
FoxO3A 
reporter
activity 
2 Way ANOVA 
variable 1 = 
treatment 
variable 2 = 
genotype 
F3,32 = 
27.341 p < 0.001 
F3,32 = 
43.198 p < 0.001 
F3,32 = 
1.118 p = 0.298 
3B pAkt (S473) / Akt 
F3,8 = 
126.233 p < 0.001 
F3,8 = 
203.625 p < 0.001 
F3,8 = 
12.691 p < 0.01 
3C pAkt (S473) / Akt 1 Way ANOVA variable 1 = 
genotype 
F2,8 = 
27.702 p < 0.001         
3D LC3B-II / LC3B-I 
F2,8 = 
12.041 p < 0.01         
3E punctae per cell 2 Way ANOVA 
variable 1 = 
treatment
variable 2 = 
genotype 
F3,67 = 
173.593 p < 0.001 
F3,67 = 
106.640 p < 0.001 
F3,67 = 
29.555 p < 0.001 
3G Beclin 1 F2,8 = 135.813 p < 0.001 
F2,8 = 
389.709 p < 0.001 
F2,8 = 
41.657 p < 0.001 
3H LC3B-II / LC3B-I 
F2,8 = 
2785.191 p < 0.001 
F2,8 = 
357.590 p < 0.001 
F2,8 = 
111.099 p < 0.001 
3I Atg12 F2,8 = 15.001 p < 0.01 
F2,8 = 
28.481 p < 0.001 
F2,8 = 
0.776 p = 0.404 
4A Hip pAkt / Akt
2 Way ANOVA 
variable 1 = 
treatment
variable 2 = 
genotype 
F3,28 = 
4.999 p < 0.05 
F3,28 = 
0.018 n.s.
F3,28 = 
6.508 p < 0.05 
4A PFC pAkt / Akt
F3,28 = 
17.239 p < 0.001 
F3,28 = 
4.354 p < 0.05 
F3,28 = 
27.685 p < 0.001 
4B  Hip Beclin1 F3,28 = 4.944 p < 0.05 
F3,28 = 
3.167 n.s.
F3,28 = 
4.299 p < 0.05 
4B PFCBeclin1
F3,28 = 
6.335 p < 0.5 
F3,28 = 
8.827 p < 0.01 
F3,28 = 
25.002 p < 0.001 
4C Hip LC3B-II/ LC3B-I 
F3,28 = 
2.187 n.s.
F3,28 = 
1.723 n.s.
F3,28 = 
7.967 p < 0.01 
4C PFC LC3B-II/ LC3B-I 
F3,28 = 
28.243 p < 0.001 
F3,28 = 
16.671 p < 0.001 
F3,28 = 
32.117 p < 0.001 
4D  Hip Atg12 F3,28 = 18.858 p < 0.001 
F3,28 = 
12.645 p < 0.001 
F3,28 = 
29.447 p < 0.001 
4D  PFC Atg12 F3,28 = 1.942 n.s.
F3,28 = 
5.887 p < 0.05 
F3,28 = 
9.383 p < 0.01 
4E   Hip Vps34 F3,28 = 33.501 p < 0.001 
F3,28 = 
21.781 p < 0.001 
F3,28 = 
25.275 p < 0.001 
4E  PFC Vps34 F3,28 = 14.334 p < 0.001 
F3,28 = 
11.231 p < 0.01 
F3,28 = 
8.125 p < 0.01 
4F  immobility F3,27 = 15.234 p < 0.001 
F3,27 = 
10.476 p < 0.01 
F3,27 = 
4.927 p < 0.05 
4F  struggling F3,27 = 25.752 p < 0.001 
F3,27 = 
13.520 p < 0.001 
F3,27 = 
4.247 p < 0.05 


Gassenetal.,SupplementalTable


figure parameter ANOVA variable 1 variable 2 variable 1 * variable 2
Suppl. 
3B
FoxO3A 
reporter
activity 
2 Way ANOVA 
variable 1 = 
treatment
variable 2 = 
genotype 
F5,48 = 
9.778 p < 0.001 
F5,48 = 
99.699 p < 0.001 
F5,48 = 
0.501 p = 0.609 
Suppl. 
3D
pAkt (S473) 
/ Akt 
F5,12 = 
5.781 p < 0.5 
F5,12 = 
17.236 p < 0.001 
F5,12 = 
0.129 p = 0.880 
Suppl. 
3F  
pAkt (S473) 
/ Akt 
F5,12 = 
1.549 n.s.
F5,12 = 
17.786 p < 0.001 
F5,12 = 
0.156 p = 0.858 
Suppl. 
3G
LC3B-II / 
LC3B-I 
F5,12 = 
1.208 n.s.
F5,12 = 
3.835 p = 0.052 
F5,12 = 
0.635 p = 0.547 
Suppl. 
3I
LC3B-II / 
LC3B-I 
F8,18 = 
3.244 p = 0.063 
F8,18 = 
14.749 p < 0.001 
F8,18 = 
1.139 p = 0.370 
Suppl. 
3J
punctae per 
cell
F5,96 = 
54.488 p < 0.001 
F5,96 = 
107.763 p < 0.001 
F5,96 = 
8.018 p < 0.001 
Suppl. 
3L Beclin 1 
F5,12 = 
1.892 n.s.
F5,12 = 
9.553 p < 0.01 
F5,12 = 
1.449 p = 0.273 
Suppl. 
3M
LC3B-II / 
LC3B-I 
F5,12 = 
182.414 p < 0.001 
F5,12 = 
95.458 p < 0.001 
F5,12 = 
8.243 p < 0.01 
Suppl. 
3N Atg12 
F5,12 = 
6.645 p < 0.05 
F5,12 = 
205.529 p < 0.001 
F5,12 = 
2.627 p = 0.113 
Suppl. 
4C 
pAkt (S473) 
/ Akt 
F3,10 = 
29.227 p < 0.001 
F3,10 = 
0.135 n.s.
F3,10 = 
0.298 p = 0.597 
Suppl. 
4C Beclin 1 
F3,10 = 
0.893 n.s.
F3,10 = 
0.210 n.s.
F3,10 = 
2.637 p = 0.135 
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RFK506 Binding Protein 5 Shapes Stress
Responsiveness: Modulation of Neuroendocrine
Reactivity and Coping Behavior
Chadi Touma, Nils Christian Gassen, Leonie Herrmann, Joyce Cheung-Flynn, Dominik R. Büll,
Irina A. Ionescu, Jan-Michael Heinzmann, Alana Knapman, Anna Siebertz, Anna-Mareike Depping,
Jakob Hartmann, Felix Hausch, Mathias V. Schmidt, Florian Holsboer, Marcus Ising, Marc B. Cox,
Ulrike Schmidt, and Theo Rein
Background: TheHsp90 cochaperone FK506 binding protein 5 (FKBP5) is an established regulator of the glucocorticoid receptor (GR), and
numerous genetic studies have linked it to stress-related diseases such as major depression or posttraumatic stress disorder. However,
translational studies including genetic animal models are lacking.
Methods: Mice deficient of FKBP5 were generated and analyzed in comparison with wildtype littermates. They were subjected to several
test paradigms characterizing their emotionality, stress reactivity, and coping behavior as well as hypothalamus-pituitary-adrenal axis
function and regulation. Moreover, protein expression of GR and FKBP5 was determined in different brain structures 8 days after stress
exposure. The combineddexamethasone/corticotropin-releasinghormone testwasperformedboth inmice andhealthyhuman subjects of
different FKBP5 genotypes. The GR function was evaluated by reporter gene assays.
Results: Under basal conditions, deletion of FKBP5 did not change exploratory drive, locomotor activity, anxiety-related behavior, stress-
coping, or depression-like behavior. After exposure to different acute stressors of sufficient intensity, however, it led to amore active coping
behavior. Moreover, loss of FKBP5 decreased hypothalamus-pituitary-adrenal axis reactivity and GR expression changes in response to
stressors. Inmice and humans, the FKBP5 genotype also determined the outcome of the dexamethasone/corticotropin-releasing hormone
test.
Conclusions: This study in mice and humans presents FKBP5 as a decisive factor for the physiological stress response, shaping neuroen-
docrine reactivity aswell as coping behavior. This lends strong support to the concept emerging fromhuman studies of FKBP5 as important
factor governing gene–environment interactions relevant for the etiology of affective disorders.
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I n the recent years, polymorphisms in the FK506 binding protein5 (FKBP5), also referred to as FKBP51, have emerged as one ofthe most important and intriguing associations with stress-re-
ated phenotypes and diseases such as major depression and post-
raumatic stress disorder (1–7). FKBP5 was originally identified as
omponent of the progesterone receptor-chaperone heterocom-
lex (8). Its role in stress regulation was first conjectured upon
iscovery of elevated FKBP5 levels in squirrelmonkeys (9,10). These
ew World primates exhibit glucocorticoid resistance together
ith markedly elevated levels of plasma cortisol but lack signs of
etrimental glucocorticoid excess (11–13). The decreased hor-
one-binding affinity of their glucocorticoid receptor (GR) (12)was
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doi:10.1016/j.biopsych.2011.07.023ater largely attributed to the inhibitory action of FKBP5 on GR
14–17).
FKBP5 possesses peptidylprolyl isomerase activity (18) and fea-
ures a domain for interaction with the central chaperone heat
hockprotein (Hsp) 90. Although interactionwithHsp90 is essential
or its inhibitory action on GR, peptidylprolyl isomerase activity is
ispensable (16). Thus, according to the current mechanistic con-
ept, FKBP5 competes with other proteins for access to the
sp90-GR heterocomplex, thereby interfering with the action of
R-stimulatory factors, in dependency of its expression levels (19).
Thewell-documented influence of FKBP5 onGR function served
s rationale for its inclusion as one of the candidates in the gene
ssociation study that first associated FKBP5 polymorphisms with
esponse to antidepressant treatment (1). Over decades, ample
vidence accumulated for an essential role of GR function in stress-
elated psychiatric disorders such as major depression and post-
raumatic stress disorder (20–22). In general, elevated levels of
lucocorticoids in response to stressful life events constitute a
ealthy adaptive reaction, provided this response is balanced and
ransient. The hypothalamus-pituitary-adrenal (HPA) axis is a key
ontrol system to balance hormonal and behavioral responses to
tressors. AhallmarkofHPAaxis regulation is thenegative feedback
xerted by glucocorticoids via GR on the secretion of stress hor-
ones (20). Substantial evidence suggests that this attenuation of
PA axis activity, which is an integral part of the adaptive response
o stressors and challenges, is often impaired in patients suffering
rom major depression (23,24). For example, major depression has
een repeatedly shown to be associated with elevated levels of
irculating glucocorticoids, decreased responsiveness to dexa-
BIOL PSYCHIATRY 2011;70:928–936
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C. Touma et al. BIOL PSYCHIATRY 2011;70:928–936 929methasone (Dex) suppression and increased adrenocortical re-
sponse to stimulation with corticotropin-releasing hormone (CRH)
in the combined Dex/CRH test (20,24). Although the exact physio-
logical consequences of prolonged glucocorticoid elevation are
not fully understood (25), it is intriguing that successful treatment
of depression mostly goes along with a normalization of HPA axis
reactivity. Moreover, remitted individuals with incompletely atten-
uated HPA axis overdrive have a higher risk of relapse (26). These
and other observations led to the formulation of the corticosteroid
receptor hypothesis of depression, which stipulates a link between
corticosteroid receptor dysfunction and major depression (23).
This hypothesis is further supportedby animal experiments (27).
For example, mice with impaired GR function due to transgenic
antisense RNA expression exhibit neuroendocrine characteristics
similar to those observed inmajor depression, including a hyperac-
tive HPA axis (28). Antidepressant treatment counteracted these
alterations (29). In addition, acquired deficit of forebrain GR pro-
duces depression-like phenotypes in behavioral and physiological
stress reactivity, which were normalized by antidepressant treat-
ment (30).
Given theestablished roleofGRand its regulatoryprotein FKBP5
in stress-related disorders and associated endophenotypes, we un-
dertook amolecular, neuroendocrine, and behavioral characteriza-
tion of Fkbp5/mice under basal conditions aswell as in response
to stressors. We considered the latter point particularly important,
because the ability of an organism to respond and the way it re-
sponds to stressors have been accepted as crucial factors in stress-
related disorders (20). Deletion of Fkbp5 resulted in alterations of
HPA axis reactivity and feedback regulation, induced more active
coping behavior, and impacted on the expression changes of GR 8
days after stress exposure. In similarity to the findings in mice,
FKBP5 genotypes in humans also altered the outcome of the Dex/
CRH test.
Methods andMaterials
Details of all experimental procedures are provided in Supple-
ment 1. All work was in accord with accepted standards of humane
care and use of experimental animals and approved by the appro-
priate local authority.
Cell Culture and Reporter Gene Assays
Conditions for cultivating cells, reporter gene assays, and plas-
mid details have been described previously (19,31–34). Briefly,
mouseembryonic fibroblast (MEF) cells derived fromknockout (KO)
and wildtype (WT) animals were cultured in medium containing
steroid-free serum for 24 hours before transfection. Plasmids used
were a steroid responsive luciferase reporter and expression vec-
tors for GR and Fkbp5. The following day, cells were exposed to Dex
and harvested for protein extraction and luciferase activities mea-
sured 1 day later.
Experimental Animals and Housing Conditions
All mice were derived from heterozygous matings. Animals ho-
mozygous for the Fkbp5 KO or WT alleles were used for the experi-
ments. The animal housing and experimental rooms were main-
tained under standard laboratory conditions. Commercial mouse
diet and water were available ad libitum. In all experiments, young
adult males were used (10–16 weeks of age). At least 2 weeks
before each experiment, mice were single-housed and habituated
to the experimental room to avoid transportation and dominance
hierarchy effects. easal Behavioral Phenotyping
Fkbp5/ and Fkbp5/ littermates were tested in paradigms
ssessing anxiety-related behavior, exploratory drive, locomotor
ctivity, stress-coping, and depression-like behavior (35). The bat-
ery of tests consistedof theopen-field test, the elevatedplus-maze
est, the dark-light box test, and the forced swim test (FST). All tests
ere performed as described previously (36,37) in the order listed
etween 9:00 AM and 12:00 AMwith an inter-test interval of 48 hours
i.e., 1 day rest between the tests, as recommended for successive
ehavioral testing) (38).
PA Axis Function and Regulation
Neuroendocrine stress reactivity (37) was assessed in the same
ice that had been characterized in the previously described be-
avioral test batteryby subjecting themtoa “stress reactivity test” 1
eek after behavioral testing. Briefly, the stress reactivity test com-
rises a 15-min restraint period and blood sampling immediately
efore and after stress exposure as well as 75 min thereafter, for
etermination of corticosterone levels. The test was performed
uring the first hours of the light phase when corticosterone levels
re at the trough of the circadian glucocorticoid rhythm (39,40).
In the Dex/CRH test (41)—assessing HPA axis functions—a
lood sample was taken 7 days before the actual test to obtain a
asal reference value (“untreated”). On the day of testing, the mice
eceived an IP injectionofDex at 9:00 AM, followedby an injectionof
RH at 3:00 PM (.15 mg/kg). Blood samples were collected immedi-
telybeforeCRH injection (“afterDex” value) and30min later (“after
RH” value). Two independent Dex/CRH tests were performedwith
aïvemice,with either a relatively high (2mg/kg) or low (.05mg/kg)
ose of Dex.
ex/CRH Test and Genotyping in Human Subjects
Healthy subjects between 20 and 44 years of age (33 men, 32
omen; mean age 27.4 years, SD 6.5, all Caucasians from German
escent) without any history of psychiatric or severe somatic disor-
ers, verified by standardized clinical interviews, were recruited
rom webpage advertising and local notice boards. Participants
ave written informed consent after all study details were ex-
lained. The studyprotocolwas approvedby theethical committee
t the Medical Department of the Ludwig-Maximilians-University
unich, Germany. Subjects received 1.5mgDex orally at 11 PM and
ere injectedwith human CRH (100g) at 3 PM the next day. Blood
amples for determination of cortisol levels were drawn 1 day be-
ore Dex treatment, immediately before CRH injection, and 30 min
hereafter.
FKBP5 genotyping was performed with pyrosequencing. The
ingle nucleotide polymorphism rs1360780 was selected, because
e found it associated with FKBP5 expression changes (1). Geno-
ype call rate was 100%, and no deviation from the Hardy-Wein-
erg-Equilibrium was observed (p .358).
ffects of Acute Stressors on Coping Behavior
In order to investigate the effects of acute stress exposureon the
oping behavior of Fkbp5/ and Fkbp5/ mice, several experi-
ents were performed with stressors of different intensity and
ddressing the response of the animals in the FST 24 hours later.
issue Protein Extraction and Immunoblotting
Mice were sacrificed under basal conditions 8 days after the last
ehavioral test or the Dex/CRH tests, and total protein was extracted
rom different brain regions. Immunoblots were performed as de-
cribed with minor modifications (16). Briefly, equal amounts of pro-
ein were separated by sodium dodecyl sulfate polyacrylamide gel
lectrophoresis, transferred to amembrane, probedwith suitable pri-
www.sobp.org/journal
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wmary and secondary antibodies, and visualized by chemolumines-
cence. For quantification, measurement of the optical densities of
immunoblot bands (with -actin or glyceraldehyde-3-phosphate de-
hydrogenase as loading controls) was performed with ImageJ soft-
ware.
Statistics
Because a normal distribution and variance homogeneity could
not always be assumed, data were analyzed with nonparametric or
parametric statistics where appropriate. All tests were applied two-
tailed. For the behavioral, neuroendocrine, and protein expression
data of mice, two independent samples were compared with the
Mann-WhitneyU test (MWU-test) or the Student t test. More than two
independent samples were compared with analysis of variance, fol-
lowed by Bonferroni corrected post hoc tests. For all tests, we consid-
ered p .1 as a trend (T) and p .05 as statistically significant.
Genetic FKBP5 effects on Dex suppressed baseline cortisol and
on the cortisol response to CRH in human subjects was calculated
with a permutation test after correcting for the effects of age and
gender. Empirical p values of the C-carrier model (representing the
rs1360780 genotype for low vs. high FKBP5 lymphocyte protein
concentrations) are reported with the parameter-free permuta-
tion–based approach with 100,000 runs.
Results
Deletion of FKBP5 Causes Mild GR Hypersensitivity
Because FKBP5 is an established inhibitor of GR hormone bind-
ing activity (15,16), its deletion (described in Supplement 1) is ex-
pected to lead to a higher hormone sensitivity of GR, if no compen-
satory mechanisms are elicited. To test this in a defined system, we
performedGR-dependent reporter gene assays inMEF cells derived
from KO and WT animals. In Fkbp5/ cells, GR exhibited a slightly
increased responsiveness of its transcriptional activity (Figure 1A).
We further addressed in MEF cells that WT animals react with an
acute elevation of FKBP5 levels upon glucocorticoid exposure
(42,43), whereas KO animals are deprived of this regulatory feed-
back loop. This should increase the difference in hormone respon-
siveness, unless FKBP5 expression in WT is already at high levels
such that a further increase would not change GR activity. We
calibrated ectopic expression of FKBP5 to yield an approximately
threefold increaseof total FKBP5andobserveda furtherdecreaseof
GR hormone responsiveness (Figure 1B).
Loss of FKBP5 Shows No Effect on Emotional Behavior Under
Basal Conditions
To assess potential effects of FKBP5 deletion and the ensuing
mild GR hyperactivity, we applied a battery of tests characterizing
the behavior of Fkbp5/ and Fkbp5/ mice under basal condi-
tions. No significant differences were revealed between the two
groups in all parameters assessed in the open-field test, the ele-
vated plus-maze test, the dark-light box test, and the FST (Table S1
in Supplement 1). Animals of both genotypes displayed compara-
ble levels of anxiety-related behavior, exploratory drive, locomotor
activity, stress-coping, and depression-like behavior, when tested
under nonstressed conditions.
FKBP5Modulates HPA Axis Function and Regulation in Mice
andMen
Dex/CRH Tests inMice. Tomore directly assess potential con-
equences of the moderate difference in GR function between
kbp5/ and Fkbp5/ mice on the neuroendocrine level, we
erformed two independent Dex/CRH tests, applying either a rela-
ively high or a relatively low dose of Dex. h
ww.sobp.org/journalIn both tests, animals of both genotypes responded to the injec-
ion of Dex with clearly decreased plasma corticosterone concen-
rations (Figures 2A and 2B). The high dose of Dex strongly sup-
ressed adrenocortical activity in Fkbp5/ as well as Fkbp5/
ice, so that corticosterone levels were below the detection limit
nd did not differ between the genotypes (after Dex value, Figure
A). When treated with the lower dose of Dex, however, FKBP5-
eficient mice showed a stronger suppression of corticosterone
ecretion compared with their WT littermates (after Dex value,
igure 2B).
To the stimulation with CRH, all mice responded with an in-
reased secretion of glucocorticoids (Figures 2A and 2B). In the
igure 1. Loss of FK506 binding protein 5 (FKBP5) changes glucocorticoid
eceptor (GR) responsiveness. (A)Reporter gene assays inmouse embryonic
broblast (MEF) cells derived from Fkbp5 knockout and wildtype mice were
ransfected with the reporter, GR, and control plasmids and treated with
ormone as indicated. (B) Western panels: MEF wildtype cells were trans-
ected with additional FKBP5 expression vector to mimic stress-induced
ncrease of Fkbp5. Expression levels were determined relative to heat shock
onstitutive 70 and quantified. FKBP5 (75 ng) expression plasmid was used
n the reporter gene assays in addition to the plasmids used in A. Reporter
esults in A and B represent data from 3 to 5 experiments performed in
riplicate; the activity at the highest hormone concentration was set to 100.
ata are given as means and SEM. Statistically significant differences are
ndicated (*p .05, **p .01; Student t test, panelA, at 1 nmol/L dexameth-
sone (Dex): t 5.03, p .007; panel B, at .3 nmol/L Dex: t 2.95, p .026,
t 1 nmol/L Dex: t 5.53, p .002; at 3 nmol/L Dex, t 2.99, p .024).igh-dose Dex experiment, corticosterone concentrations were
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C. Touma et al. BIOL PSYCHIATRY 2011;70:928–936 931only slightly elevated 30 min after CRH injection (nearly reaching
the levels observed before Dex treatment) and did not differ be-
tween Fkbp5/ and Fkbp5/mice (after CRH value, Figure 2A). In
the low-dose Dex experiment, however, the CRH injection induced
a robust increase of corticosterone concentrations, which was sig-
nificantly less pronounced in Fkbp5/mice than in their Fkbp5/
Figure 2. The Fkbp5genotype affects hypothalamus-pituitary-adrenal axis fu
CRH) testing. (A, B) Combined Dex/CRH test in mice. Corticosterone resp
elatively high (2 mg/kg, panel A) or relatively low (.05 mg/kg, panel B)
oncentrationsweremeasured inmale Fkbp5knockout (KO) andwildtype (W
0min after CRH injection (after CRH). Data are given as box plots showingm
0%percentiles (whiskers). Statistical differences between the groups are in
ach timepoint (panelA, high-doseDex,Mann-WhitneyU test (MWU-test), N
RH: U 35, p .256; panel B, low-dose Dex, MWU-test, NKO12, NWT  12
.001). (C) Stress reactivity testing. Plasma corticosterone concentrations imm
as 75 min after termination of the stressor (recovery) in male Fkbp5 KO and
MWU-test, NKO 11, NWT 13, initial:U 34, p .028, reaction:U 14, p
cortisol response to the Dex/CRH test combining a pharmacological suppre
subsequent stimulation with CRH (100g) in healthy human subjects. Plasm
23) and in noncarriers (TT) (n 7) of the FKBP5 single nucleotide polymorph
Dex) and 30 min after CRH injection (after CRH). Data are given as means
indicated (p  .1 n.s., **p  .01) above the columns for each time po
gender-corrected residuals, untreated: p .101, after Dex: p .004, after Clittermates (after CRH value, Figure 2B). (The corticosterone concentrations measured under basal con-
itions at 3:00 PM 1 week before the Dex/CRH test did not differ
ignificantly between Fkbp5/ and Fkbp5/ mice either in the
ow-dose Dex experiment (untreated value, Figure 2B) or in the
igh-dose Dex experiment (untreated value, Figure 2A).
StressReactivity Testing inMice. To further test the reactivity
n as revealed by stress reactivity andDex/corticotropin-releasing hormone
to a pharmacological suppression of adrenocortical activity with either a
of Dex and a subsequent stimulation with CRH. Plasma corticosterone
ce1weekbefore (untreated) and6hours afterDex treatment (afterDex) and
ns (lines in the boxes), 25% and 75%percentiles (boxes), as well as 10% and
ed (p .1 nonsignificant (n.s.), *p .05, ***p .001) above the columns for
10, NWT 10, untreated:U 57, p .386, after Dex:U 34.5, p .103, after
eated: U 40, p .450, after Dex: U 28, p .011, after CRH: U 14, p
tely before (initial) and after (reaction) a 15-min restraint (RS) period as well
ice. Data and statistical differences are given as described above (panel C,
recovery:U 36, p .040). (D)Dex/CRH test in humans. Graph depicts the
of adrenocortical activity with a relatively low dose of Dex (1.5 mg) and a
tisol concentrations weremeasured in C allele carriers (CC) (n 34; CT, n
s1360780 1 day before (untreated) and 16 hours after Dex treatment (after
SEM. Statistical differences between the genotypes (recessive model) are
ermutation tests with 100,000 permutations, performed with age- and
 .898). Other abbreviations as in Figure 1.nctio
onse
dose
T)mi
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dicat
KO
, untr
edia
WT m
.001,
ssion
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int (pand recovery) of theHPAaxis in amorephysiological paradigm,we
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wused a 15-min restraint period as moderate psychological stressor.
Compared with Fkbp5/mice, plasma corticosterone concentra-
tions were significantly lower in Fkbp5/ mice at all three time
oints (Figure 2C) (i.e., immediately before [initial value], directly
fter [reaction value], and 75 min after termination of the stressor
recovery value]).
Dex/CRH Test in Humans. To relate the findings on HPA
xis function and regulation in our mouse model to the situation
n humans, we performed the Dex/CRH test in 65 genotyped
olunteers screened for absence of mental and severe physical
isorders during lifetime. Individuals whose genotype previ-
usly had been associated with lower levels of FKBP5 (rs1360780
-carriers) reacted with a stronger suppression of cortisol after
ex treatment (Figure 2D). Although this finding is consistent
ith the difference observed in mice, we did not observe a
enotype-dependent difference in overall cortisol levels after
timulation with CRH.
KBP5/Mice Exhibit More Active Coping Behavior After
tress Exposure
Stressors of different intensity were used to investigate the ef-
ects of acute stress exposure on the coping behavior of Fkbp5/
and Fkbp5/mice in the FST 24 hours later. In a first experiment,
e exposed mice to a 15-min restraint stressor, returned them to
heir home cage for 15 min, and then subjected them to a 6-min
ST. In this FST, Fkbp5/ animals showed a trend toward more
ctive coping with the aversive situation (i.e., more swimming be-
avior was observed compared with their WT littermates) (Figure
A). The second FST, which was performed 24 hours after the com-
ined restraint and first FST stressor, revealed more pronounced
tatistically significant behavioral differences (Figure 3B). This ex-
eriment was also replicated with an independent batch of ani-
als, yielding very similar results (Table S2 in Supplement 1).
In a secondexperimentwith reducedoverall stress intensity, the
kbp5/ and Fkbp5/ animals were subjected to the 15-min
estraint stressor, but without FST testing shortly afterward. In this
xperiment, no differences in coping behavior between the two
roups were observed during the FST performed 24 hours after
tress exposure (Figure 3C).
In another experimentwith increased stress intensity, Fkbp5/
and Fkbp5/mice were subjected to a prolonged restraint period
of 60 min and tested in the FST 24 hours later. The FKBP5-deficient
mice again exhibited more swimming and less floating behavior
than WT animals (Figure 3D) (i.e., showed more active coping).
Confirming our assumption that 60-min restraint constitutes a
stronger stressor than 15-min restraint, the prolonged restraint
elicited a higher increase of corticosterone concentrations immedi-
ately after releasing the mice. Importantly, the genotypic differ-
ences in HPA axis reactivity were similar in both experiments
(Figures 2C and 3E), with FKBP5-deficient mice showing signifi-
cantly lower endocrine stress reactivity.
Deletion of FKBP5 Impacts on Stress-Induced Changes of
Protein Expression
We compared the expression levels of GR between WT and KO
animals 8 days after exposure to the Dex/CRH tests (Figure 2) or
after the combined exposure to the restraint (15min or 60min) and
FST (Figure 3). In the Dex/CRH tests, only the experiment with the
lower dose of Dex produced a difference between the genotypes,
with theWT animals exhibiting lower levels of GR expression in the
hippocampus, prefrontal cortex, and cerebellum (Figures 4AandB).
For the combined restraint and FST exposure, only the experi-
ment with 60-min restraint resulted in a significant change of hip- t
ww.sobp.org/journalocampal GR expression, where WT but not KO animals exhibited
educed GR expression compared with unstressed control animals
Figure 4C). In the WT mice of this experiment, we also assessed
KBP5 protein levels in the hippocampus and observed a small but
ignificant decrease of FKBP5 expression eight days after stress
xposure (Figure 4D). Similar results were obtained for the prefron-
al cortex and the cerebellum (data not shown).
iscussion
It has been recognized over the years that decisive for the devel-
pment of stress-related diseases such asmajor depression is not a
articular traumatic eventper seor aparticular genetic endowment
ut the interplay of genetic and environmental factors. Therefore, it
s crucial for increasing our understanding of affective disorders to
nvestigate how individual differences in stress responsiveness
rise and by which mechanisms an organism is able to cope with
hallenges and stressful situations. We report here that Fkbp5 gene
eletion results in a mild GR hypersensitivity, changes in neuroen-
ocrine reactivity and feedback regulation of the HPA axis, a more
ctive coping behavior after exposure to stressors, and alterations
n the stress-induced changes of GR expression. Similarly, the FKBP5
enotypes in humans shown to be associated with different FKBP5
xpression levels turned out to be linked to the outcome of the
ex/CRH test. The functional linkbetweenFKBP5andGRmost likely
orms the basis for these effects, although the possibility exists that
ther important actions of FKBP5 (19,44–46) might contribute to
he observed endophenotypes.
In general, gene KO strategies carry the risk of compensatory
olecular reactions that compromise detection of protein func-
ion. Because FKBP5 acts on GR via its interaction with Hsp90 (16),
ther inhibitory factors competing for Hsp90 binding could in prin-
iple take over the function of attenuating GR activity (19). Our
xperiments, however, indicate a more sensitive GR in Fkbp5-de-
eted MEF cells (Figure 1A), which was also supported by hormone
inding experiments in brain extracts (not shown). Thus, other
sp90 cochaperones apparently did not compensate for the loss of
KBP5 (e.g., by decreasing FKBP4) (Figure 1B). An enhanced GR
ensitivity in animals devoid of FKBP5 is themost likely explanation
or the changes in HPA axis settings observed here. This includes
he lower levels of basal morning corticosterone (Figures 2 and 3E)
nd particularly the reduced secretion of corticosterone in re-
ponse to pharmacological or psychological stressors (Figures 2C
nd 3E). This interpretation is corroborated by a recent report of a
ain of function GR knock-in mouse (47). In that study, the endog-
nous GR was replaced by the human GRM604L mutant, which is
ctivated at lower glucocorticoid concentrations than wildtype GR
48). Those mice were phenotypically normal under basal condi-
ions—with birth weight, postnatal growth, and development in-
istinguishable from WT littermates—but exhibited changes in
PA axis activity (47), in similarity to our findings in the Fkbp5/
ice presented here.
Our observation that the Dex/CRH test revealed a genotype
ifference only at the lower dose of Dex might seem surprising at
rst (Figure 2). This dose-dependencymost likely reflects the shift of
R responsiveness toward lower concentrations of hormone,
hich was observed here (Figure 1) and elsewhere (15,16). The
igher dose of Dex that did not produce a genotype effect presum-
bly amounted to a saturating concentration of hormone that acti-
ates GR irrespectively of the FKBP5 status. In contrast, the fortyfold
ower dose of Dex that exposed a genotype effect presumably
esulted in sub-saturatinghormone concentration, as evidencedby
he less pronounced suppression of corticosterone (Figure 2), a
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C. Touma et al. BIOL PSYCHIATRY 2011;70:928–936 933Figure 3. FKBP5modulates copingbehavior after stress exposure. (A, B)Copingbehavior of Fkbp5KOandWTmicewas assessed in the forced swim test (FST)
performed shortly after exposure to a 15-min RS stressor (A) and 24 h after the first FST (B). Data are given asmeans and SEM. Statistical differences between
the groups are indicated (p .1 n.s., p .1 trend (T), *p .05, **p .01) in both panels above the columns for each behavioral pattern (panel A, first FST,
MWU-test, NKO 11, NWT 11, struggling:U 46, p .341, swimming:U 34, p .082, floating:U 48, p .412; panelB, second FST,MWU-test, NKO 11,
WT 11, struggling:U 56, p .768, swimming:U 22, p .011, floating:U 24, p .017). (C, D) Coping behavior ofmale KO andWTmicewas assessed
n the FST 24 hours after either 15-min (C) or 60-min (D) of RS stress. Data and statistical differences are given as described above (panel C, MWU-test, NKO
1, NWT 11, struggling:U 46, p .341, swimming:U 34, p .082, floating:U 48, p .412; panelD, MWU-test, NKO 12, NWT 12, struggling:U 71,
 .954, swimming:U 27, p .009, floating:U 31, p .018). (E) Plasma corticosterone concentrations immediately before (initial) and after (reaction) the
0-min RS period (c.f. panel D) were determined. Data are given as box plots showing medians (lines in the boxes), 25% and 75% percentiles (boxes) as well
s 10th and 90th percentiles (whiskers). Statistical differences between the groups are indicated (p .1 T, ***p .001) above the columns for each time point
MWU-test, NKO 12, NWT 12, initial: U 41, p .073, reaction: U 3, p .001). Other abbreviations as in Figures 1 and 2.
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wcondition inwhich the dependency of GR activity on FKBP5 expres-
sion is most pronounced (15,16). Notably, the differences we ob-
served in response to the lower dose of Dex between FKBP5-
expressing and nonexpressing mice are paralleled in humans,
where the genotype previously shown to be associated with lower
levels of FKBP5 (1) also exhibited lower levels of cortisol after Dex
treatment (Figure 2).
Expression changes of genes relevant to the function of theHPA
axis have been frequently described to be associated with stress
exposure—in particular stressful events during sensitive periods of
early development (49). For example, in rats, lower levels of mater-
nal care led to decreased GR expression in the hippocampus of the
offspring (50). Maternal separation led to decreased expression of
GR in the hippocampus and forebrain (51,52), apparently in a time-
dependent fashion, because it is preceded by an increase of GR
expression (51). Exposure of pregnant rats to Dex also caused GR
expression changes in the offspring, which was dependent on the
brain region and duration/timing of treatment (53). In humans, a
postmortem analysis of suicide victims revealed an association of
childhood abuse with decreased hippocampal GR expression (54).
Because there is more evidence linking GR expression to psycho-
pathological conditions (20,55), there are intense research efforts
Figure4.FKBP5modulates stress-inducedchangesofproteinexpression. (A
andprefrontal cortex (PFC)weredetermined8days after completionof the c
levels (panelA: high-doseDex, panelB: low-doseDex). Brains from sevenma
performed in triplicates. Depicted bands on the immunoblots represent sam
graphs above. Data are given as means and SEM. Statistical differences bet
brain region (panelA, high-doseDex, Student t test, NKO 7, NWT 7, HIP: t
ex, Student t test, NKO 7, NWT 7, HIP: t 1.76, p .008, CER: t 1.98, p
ere determined in six Fkbp5 KO and six WT littermates 8 days after the stre
wo FST or 60-min RS followed by one FST on the next day or unstressed co
mmunoblot experimentswereperformed in triplicates, andGR signalswere
lotdepicted shows12adjacentbandswith2bands representative for each
f variance revealed significant groupdifferences for treatment [F(2,30) 14
actors was not significant (p .150). (D) FKBP5 protein levels were determi
ame procedure. Blots depicted show two adjacent immunoblot bands each
ignificant group differences for treatment [F(2,15) 6.7, p .009]. Signific
espective columns (*p .05, ***p .001). Other abbreviations as in Figureaimingatunderstanding themechanismsgoverningprogramming o
ww.sobp.org/journalf GR. Epigenetic mechanisms are very likely to contribute
54,56,57), and our findings of a genotypic difference in GR expres-
ion after stress exposure (Figure 4) put FKBP5 forward as a candi-
ate to contribute to stress-induced GR expression changes. Our
bservation that the genotypic difference was dependent on the
ose/intensity of the pharmacological/psychological stressor most
ikely relates to the hormone responsiveness of GR, where differ-
nces were exposed at sub-saturating concentrations of steroids
ut barely at concentrations above and below.
It is worth mentioning that our study was limited to male mice.
emales were not included, due to methodological difficulties of
onitoring the estrous cycle in a noninvasive manner, which is
andatory to avoid systematically biasing the results. Neverthe-
ess, it will be important to address a potential gender difference in
he effect of FKBP5 in preclinical models, because prevalence rates
f major depression are higher in women (58). Actually, one clinical
tudy suggests a gender difference in the FKBP5-genotype associ-
tion with major depression (59).
The effect of FKBP5 deletion on HPA axis parameters discussed
n the preceding text can be interpreted as a compensatory reac-
ion to altered GR sensitivity restoring an adequate balance of re-
eptor and hormone and therefore should not have further physi-
Rprotein levels in thebilaterallypooledhippocampi (HIP), cerebellum (CER),
nedDex/CRH tests (cf. Figure 2) by immunoblotting andnormalized to actin
ce for each genotype and conditionwere extracted, and immunoblotswere
from six individual mice, corresponding to the conditions displayed in the
the groups are indicated (*p .05, **p .01) above the columns for each
1, p .161, CER: t .765, p .215, PFC: t .717, p .343; panelB, low-dose
4, PFC: t 1.85, p .007). (C)GR protein levels in the bilaterally pooled HIP
eriments presented in Figures 3B and 3D (i.e. either 15-min RS followed by
subjects [six mice of each genotype left undisturbed in their home cages]).
alized toglyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. The
imental group, respectively. Statistical analysis employing two-wayanalysis
.001] and Fkbp5genotype [F(1,30) 7.8, p .009]. The interaction of both
the same six WT animals used for determination of GR in panel Cwith the
constitute representative examples. One-way analysis of variance revealed
fferences in the pairwise Bonferroni post hoc tests are indicated above the
d 2., B)G
ombi
lemi
ples
ween
 .65
 .03
ss exp
ntrol
norm
exper
.4, p
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and
ant dilogical consequences. Accordingly, we did not find genotype-
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However, by deleting Fkbp5, the animals are deprived not simply of
a static factor that calibrates GR activity but also of the ultra-short
intracellular feedback loop, a peculiar hallmark of molecular stress
regulation linking FKBP5 and GR. This feedback loop leads to an
increase of FKBP5 upon GR activation (60,61), thereby limiting ex-
tended, excessive activation of GR. The lack of this feedback loop in
Fkbp5/ animals might be the basis for our observation that phe-
notypic differences in coping behavior during the FST are exposed
only if preceded by stressors of sufficient strength (Figure 3). Very
recently, this was similarly shown for anxiety-related behavior (62),
further corroborating the relevance of the Fkbp5/mousemodel.
In this respect, it is intriguing that several studies in humans
attest to the concept that FKBP5 is decisive for the development
of stress-related mental disorders only in combination with trau-
matic events (2,63–65). We hypothesize that, taken together with
our results in mice, the reported polymorphisms are linked—di-
rectly or indirectly—to theultra-short feedback loopconnectingGR
and FKBP5 as a crucial component of stress regulation. Among the
possible mechanisms, genetic polymorphisms might change pro-
gramming of FKBP5 expression, because it has been shown re-
cently that FKBP5 is amenable to epigenetic regulation (43). In
conclusion, our findings translate clinical observations on FKBP5
into animal-based experimental systems. This should encourage
moredetailed studies testing thehypothesis that genotype-depen-
dent reaction of FKBP5 expression to stressful life events deter-
mines the risk for development of affective disorders, ultimately
leading to improved treatment regimes.
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Abstract
Background: Tetratricopeptide repeat (TPR) motif containing co-chaperones of the chaperone Hsp90 are considered
control modules that govern activity and specificity of this central folding platform. Steroid receptors are paradigm clients of
Hsp90. The influence of some TPR proteins on selected receptors has been described, but a comprehensive analysis of the
effects of TPR proteins on all steroid receptors has not been accomplished yet.
Methodology and Principal Findings: We compared the influence of the TPR proteins FK506 binding proteins 51 and 52,
protein phosphatase-5, C-terminus of Hsp70 interacting protein, cyclophillin 40, hepatitis-virus-B X-associated protein-2,
and tetratricopeptide repeat protein-2 on all six steroid hormone receptors in a homogeneous mammalian cell system.
To be able to assess each cofactor’s effect on the transcriptional activity of on each steroid receptor we employed
transient transfection in a reporter gene assay. In addition, we evaluated the interactions of the TPR proteins with the
receptors and components of the Hsp90 chaperone heterocomplex by coimmunoprecipitation. In the functional assays,
corticosteroid and progesterone receptors displayed the most sensitive and distinct reaction to the TPR proteins.
Androgen receptor’s activity was moderately impaired by most cofactors, whereas the Estrogen receptors’ activity was
impaired by most cofactors only to a minor degree. Second, interaction studies revealed that the strongly receptor-
interacting co-chaperones were all among the inhibitory proteins. Intriguingly, the TPR-proteins also differentially co-
precipitated the heterochaperone complex components Hsp90, Hsp70, and p23, pointing to differences in their modes
of action.
Conclusion and Significance: The results of this comprehensive study provide important insight into chaperoning of
diverse client proteins via the combinatorial action of (co)-chaperones. The differential effects of the TPR proteins on steroid
receptors bear on all physiological processes related to steroid hormone activity.
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Introduction
Steroid hormones are lipophilic signalling molecules, mediating
a vast variety of physiological effects that depend on the cellular
context of the target tissue. They act via steroid hormone receptors
(SR), which belong to the nuclear receptor superfamily of ligand-
activated transcription factors and serve as regulators of various
target genes [1–3]. Upon binding to hormone, SR accumulate in
the nucleus and either enhance or decrease transcription by
interacting with their cognate DNA elements or by ‘‘cross-talk’’
with other transcription factors [4–6].
Hormone binding and activity of SR is shaped by molecular
chaperones [7]. In general, molecular chaperones are highly
conserved and abundant proteins that change the folding energy
landscape for their client proteins to assist them in reaching their
native conformation in an efficient and timely manner [8,9]. SR
interact with a heterocomplex consisting of the heat shock protein
(Hsp) 90, Hsp70, Hsp40, Hsp70/Hsp90 organizing protein (HOP),
p23 and various cochaperones in a stepwise fashion to attain a
conformational state competent of binding to hormone with high
affinity [10]. The model that emerged from research over the last
two decades states that the initial folding steps are aided by Hsp70
based chaperones and co-chaperones, while the final steps are
expedited through Hsp90-centred heterocomplexes [11].
Both Hsp70 and Hsp90 feature a C-terminal EEVD motif that
serves as acceptor site for cochaperones that harbour a
tetratricopeptide repeat (TPR) domain [12]. In particular the
Hsp90-interacting TPR proteins have received broad attention as
proposed regulators of SR function [11,13]. Among these TPR
proteins are the carboxyl terminus of Hsc70-interacting protein
(CHIP), Cyclophillin-40 (Cyp40), the immunophilin FK506-
binding proteins (FKBP) 51 and 52, protein phosphatase 5
(PP5), the tetratricopeptide repeat protein 2 (TPR2) and the
hepatitis virus B X-associated protein 2 (XAP2).
Many of the TPR proteins bring additional molecular functions
to the SR-chaperone heterocomplexes. CHIP contains a C-
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11717
terminal U-box that interacts with ubiquitin-conjugating enzymes
and has been reported to promote degradation of various steroid
receptors [14–17]. The immunophilin and peptidylprolyl isomer-
ase (PPIase) Cyp40 has also been identified in SR-heterocom-
plexes, but its role regarding SR-function is still unclear [18].
FKBP51, another PPIase, was characterised as a cellular factor
contributing to the glucocorticoid resistance observed in New
World primates [19,20]. It inhibits glucocorticoid receptor (GR)
activity by lowering hormone binding affinity of the receptor and
delaying nuclear translocation [20,21], and also inhibits the
mineralocorticoid receptor [22]. In contrast, the highly homolo-
gous FKBP52 was found to positively modulate SR function
and to be critical for progesterone and androgen function
in vivo [18,23–27]. While the PPIase protein domains of FKBP51
and FKBP52 play an important role in GR’s regulation, the
function of the enzymatic PPIase activity remains enigmatic
[18,21,28].
PP5 is the only TPR-domain containing phosphatase identified
so far; it has been shown to modulate a variety of cellular
pathways [29]. The role of PP5 in SR signalling appears
controversial so far, possibly due to the different approaches
and experimental systems. Both positive and negative modulatory
effects of PP5 on steroid dependent transcription have been
reported. Down-regulation of PP5 expression was shown to
increase GR activity in reporter gene assays [30] and transcrip-
tion of estrogen receptor (ER) target genes [31] suggesting a
negative modulatory role of PP5 in steroid dependent signalling.
In contrast, in a different study siRNA-mediated PP5 knock-
down lead to a decrease in transcription of GR target genes [32].
In yeast, the PP5 homolog Ppt1 acts as a positive modulator of
GR, possibly by removing inhibitory phosphates from Hsp90
[33].
TPR2 is a J-domain containing cochaperone which has been
demonstrated to modulate GR and PR signalling [34,35]. It may
act by mediating the retrograde transfer of substrates from Hsp90
onto Hsp70 [34]. XAP2 has been well studied for its role in
regulating the activity of the arylhydrocarbon receptor (AhR) class
of nuclear receptors [36]. Recently, XAP2 was shown to inhibit
GR-mediated transcription [37].
Based on evidence from the literature and our own studies on
the GR-inhibitory role of FKBP51, we had initiated a genotyping
study that revealed a genetic association of this TPR protein with
the response to medication in major depression [38]. Meanwhile,
FKBP51 has been included in several studies and attracted great
attention for the association of its genetic polymorphisms and gene
expression level with a number of stress-related phenotypes and
neuropsychological diseases, such as major depression or post
traumatic stress disorder [38–46]. All these findings corroborate a
physiological role of FKBP51 in stress regulation, most likely via its
action in GR signalling.
Since several TPR proteins should be able to compete with
FKBP51 for binding to the binding site for TPR proteins in an
Hsp90 dimer [47–49], we assume that the overall impact of
FKBP51, or any other TPR protein, on GR, or SR in general,
depends on the relative abundance and mode of action of the
other TPR proteins present in the same cell. Knowledge about
each of these factors’ capability to influence SR function might
provide the basis for the understanding of tissue responsive-
ness to steroid hormones. A comprehensive comparison of the
TPR-proteins on the function of all steroid receptors in a
homogenous mammalian system has not been accomplished yet.
Thus, we assessed the impact of the TPR proteins CHIP,
Cyp40, FKBP51, FKBP52, PP5, TPR2 and XAP on each of
the SR.
Results
Different responsiveness of the steroid hormone
receptors in reporter gene assay
To set up an assay for the determination of the influence of the
seven selected TPR proteins CHIP, CYP40, FKBP51, FKBP52,
PP5, TPR2 and XAP2 on the six steroid receptors GR, MR, PR,
AR, ERa and ERb, we established reporter gene assays for each of
the receptors. For GR, MR, PR and AR, we made use of the
hormone-responsive elements of the MMTV LTR promoter that
was linked to the structural part of the firefly luciferase gene [50].
To measure the activity of the two ER receptors we used a
luciferase reporter plasmid with two copies of an estrogen
responsive element instead of the MMTV LTR [51]. For each
receptor, we used two sub-saturating concentrations of hormone as
well as one concentration well in the range of saturation.
GR and PR displayed the widest, AR a considerable, and MR
and the two ERs a moderate range of hormone inducible activity
in human neuronal SK-N-MC cells (Fig. 1). We chose this cell line
for two reasons, first because is largely devoid of steroid receptors,
and second because of its neuronal origin.
Since the effects of FKBP51 on GR have been reported to be
most pronounced at sub-saturating concentrations of hormone, we
focused our further analyses on conditions that yielded significant,
but not yet full activation of the respective steroid receptor. In
addition, we also included one saturating concentration of
hormone for each receptor.
Steroid receptors display differential sensitivity to TPR-
proteins
To assess the effect of the TPR proteins on steroid receptor
activity, each of the FLAG-tagged TPR proteins was co-expressed
with each of the HA-tagged steroid receptors GR, MR, PR, AR,
ERa, or ERb, respectively, along with reporter and control
plasmids. Since mammalian cells, in contrast to yeast, feature a
number of different receptor-relevant TPR proteins, we reasoned
that overexpression of a specific TPR protein is necessary to
significantly enhance occupancy of the TPR acceptor site on
Hsp90 by this specific cofactor. To test whether this is indeed the
case under the conditions chosen we first evaluated the degree of
overexpression for each of the TPR cofactors (Fig. 2A). Cells were
transfected with plasmids encoding for one of the TPR proteins
and probed their abundance in cell lysates using Western blot
analysis. Each of the TPR cofactors was at least 4 fold enhanced
over the endogenous levels (Fig. 2A).
Since our experimental design was further based on the
assumption that selectively enhancing the level of one of the
TPR cofactor results in changing the composition of the Hsp90
heterocomplexes, we tested this at the example of FKBP52
overexpression. Cells were transfected with FKBP52 expressing
plasmid, and Hsp90 complexes were immunoprecipitated from
cell lysates of FKBP52 overexpressing cells and control cells. While
more FKBP52 was co-precipitated with Hsp90 complexes, all the
other investigated TPR cofactors were less abundant (Fig. 2B,
Cyp40 was below detection limit). As an important control, the
interaction of Hsp90 with the non TPR protein p23 was not
changed by increasing FKBP52 (Fig. 2B).
The first observation we made in the reporter gene assays was
that, in general, the changes in receptor activity upon co-
expression of TPR cofactors were more pronounced for GR,
MR, and PR than for AR, and even more than for the two ERs,
which were almost not affected (Figs. 3 and 4). Strong inhibitors of
GR were CHIP, FKBP51, PP5, TPR2, and XAP2, while CYP40
and FKBP52 showed virtually no effect (Fig. 3A). As shown for
TPR Proteins Influence SR
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GR, at saturating concentrations of hormone the inhibitory effect
was greatly diminished, even though TPR2, for example, still
reduced GR’s activity twofold (Fig. 3B). Similar observations were
made with saturating concentrations of hormone at the other
receptors (data not shown).
The TPR reactivity profile of MR was very similar, except for
PP5 and XAP, which exerted only a marginally inhibitory effect
on MR (Fig. 3C). Albeit we were using stripped serum free of
steroids, we observed a significant activity of MR even in the
absence of added hormone, which was affected by the TPR
cofactors in the same way as the hormone-stimulated activity
(Fig. 3C and data not shown). To test whether any serum
component might have contributed to hormone-independent
activation of MR we cultivated transfected cells in serum free
media for 24 h before measuring reporter activity. Serum
withdrawal reduced MR-dependent transactivation, suggesting
that factors other than glucocorticoids are present in steroid free
media which partially activate MR’s transcriptional activity
(Fig. 3D). This effect appeared to be additive to the glucocorti-
coid-mediated effect, because stimulation with sub-saturating
concentrations of fludrocortisol (0.03 nM) in stripped serum
containing media resulted in higher MR activation than in serum
free media (Fig. 3D).
Similarly to GR, PR showed the highest activity when co-
expressed together with CYP40 or FKBP52 (Fig. 4A). The effects
of the TPR-cofactors were noticeably attenuated in the case of AR
(Fig. 4B). Only co-expression of FKBP52 maintained AR activity,
while all the other TPR cofactors reduced this receptor’s activity to
a moderate degree, with TPR2 being the strongest inhibitor (5 fold
inhibition, Figure 4B). ERa and ERb showed almost no reaction
to the presence of TPR cofactors under our conditions, except for
TPR2, which reduced the activity of these receptors about 2 fold
(Figs. 4C, D).
We also monitored the expression levels of the co-expressed
receptors and TPR proteins. There were some variations
throughout the experiments, but overall there were no gross
alterations in the levels of the steroid receptors in dependence of
the co-expressed TPR cofactor, except for CHIP which often,
albeit not consistently, led to lower receptor expression levels
(Figs. 3 and 4 examples in the panels below the activity assay
graphs). This was not unexpected, because CHIP has been
identified as E3 ligase and been shown to reduce the levels of GR
[15]. The levels of the co-expressed TPR proteins also varied
between experiments. Overall, Cyp40 and TPR2 had a tendency
to be expressed at lower levels, and to a lesser extent also FKBP51,
while the other cofactors expressed at the same levels.
The estrogen receptors show little sensitivity to
geldanamycin
Since most of the TPR proteins had little impact on ERs’
transcriptional activity, we wondered whether these two receptors
are dependent on functional Hsp90 at all under our assay
Figure 1. Response of steroid hormone receptors in MMTV-reporter gene assays. Neuronal SK-N-MC cells were transfected with a plasmid
expressing one of the HA-tagged SRs, the MMTV firefly-luciferase reporter plasmid when transfecting GR, MR, PR, or AR, an ERE firefly-luciferase
reporter plasmid for ERa and ERb, and the Gaussia-KDEL control plasmid. After transfection, the cells were cultivated for 24 h in the presence of the
indicated concentrations of hormone (DHT: Dihydrotestosterone) or EtOH as solvent control. Receptor activity represents firefly data normalized to
Gaussia activities + S.E.M. of at least four independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0011717.g001
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conditions. Therefore, we applied the specific Hsp90 inhibitor
geldanamycin (GA), which has been shown to block Hsp90 activity
by binding to its ATP pocket [52,53]. We performed reporter gene
assays for ERa, ERb, and GR in the presence or absence of GA
(Fig. 5). While GA efficiently reduced the activity of GR (Fig. 4C),
it had very little effect, if any, on the activity of ERa and ERb
(Figs. 5A,B). Whatever the reason for the apparent Hsp90-
independent action of these two receptors is, it could explain why
the Hsp90 cofactors have so little impact on their activity.
It has been found that GA leads to degradation of Hsp90 client
proteins such as GR [54–56]. To test whether the differential
responsiveness of GR and ER to GA is also reflected on the level of
protein stability, we measured the expression levels of GR and ER
upon GA treatment. Neither GR nor ER were significantly
changed in their protein levels after exposure of transfected HEK
cells (Fig. 5) or SK-N-MC cells (data not shown) with GA, which
could be due to the much lower concentrations of GA used here
compared to other studies [54,55].
Cyclophilin 40 is unable to rescue receptor activity
FKBP52, which does not change the activity of GR when co-
expressed with this receptor in mammalian cells (Fig. 3A, and
[21]), has been shown to be able to attenuate the inhibitory effect
of FKBP51 [21]. In our screen of the activity profiles of the TPR
proteins Cyp40, like FKBP52, had no or very little effect on steroid
receptors (Figs. 3 and 4). Thus, the question arose, whether an
effect of Cyp40 on GR or MR may become apparent under
conditions of compromised receptor activity, i.e. when an
inhibitory protein is co-expressed. Therefore, we coexpressed
FKBP51 at moderate levels to inhibit GR and MR, and added
increasing amounts of Cyp40 expressing plasmid (Fig. 6). Even
though Cyp40 was expressed up to levels that exceeded those of
FKBP51 (both proteins were FLAG tagged, allowing a direct
comparison in a Western blot) and well above endogenous levels, it
was unable to rescue the activity of GR or MR (Figs. 6A and B).
This is in contrast to FKBP52, which has been shown to be able to
revert the inhibitory action of FKBP51 [21].
Figure 2. TPR proteins are significantly enhanced upon ectopic expression and change Hsp90 heterocomplex composition. A, SK-N-
MC cells were transfected with plasmid expressing one of the TPR proteins, lysed after 48 h and levels of the respective TPR protein was determined
by Western blot analysis. B, HEK-293 cells were transfected with FLAG tagged Hsp90 along with FKBP52 expressing plasmid or control plasmid. Hsp90
was precipitated from lysates and the levels of co-precipitated cofactors were determined by Western blot.
doi:10.1371/journal.pone.0011717.g002
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Binding profiles of TPR proteins to steroid receptor-
Hsp90 heterocomplexes
The ability of TPR proteins to access heterocomplexes of steroid
receptors and Hsp90 is assumed as prerequisite for their impact on
these receptors. Therefore, we evaluated the relative incorporation
of the TPR-proteins into steroid receptor complexes employing
complementary co-immunoprecipitation. The estrogen receptors
were not included, because they were only marginally affected by
most of the TPR proteins. We expressed each of the HA-tagged
steroid receptors in combination with each of the seven FLAG-
tagged TPR proteins and performed co-immunoprecipitations
with antibodies directed against the HA-tagged receptors or the
FLAG-tagged TPR proteins, respectively, and visualized co-
precipitated proteins by Westernblot analysis.
Figure 3. GR and MR activities in the presence of different TPR-proteins. A-C, SK-N-MC cells in 96 well plates were transfected with the
MMTV-Luc, Gaussia-KDEL control plasmid, a plasmid expressing one of the HA-tagged steroid hormone receptor (GR in A and B, MR in C and D) and
constant amounts (200 ng) of a plasmid expressing one of the FLAG-tagged TPR-proteins. After transfection, the cells were cultivated for 24 h in the
presence of hormone or vehicle as indicated. Relative receptor activity represents firefly data normalized to Gaussia activities and presented as
relative stimulation to control + S.E.M. of at least four independent experiments performed in duplicate. Control cells were transfected with cloning
plasmid instead of the TPR protein expressing plasmid. Lower panels of A and C, immunoblot of cell extracts, probed with anti-HA antibody
visualizing steroid receptor expression, the same membrane probed with FLAG antibody demonstrating expression of TPR proteins and with actin
antibody as loading control. D, After transfection, cells were cultivated in 0.1% or 10% SF-FCS containing media for 24 h in the presence of 0.03 nM
fludrocortisol, or EtOH as vehicle control. Firefly luciferase data were normalized to Gaussia luciferase activities and are presented as relative
stimulation + S.E.M. of three independent experiments performed in triplicate. * denotes p-values #0.001.
doi:10.1371/journal.pone.0011717.g003
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Figure 4. PR, AR, ERa and ERb activities in the presence of different TPR proteins. SK-N-MC cells were transfected with the MMTV-Luc (for PR
andAR assays), or the ERE-Luc reporter plasmid (for ERa andERb assays), theGaussia-KDEL control plasmid, a plasmid expressing theHA-tagged steroid hormone
receptor as indicated and the plasmid expressing a FLAG-tagged TPR-protein. After transfection, cells were cultivated for 24 h in the presence of hormone as
indicated. Relative receptor activity represents firefly data normalized to Gaussia activities and presented as relative stimulation to control + S.E.M. of at least four
independent experiments performed in duplicate. Control cells were transfected with cloning plasmid replacing the TPR protein expression plasmid in the
transfection mixture. Lower panels of A–D display immunoblots of cell extracts, probed with anti-HA antibody visualizing steroid receptor expression, the same
membrane probed with FLAG antibody demonstrating expression of the TPR proteins and with actin antibody as loading control. * denotes p-values#0.001.
doi:10.1371/journal.pone.0011717.g004
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Since we observed varying efficiencies in the amount of
precipitated protein using HA- or FLAG-directed antibodies, co-
precipitated proteins were normalized to the precipitated primary
target, and in case of HA-directed IPs also to the relative
expression of the different TPR proteins.
For GR, the receptor IP revealed CHIP, FKBP51 and TPR2 as
strong binders to the heterocomplex (Fig. 7). The FLAG-IPs
targeting the TPR proteins revealed a similar binding pattern. We
observed that Cyp40 exhibited weak interaction with the
heterocomplex, which may account for its inability to compete
the inhibitory effect of FKBP51. Notably, the strongest binders all
were strongly inhibitory proteins. On the other hand, PP5, which
also significantly reduced GR activity, in comparison displayed
only moderate interaction.
For MR, the interaction pattern of the TPR cofactors was
similar to that of GR. Again, CHIP, FKBP51 and TPR2 exhibited
strong interaction, while Cyp40 showed very little binding, both
when immunoprecipitating the receptor or the cofactor (Fig. 8 A
and B). Of note, the inability of PP5 to inhibit MR’s
transcriptional activity was not reflected by a corresponding low
incorporation into MR heterocomplexes.
In the case of PR, we observed the strongest interaction with the
PR-Hsp90 heterocomplex for CHIP, FKBP51, and TPR2 (Fig. 9),
which in the reporter gene assay also were the ones that exhibited
the strongest inhibitory activity (Fig. 4A). Remarkably, XAP2 and
PP5, which also reduced PR’s transcriptional activity, bound only
weakly to the complex.
Although AR showed less activity change in response to co-
expression of TPR cofactors than GR, MR and PR, the TPR
cofactors exhibited a distinct binding profile (Fig. 10). The most
efficient binding was observed for TPR2, in the presence of which
AR was least transcriptionally active (Fig. 4B). In general though,
there was no strict correlation between binding efficiency to the
Hsp90-AR heterocomplex and the influence on the transcriptional
activity of AR. For example, in the presence of CHIP or Cyp40,
AR exhibited a very similar transcriptional activity, but these two
TPR proteins differed markedly in their ability to access the AR-
Hsp90 heterocomplex (Figs. 4B and 10).
TPR cofactors favor differently composed multi-
chaperone heterocomplexes
During maturation, the steroid receptor proceeds through a
multi-chaperone machinery in which each step is characterized by
a relative abundance of distinct chaperones [7]. Therefore, it is
possible that preference of the TPR cofactors to distinct
heterochaperone complex compositions represents an important
mechanistic aspect of their function. Thus, we compared the
abundance of endogenous components of the chaperone machin-
ery co-precipitating with the immunoadsorbed TPR-cofactors.
Since the FLAG-tagged proteins were precipitated with
different efficiencies (although amounts of plasmids were adjusted
so that the TPR proteins were expressed at similar levels, compare
Figs. 7–10), the amount of co-precipitated Hsp90, Hsp70 and p23
was normalized to the amount of precipitated TPR cofactor. We
consistently observed some nonspecific binding of Hsp70 to the
FLAG agarose resin, and therefore, considered only levels
exceeding the background binding as indicative of Hsp70
interaction. Co-expression of the different steroid receptors did
not change the relative co-precipitation of Hsp70, Hsp90 and p23.
Therefore, we used the results of experiments with different steroid
receptors to determine the relative binding of these components to
the TPR-proteins.
Hsp90 interaction was detected for all TPR cofactors investi-
gated here, as expected. However, there was a considerable
difference in the relative amount of co-precipitated Hsp90
(Fig. 11A and B). FKBP51 and FKBP52 displayed the strongest
Hsp90 interaction, and PP5 still about 4 fold higher interaction
than CHIP, CYP40, TPR2 and XAP2, which all bound at
comparable levels. Notably, while p23 interaction reflected the
relative Hsp90 co-precipitation in general, p23 co-precipitated
with FKBP52 less than with FKBP51 or PP5 in relation to the
Hsp90 association (Fig. 11C). Apparently, FKBP51 and PP5 favor
p23 containing Hsp90 heterocomplexes more than FKBP52,
possibly by stabilizing the interaction between Hsp90 and p23.
Hsp70 binding was detected for CHIP and TPR2, as reported
previously [34,57]. No Hsp70 binding was detected for CYP40,
FKBP52, PP5 and XAP2, but surprisingly, for FKBP51. Although
Figure 5. Estrogen receptors display little sensitivity to the Hsp90 inhibitor geldanamycin. SK-N-MC cells were transfected with 0.25 mg
of one of the plasmids expressing ERa (A), ERb (B) or GR (C), together with either ERE-Luc (A,B) or MMTV-Luc (C) as reporter plasmid and the Gaussia-
KDEL control plasmid. After transfection, the cells were cultivated for 24 h in the presence of hormone and 10 ng/ml GA as indicated. Relative
receptor activity represents Firefly data normalized to Gaussia activities and is presented as relative stimulation to control + S.E.M. of at least four
independent experiments performed in duplicate. Lower panels, analysis of receptor expression after GA treatment in the presence or absence of
hormone (10 nM estrogen, 500 nM cortisol).
doi:10.1371/journal.pone.0011717.g005
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this binding was clearly weaker than that observed for CHIP and
TPR2, it was significantly more than the virtually non existent
Hsp70 binding of FKBP52 (p= 0.007 in an unpaired student’s t-
test). This could indicate that FKBP51 favors early stages of the
folding cycle, which could contribute to its inhibitory function.
Loss of FKBP52 impairs GR function
The experiments described so far were based on increasing the
abundance of a specific TPR cofactor in Hsp90 heterocomplexes.
Considering the plethora of TPR cofactors in the cell, we
pondered on the ability of mammalian cells to compensate for
the loss of one of the proteins. Based on the inability of enhanced
FKBP52 to significantly increase GR function, we reasoned that
loss of an inhibitory factor, for example FKBP51, would have little
effect. Therefore, we experimentally addressed the effect of loss of
the established positive GR regulator FKBP52. Since our attempts
to reduce FKBP52 using si-RNA resulted in only partial reduction
(data not shown), we used mouse embryonic fibroblast (MEF)
FKBP52 KO and WT cells. We found that stimulation of GR
activity at saturating concentrations of hormone was not
significantly affected (data not shown). However, higher concen-
trations of hormone were needed in FKBP52 ko cells to elicit a GR
response comparable to that in WT MEF cells (Fig. 12).
Since cells derived from different animals and cultivated for
several generations can differ in numerous factors, it was
mandatory to test whether the difference in the cortisol
responsiveness between WT and FKBP52 KO MEF cells was
indeed due to loss of FKBP52. Therefore, we overexpressed
FKBP52 in FKBP52 KO MEF cells, which rendered the cortisol
responsiveness indistinguishable from that of WT MEF cells
(Fig. 12).
Discussion
How are molecular chaperones able to assist correct folding of a
plethora of structurally divergent proteins? In general, the various
chaperone factors protect non-native protein chains from
misfolding and aggregation, but do not contribute conformational
information to the folding process [8]. They interact with features
of non-native protein folds that are common to many proteins,
such as hydrophobic stretches and unstructured backbone regions,
and provide nano-compartments to shield proteins during their
folding process from other proteins. Hsp90 regulates mainly a wide
range of signal transduction molecules, and thus belongs to the
more specialised, but still very versatile chaperones [9,58]. Our
study provides a better understanding of this versatility through
combinatorial compositions of the Hsp90-client heterocomplexes.
Of the six steroid receptors, the closely homologous GR, MR
and PR exhibited the strongest reaction to changes in the TPR-
protein make-up of the cell (Fig. 2 and 3). AR, and the ERs in
particular, were less affected by co-expressing any of the co-
chaperones. This may be explained by a diminished Hsp90-
dependency of ER, at least in our cellular set-up, corroborated by
the ineffectiveness of GA towards ER. Others have also provided
evidence that ER may operate independently of Hsp90 [59,60],
which contrasts reports on lower ER activity where Hsp90
function was compromised [61–64]. It should be noted, though,
Figure 6. Cyp 40 is unable to compete the inhibitory effect of
FKBP51. SK-N-MC cells were transfected with the MMTV-Luc reporter
plasmid, the Gaussia-KDEL control plasmid, one of the plasmids
expressing the HA-tagged GR or MR as indicated, and plasmids
expressing FKBP51 and Cyp40 at the indicated amounts. After
transfection, the cells were cultivated for 24 h in the presence of
10 nM cortisol (A) or 0.03 nM Fludrocortisol (B). Bar graphs indicate the
relative reporter activity representing Firefly measurements normalized
to Gaussia activities and presented as relative stimulation + S.E.M. of
three independent experiments performed in triplicate. Lower panel of
A displays immunoblots of cell extracts, probed with HA antibody
demonstrating GR expression and the same membrane probed with
FLAG antibody to detect overexpressed FKBP51 and Cyp40, and actin as
control. In addition, antibodies directed against FKBP51 or Cyp40 were
used to visualize the combined levels of endogenous and ectopic TPR
protein.
doi:10.1371/journal.pone.0011717.g006
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Figure 7. TPR-proteins differently interact with GR heterocomplexes. HEK-293 cells were transfected with 5 mg of a plasmid expressing HA-
tagged GR together with 2-10 mg (to achieve similar expression levels) of one of the plasmids expressing a FLAG-tagged TPR protein. After 48-72 h
cultivation in SF-FCS containing media, cells were harvested, lysed, and protein extracts prepared for immunoprecipitation of either the HA-tagged
GR (A), or the FLAG-tagged TPR-proteins (B). A, Precipitation of HA-GR. Displayed is an example of an immunoblot that was probed with FLAG
antibody to visualize co-precipitated TPR-proteins (upper right panel), and an immunoblot of the same membrane probed with HA antibody
demonstrating precipitated GR (lower right panel). Left panel, quantification of the relative binding of the TPR-proteins to the steroid receptor
heterocomplexes. FLAG- and HA-immunoblot signals of the eluates and FLAG immunoblot signals of the cell extracts, demonstrating expression of
TPR proteins (C), were scanned and subjected to densitometry. The signal from the co-precipitated FLAG protein was corrected first by the amount of
precipitated receptor and second by the amount of the TPR-protein present in the respective cell extract. Binding of TPR-proteins is presented
relative to the mean of the normalized FLAG-eluate signals of CHIP, FKBP51, FKBP52, and PP5. Quantification represents the means of three
independent experiments +S.E.M. B, precipitation of TPR proteins. Upper right panel, coomassie stained gel of eluates visualizing precipitated TPR-
proteins (arrowheads) and co-precipitated Hsp90 and Hsp70. Lower right panel, immunoblots of eluates probed with HA antibody to demonstrate
binding of GR to TPR-protein heterocomplexes. Left panel, quantification of the relative binding of co-precipitated proteins to the precipitated TPR-
proteins. For quantification, signals were scanned and subjected to densitometry. Each HA immunoblot signal of the eluate was corrected by the
amount of precipitated TPR-protein. Binding of steroid receptors is presented relative to the mean of the corrected HA eluate signals. Quantifications
represent means of three independent experiments +S.E.M.
doi:10.1371/journal.pone.0011717.g007
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that high doses of GA of 0.2–1 mg/ml have been used in these
reports. We used a 20–100 fold lower concentration of GA, which
efficiently reduced GR activity, like we also have observed
previously [65]. We cannot exclude the possibility that ER activity
could be impaired also in our cellular system at very high
concentrations of GA, which however, would raise the question of
non-specific effects of GA. We propose that the Hsp90-
dependency of ER is cell-type dependent, and possibly affected
by the presence or absence of additional, yet to be revealed factors.
In addition, high doses of GA have been reported to induce
reactive oxygen species in cells [66–69], which might contribute to
differences in the effects of GA on ER at different concentrations.
Our study also documents numerous differences in the efficacies
of the TPR proteins’ influence on SR. Cyp40 exhibited only a
minor effect on AR and PR, and no effect on GR, MR and the
ERs, which concurs with its small binding affinity to Hsp90 and
Figure 8. Differential interaction of TPR-proteins with MR heterocomplexes. HEK-293 cells were transfected as described for figure 7,
except that HA-MR was expressed instead of HA-GR. Cells were processed and protein interactions were analyzed also as described for figure 7. In A,
binding of TPR-proteins is presented relative to the mean of the normalized FLAG-eluate signals of CHIP, FKBP51, FKBP52 and PP5. Quantification
represents means of three independent experiments (two for TPR2) +S.E.M.. In B, binding is normalized as in figure 7. C, FLAG- and HA-immunoblot
signals of the cell extracts, demonstrating expression of TPR proteins and MR. Quantifications represent means of three independent experiments
+S.E.M.
doi:10.1371/journal.pone.0011717.g008
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steroid receptor heterocomplexes in comparison to other TPR
proteins (Fig. 6–10). Work in yeast, which expresses the two Cyp40
homologues Cpr6 and Cpr7, revealed an involvement of Cpr7,
but not Cpr6 in the hormone-dependent activity of GR [70,71]. In
addition, Cpr6 did not influence Hsp90 activity [72]. In
mammalian cells, the effect of Cyp40 on steroid receptors has
not been directly assessed. However, cyclosporine A, which is
known to target Cyp40 as well as Cyp18, somewhat diminished
AR function in LNCaP cells [73].
CHIP efficiently inhibited the transactivational activity of GR,
MR, PR, and moderately affected AR. It has been reported that
CHIP induces degradation of GR, AR and ERa [15–17] and
reduces hormone binding of GR [15]. With respect to steroid
receptor degradation, we observed a tendency towards lower
receptor amounts, but no consistently significant effect. Since
saturating concentrations of hormone greatly attenuated the
inhibitory effect of CHIP on all steroid receptors (Fig. 2B for
GR and data not shown for MR, PR, AR), mechanisms in
Figure 9. Differential interaction of TPR-proteins with PR heterocomplexes. HEK-293 cells were transfected as described for figure 7, except
that HA-MR was expressed instead of HA-GR. Cells were processed and protein interactions were analyzed also as described for figure 7. In A, binding
of TPR-proteins is presented relative to the mean of the normalized FLAG-eluate signals of CHIP, FKBP52, PP5 and TPR2. Quantification represents
means of three independent experiments (two for FKBP51) +S.E.M. In B, binding is normalized as in figure 7. C, FLAG- and HA-immunoblot signals of
the cell extracts, demonstrating expression of TPR proteins and PR. Quantifications represent means of three independent experiments +S.E.M.
doi:10.1371/journal.pone.0011717.g009
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addition to protein degradation must be responsible for the
observed inhibition, most likely reduction of hormone binding.
Moreover, the interaction of CHIP with Hsp70 may lead to an
influence on SR at early stages of the folding cycle, similarly to
TPR2 [34]. AR may be a special case, as CHIP interacts not only
via Hsp90 with the LBD of this receptor, but also via its C-
terminus with a conserved motif at the N-terminus of the receptor
[17].
Increasing or reducing the levels of TPR2 has been shown to
reduce the activity of GR and PR [34,35], while other steroid
receptors had not been analyzed before. In our experiments,
increased levels of TPR2 resulted in a strong reduction of the
activity of all SR, in contrast to the other investigated TPR
proteins, which exhibited at least some selectivity in their action on
SR. Our finding of strong interaction of TPR2 with Hsp70, but
only moderate interaction with Hsp90 in comparison with other
TPR proteins, supports the hypothesis that TPR2 acts by
interference at early stages of the SR folding cycle [34,35].
Furthermore, TPR2 still displayed considerable inhibitory activity
at saturating conditions of hormone. Thus, TPR2 most likely
Figure 10. Differential interaction of TPR-proteins with AR heterocomplexes. HEK-293 cells were transfected as described for figure 7,
except that HA-MR was expressed instead of HA-GR. Cells were processed and protein interactions were analyzed also as described for figure 7. In A,
binding of TPR-proteins is presented relative to the mean of the normalized FLAG-eluate signals of CHIP, FKBP51, and TPR2. Quantification represents
means of three independent experiments (two for XAP2) +S.E.M. In B, binding is normalized as in figure 7. C, FLAG- and HA-immunoblot signals of the
cell extracts, demonstrating expression of TPR proteins and AR. Quantifications represent means of three independent experiments +S.E.M.
doi:10.1371/journal.pone.0011717.g010
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operates through mechanisms in addition to reducing hormone
binding affinity [34].
For XAP2, a moderate interaction with Hsp90 has been found
before [37,74], but there were no reports on incorporation into SR
heterocomplexes. We reveal here the potential of XAP2 to interact
with SR. This leads to a differential impact on the transcriptional
activity of the receptors, with the strongest effects observed for GR
and PR, while MR displayed little reaction to the presence of
XAP2. XAP2 also interacts with other receptors, such as AhR
[74], peroxisome proliferator-activated receptor a [75] and
thyroid hormone receptor b1 [76]. These interactions go along
with an inhibition of the transcriptional activity of PPARa, and a
stimulation of AhR and THRb1. XAP2 also affects nuclear
translocation of AhR [77,78] and GR [37].
FKBP51 and FKBP52 are the most intensely investigated TPR
cofactors of steroid receptors. In particular for GR, important
insight was gained from experiments in yeast, that characterised
FKBP52 as stimulatory GR cofactor, while FKBP51 had no effect
[18]. Studies in mammalian cells reported a strong inhibitory
action of FKBP51 on GR, while over-expression of FKBP52 had
no effect [20,21,79,80]. In at least some mammalian cells, a
positive effect of FKBP52 on AR- and GR-signaling has been
observed [23,24,81]. Gene knock-out studies in mice revealed an
essential influence of FKBP52 on AR- and PR-related physiolog-
ical processes, while ablation of the FKBP51 gene did not result in
an overt phenotype [24–27]. Very recently, a stimulatory effect of
FKBP51 on AR has been reported in prostate cancer cells [82,83].
We have obtained preliminary evidence that this may be a cell-
type-specific effect (data not shown).
In the study presented here, FKBP51 and FKBP52 exhibited
divergent effects on the transcriptional activities of GR, MR, PR
and AR. Consistent with a previous report on GR [84], we also
observed a stronger incorporation of FKBP51 in SR hetero-
complexes than of FKBP52. At the same time, the interaction of
both proteins with Hsp90 was comparable. Thus, the interaction
with Hsp90 is not the sole determinant for the efficiency of
integration into SR-heterocomplexes. Our interaction analyses
further revealed a higher abundance of p23 in Hsp90 complexes
Figure 11. TPR cofactors differentially recruit components of the multichaperone heterocomplex. HEK cells were transfected and TPR
cofactors immunoprecipitated as described in the legends to figures 7–10. The relative amounts of the precipitated TPR cofactors, the co-precipitated
Hsp70 and Hsp90 were determined by densitometry of a coomassie stained gel of the eluates (A, upper panel), and the relative amount of p23 by
densitometry of the immunoblot signals (A, lower panel). B and D, quantification of the relative binding of co-precipitated Hsp90 (B) and Hsp70 (D).
Hsp90 signals and Hsp70 signals (only intensities above background binding were taken into consideration) were normalized to signals of the
respective precipitated TPR cofactors. Data are presented as relative binding + S.E.M. of at least 12 independent experiments with different steroid
receptors. C, quantification of the relative binding of co-precipitated p23. The p23 immunoblot signals were related (normalized) to the respective
TPR cofactor signal. Binding of p23 is presented relative to the mean of the normalized p23 eluate signals of the complete set of TPR-proteins.
doi:10.1371/journal.pone.0011717.g011
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with FKBP51 than in Hsp90 complexes with FKBP52. This may
be explained by the possibly different interaction surfaces of Hsp90
that are engaged in binding these two immunophilins. FKBP52, in
addition to the classic C-terminal MEEVD motif, recognises
amino acids at the ATP binding pocket [85], which may impinge
on p23 interaction. It should be noted, though, that binding of
FKBP51 to this N-terminal site has not been tested yet [85].
Whatever the explanation is for the differential recruitment of p23,
the increased presence of p23 may be related to the inhibitory
action of FKBP51 on GR [86]. In addition, the recruitment of
Hsp70 by FKBP51, albeit minor, could also add to the differential
action of FKBP51 and FKBP52, as Hsp70 is absent in mature
receptor heterocomplexes.
Our experiments revealed an inhibitory effect of PP5 that was
most pronounced in the case of GR. Previous studies examining
the effect of PP5 on GR produced partly inconsistent results.
Expression of the TPR domain of PP5 in CV-1 cells abolished
GR-dependent transcription [87], like probably the over-expres-
sion of any functional TPR-domain would do. On the other hand,
over-expression of the PP5 TPR domain slightly stimulated the
transactivation of ERa and ERb [31], which reinforces the notion
that the ERs differ in their TPR-protein dependency from the
other SRs. Expression of full-length PP5 inhibited ERa and ERb,
probably via dephosphorylation of ER [31]. Knock-down of PP5
increased GR-dependent reporter gene activity in one study [30],
while another study discovered a reduction of endogenous mRNA
levels of GR-dependent genes [32]. In yeast, no effect of PP5 on
GR was observed and PP5 was unable to compete with FKBP52
to decrease the GR-stimulation of this protein [18]. The inactivity
of PP5 in yeast, which is insufficiently endowed with TPR-
cofactors positive for GR, is compatible with our observations of
the inhibitory action of PP5 in mammalian cells. Another study in
yeast reported a positive effect of the PP5 yeast homologue Ppt1
on GR function, possibly due to removal of chaperone-inhibitory
phosphates on Hsp90 [33]. It is not known whether this seeming
discrepancy can be explained by differences between PP5 and its
yeast homologue Ppt1, or by differences in GR regulation between
yeast and mammalian cells in general.
The effects of the TPR proteins on SR observed here were
significantly attenuated by saturating concentrations of hormone.
This is consistent with an effect on hormone binding affinity.
Different laboratories including ours provided evidence that later
steps in steroid signal transduction are also affected by TPR
cofactors, for example nuclear translocation [21,88,89] and
dynamics of intranuclear mobility [90], which requires future
experiments to clarify their relative contributions. Our results
substantiate the concept that a delicate balance of TPR cofactors
governs SR activity in a given cell or tissue, probably in a
combinatorial fashion. The recent description of the N-terminal
FKBP52 binding site on Hsp90 [85] opens the possibility for
various combinations of two TPR proteins in the same SR
heterocomplex. Alternatively, the dynamic assembly and disas-
sembly of heterocomplexes may enable the sequential contribution
of specific functions by the different TPR proteins.
Materials and Methods
The MMTV-Luc reporter plasmid has been described previ-
ously [91]. ERE-Luc reporter plasmid and ERa and ERb cDNA
were a kind gift of Christian Behl (University Mainz). N-terminally
HA-tagged ERa and ERb were subcloned from ER cDNA into
the pRK5-SV40 backbone. The plasmids expressing the N-
terminally HA-tagged receptors GR, MR, PR and AR (pRK7
backbone) were kindly provided by Anke Hoffmann (MPI of
Psychiatry, Munich) and the plasmid expressing Hsp90-FLAG by
Len Neckers (NIH, Bethesda). The Gaussia-KDEL was construct-
ed from a pCMV-GaussiaLuc1 plasmid (PJK) by linking the
KDEL peptide sequence C-terminally via PCR, and subcloning
into pRK5-SV40 backbone. TPR-proteins were all expressed as
C-terminal FLAG-fusions in the pRK5-SV40 vector. The cDNA
of CHIP was provided by Cam Patterson (University of North
Carolina), of Cyp40 and TPR2 by Ulrich Hart (MPI of
Biochemistry, Martinsried), of PP5 by Michael Chinkers (Univer-
sity of South Alabama). The plasmids expressing the FKBP51 and
FKBP52 FLAG-fusions and the untagged FKBP52 in pRK5-
SV40 were described previously [21]. The XAP2 plasmid is
described in [37]. All plasmids were verified by sequencing. Primer
sequences and cloning details are available upon request.
Cell culture, transfection and reporter gene assay
Mouse embryonic fibroblasts (Marc Cox and David Smith,
Mayo Clinic Scottsdale, Arizona, USA), human neuroblastoma
SK-N-MC (ATTC HTB-10) and HEK-293 (ATTC CRL-1573)
cells were cultured under conditions described previously [92,93].
For the MMTV-luc reporter gene assay, cells were seeded in 96
well plates (SK-N-MC 30,000 cells/well; MEF 10,000 cells/well)
in medium containing 10% charcoal-stripped, steroid-free serum
and cultured for 24 h before transfection using ExGen (Fermentas)
as described by the manufacturer. Unless indicated otherwise, the
amounts of transfected plasmids per well were 60 ng of steroid
responsive luciferase reporter plasmid MMTV-Luc, 5–7.5 ng of
Gaussia-KDEL expression vector as control plasmid, 25 ng of
plasmids expressing HA-tagged steroid hormone receptors (mGR
in case of MEF cells) and up to 300 ng of plasmids expressing
TPR-domain containing cofactors (not exceeding 200 ng per
single TPR-protein expression plasmid). If needed, empty
expression vector was added to the reaction to equal the total
amount of plasmid in all transfections. 24 h after transfection, cells
were cultured in fresh medium supplemented with hormone as
indicated or ethanol as control for 24 h. To measure reporter gene
Figure 12. Loss of FKBP52 affects GR responsiveness to
cortisol. FKBP52-KO MEF cells (open symbols) or WT MEF cells (closed
circles) were transfected with the MMTV-Luc reporter plasmid, the
Gaussia-KDEL control plasmid, a plasmid expressing the HA-tagged
mGR and either a plasmid expressing FLAG-tagged FKBP52 (+ect.52) or
empty vector. After transfection, cells were cultivated for 24 h in the
presence of hormone. Relative receptor activity represents firefly data
normalized to Gaussia activities and is presented relative to the activity
at saturating 300 nM corticosterone +S.E.M. of three independent
experiments, each performed in triplicates. Significance of different
receptor activation between FKBP52 KO cells and FKBP52 KO cells
ectopically expressing FLAG-tagged FKBP52 was evaluated by one
sampled T-test (* denotes p-values #0.001).
doi:10.1371/journal.pone.0011717.g012
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activity cells were washed once with PBS and lysed in 50 ml passive
lysis buffer (0.2% Triton X-100, 100 mM K2HPO4/KH2PO4
pH 7.8). Firefly and Gaussia luciferase activities were measured in
the same aliquot using an automatic luminometer equipped with
an injector device (Victor III, Wallac and Tristar, Berthold).
Firefly activity was measured first by adding 50 ml Firefly substrate
solution (3 mM MgCl2, 2.4 mM ATP, 120 mM D-Luciferin) to
10 ml lysate in black microtiter plates. By adding 50 ml Gaussia
substrate solution (1.1 M NaCl, 2.2 mM Na2EDTA, 0.22 M K2H
PO4/KH2PO4, pH 5.1, 0.44 mg/ml BSA, Coelenterazine 3 mg/
ml) the firefly reaction was quenched and Gaussia luminescence
was measured after a 5 s delay. Firefly activity data represent the
ratio of background corrected Firefly to Gaussia luminescence
values. The fold stimulation reached at saturating concentrations
of hormone was for GR about 1000, which is in the range of
previous publications [65,91], MR 3.7, PR 970, AR 6, ERa 4, and
ERb 6.3. To compare the effects of co-expressed TPR proteins,
the stimulation in the absence of the TPR protein was set to 100,
and the stimulation in the presence of co-expressed TPR protein
was referred to this value.
To check expression of receptors and TPR-proteins replicate
lysates were pooled, briefly sonicated and cleared by centrifuga-
tion. Alternatively receptors and TPR-proteins were coexpressed
in 6 well plates with the same receptor to TPR-protein ratios as for
the 96 well plates. To this end, SK-N-MC cells were seeded in 6
well plates (500,000 cells/well) in medium containing 10% steroid-
free serum and cultured for 24 before transfection of 0.25 mg HA-
tagged steroid hormone receptors and corresponding amounts of
plasmids expressing TPR-proteins per well using ExGen (Fermen-
tas) as described by the manufacturer. If needed, empty expression
vector was added to the reaction to equal the total amount of
plasmid in all transfections. Cells were cultured as for the reporter
gene assay and lysed in buffer containing 20 mM Tris-HCl
pH 6.8, 0.67% SDS, 3.3% Sacharose completed with Protease
Inhibitor Cocktail (Sigma), briefly sonicated and cleared by
centrifugation. Lysates were analyzed by SDS-PAGE followed
by immunoblot.
Statistical Analysis
To improve our understanding of the effects of various TPR
proteins on steroid receptor mediated gene transcription, we
performed one sample t-tests to evaluate the significance of
difference of the hormone-stimulated activity of the receptor in the
presence versus absence of coexpressed TPR protein. Significance
values were corrected according to the Bonferroni procedure. The
most pronounced differences with a significance level of p#0.001
are labelled in figures 3, 4 and 12 (*).
Immunoblot
Immunoblot detection of proteins was performed largely as
described [94]. Briefly, proteins were transferred from SDS gels to
a nitrocellulose membrane (Schleicher & Schuell, GmbH). Non-
specific binding to membrane was blocked by 5% nonfat milk in
Tris-buffered saline supplemented with 0.1% Tween-20, and then
one of the following specific primary antibodies were added: Actin
(I-19, Santa-Cruz), FLAG tag-HRP (M2, Sigma); hemagglutinin
tag-HRP (Roche Applied Science); p23 (ABR), FKBP52 (Anti-
FKBP59, Stressgen), CHIP (PC711, Calbiochem), Cyp40 (ABR,
PA3-022), FKBP51 (F14, Santa Cruz), XAP2 (ARA9, NB100-127,
Novus Biologicals), TPR2 (kind gift of Ulrich Hartl), PP5/PPT
(BD Biosciences). Signals were visualized by appropriate secondary
antibodies conjugated to horseradish peroxidase and the ECL
system (Millipore, Billerica, USA) and documented on X-ray film.
Immunoprecipitation
For immunoprecipitation of FLAG-tagged TPR proteins or
HA-tagged steroid receptors, HEK-293 cells were transfected with
2–10 mg of a plasmid expressing a TPR protein (amounts were
adjusted to ensure comparable expression levels) and 5 mg of a
plasmid expressing a steroid receptor. For Hsp90 precipitations,
10 mg of FLAG-tagged Hsp90 expression plasmid were transfected
together with 10 mg of FKBP52 plasmid. HEK 293 cells were
chosen, because they efficiently expressed the proteins and showed
the same results in reporter gene assays as SK-N-MC cells.
Transfection was performed by electroporation of one confluent
10 cm (60 cm2) dish (,56106 cells) using a GenePulser (Bio-Rad,
USA) at 350 V/700 mF in 400 ml of electroporation buffer
(50 mM K2HPO4/KH2PO4, 20 mM KAc, pH 7.35, 25 mM
MgSO4). Electroporated cells were replated in fresh medium
containing 10% steroid-free serum containing medium and
cultured for 3 days. Cells were harvested in cold PBS and lysed
by resuspension in Lysis-Buffer A9 (130 mM NaCl, 20 mM
Na2MoO4, 1 mM EDTA, 20 mM Tris-HCl pH 7.5, 10%
Glycerol, 0.5% Triton X-100, completed with Protease Inhibtor
cocktail, Sigma) for FLAG-TPR protein and receptor HA-IP, or in
Hsp90 Lysis Buffer (20 mM Tris-HCl pH 7.5, 50 mM NaCl,
20 mM Na2MoO4, 1 mM EDTA, 1 mM EGTA, 0.1% NP-40,
10% Glycerol, 0.5 mM DTT, completed with Protease Inhibitor
cocktail, Sigma and Phosphatase Inhibitor cocktail, Roche) for the
Hsp90 FLAG-IPs, followed by brief sonication (Branson Cell
Disruptor B15, 365 s, output 3) and incubation on ice for 1 h.
The lysate was cleared by centrifugation (10 min, 25.000 rcf, 4uC)
and the protein concentration was determined. 1–2 mg of lysate
was incubated overnight at 4uC with the anti-FLAG M2 agarose
affinity resin (Sigma) or with anti-HA agarose affinity resin
(Sigma), respectively. FLAG-beads (30 ml slurry) were treated as
recommended by the manufacturer. The next day, the beads were
washed 3 times with Lysis Buffer without detergent and samples
were eluted with 70 ml of 16FLAG-peptide solution (Sigma, 100–
200 mg/ml) or HA-peptide solution (Sigma, 100 mg/ml), respec-
tively, in 16 Tris-buffered saline (150 mM NaCl, 10 mM Tris-
HCl pH 7.0).
For analysis of the (co)precipitated proteins, 5–15 mg of the cell
lysates or 25 ml of the immunoprecipitates were separated by SDS-
PAGE under denaturing conditions. Coomassie staining was used
for detection of immunoprecipitated TPR-proteins and coimmu-
noprecipitated Hsp90 and Hsp70 in the FLAG-IP. For all other
detections immunoblots were used, i.e. the (co)precipitated steroid
receptors in the FLAG- and HA-IP, co-precipitated FLAG tagged
TPR-proteins in the HA-IP, and p23 in the FLAG-IP. To analyze
relative binding, the signals were subjected to densitometry. The
coomassie stained gels or films were scanned at 16 bit with a
calibrated densitometer (GS800, Bio-Rad, USA) and analyzed
with the Kodak 1D Image Analysis software.
To calculate the relative binding of co-precipitated proteins we
proceeded as follows: For relative binding of the receptors to the
precipitated TPR-proteins (FLAG-IP) the HA-immunoblot signals
of the eluates were first normalized with the Coomassie density
signals of the precipitated TPR proteins. To be able to compare
results between different experiments, we calculated these data to
represent relative receptor binding among the TPR proteins. To
this end, the normalized receptor (HA-IB) signal for each TPR
protein was divided by the mean of the normalized receptor
signals of all TPR proteins in each experiment. These ratios could
then be averaged throughout the different experiments.
Conversely, to calculate the relative binding of the associated
TPR proteins to the precipitated receptors (HA-IP), the FLAG-
immunoblot signals of the HA-IP eluates were normalized first
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with the HA-immunoblot signals of the HA-IP eluates (to correct
for variations in precipitation efficiencies of the receptors), and
second to the FLAG-immunoblot signals of the lysate (to correct
for differences in TPR protein expression). To calculate the mean
of different experiments, like for the FLAG-IP, the normalized
signals of each TPR protein were represented in reference to the
relative binding of the other TPR proteins. Because of variabilities
of the HA-IPs, the relative binding of each TPR protein were not
normalized to the mean of all TPR proteins, but for each receptor
to the mean of a subset of TPR proteins. The subset of TPR
proteins used to calculate the mean binding in different
experiments are displayed in the figure legends of each receptor.
To analyze the relative binding of Hsp90, the Hsp90 (FLAG-
IP)- Coomassie signals were normalized to the Coomassie signals
of the precipitated TPR proteins and this relative binding was used
to calculate the mean binding in different experiments.
To analyze relative Hsp70 binding to TPR proteins (FLAG-IP),
first the Hsp70 signal of the control reaction ( = background Hsp70
binding) was subtracted from the Hsp70 coomassie signals of each
TPR protein, and these values were then normalized to the
coomassie signals of the precipitated TPR proteins. Slightly
negative values were considered as no binding and set to zero.
This relative binding was used to calculate the mean binding in
different experiments. To analyze significant binding of Hsp70 to
FKBP51, a two tailed heteroscedastic students t-test were applied.
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